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Abstract
This dissertation focuses on structural and functional studies related to the interaction
between proteins and nucleic acids and their applications. The work reported here
includes two projects. The first part of the thesis is on the mutational and combinatorial
analysis of HIV-1 nucleocapsid protein (NCp7). Sixteen mutants of NCp7 were
constructed and over-expressed in E. coli. The dissociation constants (Kd) between the
mutant proteins and the major packaging signal in HIV-1, SL3 RNA, were measured using
tryptophan fluorescence titration assay and/or isothermal titration calorimetry (ITC)
assay. Most mutants show tolerance of the mutation but some mutants, including F16A,
I24A and K14E-E21K, suffered moderate to significant loss of affinity for SL3 RNA,
indicating the roles of the affected residues in the interaction between NCp7 and SL3.
The second part focuses on the development of methods for aptamer discovery. Two
prototype platforms were set up to imitate the two main-stream next-generation
sequencing (NGS) technologies, bridge amplification based and emulsion PCR based NGS
technologies. Proof-of-principle experiments were carried out and optimized to evaluate
the practicality of these platforms in high-throughput and multiplexed aptamer
discovery.
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Part I. Mutational and Combinatorial
Analysis of HIV-1 Nucleocapsid Protein
(NCp7)

Chapter 1. Introduction
This dissertation focuses on structural and functional studies related to the interaction
between proteins and nucleic acids and their applications. Work on two projects is
reported in the following chapters in two parts. The first part of the thesis is on the
mutational and combinatorial analysis of HIV-1 nucleocapsid protein, also known as
NCp7. It covers the topics of construction of HIV-1 NCp7 mutants via site-directed
mutagenesis, characterization of the mutant and wild type proteins, affinity assays for
NCp7 variants with HIV-1 SL3 RNA, including tryptophan fluorescence titration and
isothermal titration calorimetry. The following is a general introduction to these topics.

1.1. AIDS and HIV

Acquired Immunodeficiency Syndrome (AIDS) is a disease that affects human immune
system. It progressively breaks down the patient’s immune system and makes the
victims more vulnerable to infections and tumors. AIDS is categorized as a bloodborne
infectious disease and a sexually transmitted disease (STD) because it can be passed on
by an exchange of bodily fluids [1]. Since its first public report in 1981 by the USCDC [2],
AIDS has quickly escalated from an epidemic into a global pandemic. In 2010, the Joint
United Nations Programme on HIV/AIDS (UNAIDS) estimated in its annual global report
that there were 33.3 million people living with the disease at the end of 2009, including
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2.6 million people that were newly infected in the year of 2009. The disease killed 1.8
million people in 2009, including 260,000 children of age 15 or younger. At present,
AIDS has a prevalence of 0.8% in global adult population aged 15-49 [3]. These numbers
are likely to increase further as researchers still have found no cure for AIDS after
almost thirty years of hard work [4].

Human Immunodeficiency Virus (HIV) has been recognized as the causative agent of
AIDS. It’s a retrovirus, meaning its genetic information is carried by RNA instead of DNA.
HIV uses reverse transcriptase to transcribe its RNA to DNA, which in turn integrates
into the host’s DNA [5]. HIV can be divided into two species, HIV-1 and HIV-2, with HIV-1
being more infective and prevalent [6, 7]. As of today, we have been able to control the
disease with an antiretroviral drug cocktail regimen, by targeting multiple stages of
HIV’s replication cycle [8-10]. But current treatments are unable to eradicate the
dormant virus integrated in the genomic DNA of the host. Moreover, HIV virus is known
for its high mutation rate [11-15]. So new anti-HIV drugs and vaccines are needed to
attack resistant strains, reduce side effects, improve the effectiveness of therapies and
prevention methods, as well as to control treatment cost [16-20].

1.2. HIV Replication cycle

Understanding HIV’s replication cycle has been key to the treatment of AIDS. Many
details have been revealed about HIV and other retroviruses. As depicted in Figure 1-1
-3-

(D’Souza and Summers, 2005 [21]), a typical replication cycle of HIV-1 can be roughly
divided into 9 steps:

Step 1: Attachment. The surface subunit of HIV-1’s Env protein, gp120, recognizes and
binds to the CD4 receptors on the surface of HIV-1’s host cells (T cells,
macrophages and dendritic cells) [22]. The binding to CD4 induces a
conformational change of gp120 [23, 24], leading to its high-affinity binding to
chemokine receptors, including CCR5 and CXCR4 [25, 26], which function as coreceptors for HIV-1 on the host cell surface.

Step 2: Fusion. Interactions of gp120 with co-receptors trigger a cascade of
conformational changes of Env that result in activation of the trans-membrane
subunit of Env, gp41 [27]. The free energy released when gp41 undergoes
conformational change then induces the fusion of virion and cell membranes
[28]. The HIV-1 capsid core containing its genetic material is then released into
the cytoplasm of the host cell.

Step 3: Uncoating and Reverse Transcription. After viral entry, the HIV-1 capsid core
disassembles, in which the capsid proteins (CA) are dissociated from the HIV-1
nucleoprotein complex. This event is called uncoating. Uncoating of the capsid
core is accompanied with the formation of subviral particles called reverse-
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transcription complexes (RTCs) and pre-integration complexes (PICs) [29, 30], in
which the positive strand of viral RNA is transcribed to double-stranded DNA [5].

Step 4: Integration. The PICs containing the double-stranded proviral DNA are
transported through the nuclear membrane. The proviral DNA is then inserted
into the genomic DNA of the host with the help of the viral integrase [31]. The
integrated proviral DNA is replicated together with the host genome but lies
dormant in the latent stage of the replication cycle until being activated or
induced by cellular or viral signals [32, 33].

Step 5: Transcription and Translation. Utilizing the host’s transcription machinery, HIV-1
viral transcription from proviral DNA is initiated and driven by cellular
transcription factors and the viral trans-activating protein Tat [34]. In the early
stage, most mRNA is spliced and used to encode viral accessory proteins Tat, Rev
and Nef. Full-length viral RNA is later transported to the cytoplasmic ribosome
for translation with the help of Rev protein. Three viral polyproteins, Gag, GagPol and Env, are synthesized in the cytoplasm and at the endoplasmic reticulum.
These polyproteins are later processed by proteolytic cleavage to generate
structural and functional viral proteins [35].

Step 6: Genome Recognition. After the viral Gag and Gag-Pol polyproteins are
synthesized, they recognize the full length viral RNA by the interaction between
-5-

the NC domain of Gag protein and the packaging signal at the 5’-end of viral RNA.
Upon recognition of the viral RNA, Gag polyproteins assemble into multimeric
structures around the RNA molecule and localize to the cell membrane [36].

Step 7: Assembly. As Gag polyproteins accumulate on the inner surface of the plasma
membrane, they recruit the Env polyproteins, which are transported from the ER
onto the cell surface via the secretory pathway, and start the assembly process
of virus particles [35]. An immature particle is first formed with a relatively stable
capsid core of spherical shape [37].

Step 8: Budding. The assembly of immature virion particles induces the formation of a
bud on cell membrane and eventually the departure of the bud from host cell
membrane. During this process, the virion particle acquires a plasma membranederived lipid envelope that incorporates Env polyproteins and is tightly
associated with a layer of Gag polyproteins. Budding offers a non-lytic approach
for virus egress and allows the host cell to remain viable and continue to
produce more progeny virions [37].

Step 9: Maturation. The freshly budded virion particle is immature and non-infectious.
During and immediately after budding, the virion undergoes a dramatic
morphologic change known as maturation. This step involves proteolytic
cleavage of the Gag and Gag-Pol polyproteins and a large-scale rearrangement of
-6-

the cleavage products resulting in the structural transition of the virus core from
a spherical to a conical shape [37-39].

1.3. Gag Polyprotein and NC (Nucleocapsid) Domain

The HIV-1 genome contains nine open reading frames (ORFs), as shown in Figure 1-2
(Freed, 1998 [36]). Three of these ORFs encode the Gag, Pol and Env polyproteins, which
are later processed by viral and cellular proteases to generate individual structural
proteins and enzymes [35]. The other six ORFs encode six accessory proteins that have
regulatory or protective roles in the viral replication cycle [35, 40].

The 55kD Gag polyprotein is a major structural protein of HIV-1. During the maturation
step of the viral replication cycle, it is proteolyzed into four proteins, MA (matrix), CA
(capsid), NC (nucleocapsid) and p6, which make up the virion core containing the viral
genomic RNA [35]. The Gag protein has important roles in many steps of HIV-1’s
replication cycle, including viral particle assembly, localization, budding, maturation,
early post-entry steps and reverse transcription [36].

Many of the Gag polyprotein’s functions are associated with the NC (nucleocapsid)
domain or the mature NC protein [36, 41-56]. The most significant function of the NC
domain or NC protein is to recognize the viral genomic RNA for correct virus packaging
in a sequence-specific manner [57-61]. In the gag precursor, the NC domain is
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responsible for full discrimination of genomic from non-genomic RNA via several RNANC interactions [62-66]. NC also interacts with viral RNA or proviral DNA in a sequencenonspecific manner. In a HIV-1 virion particle, there are 2000 to 3000 gag precursors
coating the dimeric viral RNA, equivalent to about one NC protein per every seven
nucleotides [42, 67]. This Histone-like coating pattern of NC protects viral RNA or
proviral DNA from nuclease digestion [46]. The NC domain or mature NC protein can
destabilize sequence-nonspecific nucleic acid duplex [52], facilitate nucleic acid strand
annealing and complex nucleic acid secondary structure rearrangements [52],
chaperone viral RNA’s conformational rearrangement [68], activate viral RNA’s
dimerization [69], anneal the primer tRNA onto the genomic RNA for reverse
transcription [70], and facilitate efficient minus- and plus-strand transfer in reverse
transcription [71]. NC protein promotes primer-specific synthesis of proviral DNA and
reduces non-specific self-primed reverse transcription of viral and cellular RNAs. NC also
contributes to the high mutation rate of HIV-1 by enhancing the incorporation of
mutations during minus strand DNA elongation [42].

NC also interacts with various viral and cellular proteins to perform its multiple
functions. NC domain is essential to the self association of Gag polyprotein. It works in
concert with MA and p6 domains as the driving force behind Gag multimerization and
the assembly process of HIV-1 [72, 73]. NC is directly involved in the recruitment of HIV1 reverse transcriptase (RT) into nucleoprotein complexes. In collaboration with Vif, NC
enhances RT processivity to promote synthesis of full-length cDNA [44, 74, 75]. NC is
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also reported to regulate the timing of reverse transcription by inhibiting premature
cDNA synthesis by RT during virion assembly [76, 77]. NC is required for incorporation of
Vpr into the viral particle. Moreover, NC improves RNA recognition by Vpr through
interaction with the C-terminus of Vpr [78, 79]. NC protein can stimulate the integration
of HIV-1 proviral DNA by HIV-1 integrase [80, 81]. By directly binding F-actin, NC domain
mediates the association of Gag precursor with the host cell cytoskeleton and plays a
role in virus assembly and budding [82]. NC domain binds cellular protein Alix and
cooperates with p6 domain on Gag precursor to recruit cellular proteins, such as HP68,
Tsg101, EF-1α, Staufen, VAN and many other cellular proteins, which are proved or
hypothesized to participate in viral assembly, budding, morphogenesis and other steps
of HIV-1 replication cycle [55, 83, 84]. The cellular protein APOBEC3G, which is shown to
have an anti-retroviral activity, is encapsidated into virus-like particles through a direct
interaction with NC [49, 85]. Drugs to attack the nucleocapsid have the potential to
interfere with critical functions at many stages of the viral replication cycle [45, 86].

The mature HIV-1 nucleocapsid protein contains 55 amino acid residues (see Figure 1-3)
and has an apparent molecular weight around 7kD, hence the name NCp7. NCp7 has a
highly conserved amino acid sequence among HIV-1 strains, as shown in Figure 1-4 (Lin
and Borer, unpublished data [87]), and has several distinct structural features:

(1) NC or NCp7 contains two conserved CCHC zinc finger motifs in the form: Cys-X2Cys-X4-His-X4-Cys (X is any amino acid residue) [88-90]. This CCHC type zinc finger
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motif is highly conserved among retroviral nucleocapsid proteins and is relatively
rare among cellular zinc finger proteins in which CCHH or CCCC motifs are more
common [91, 92]. In coordination with zinc ions in a 1:1 stoichiometry, these zinc
fingers maintain a unique backbone structure and play an essential role in viral
genomic RNA packaging and infectivity. The zinc fingers, especially the intact Nterminal zinc finger, are required for the binding specificity and target selectivity
of NC for viral genomic RNA [93, 94]. Intact structure of the zinc fingers is
required for the temporal control of reverse transcription by NC throughout the
virus replication cycle [76, 77]. Mutations within the zinc fingers are usually
inhibitory. Zinc finger mutations can impair intracellular HIV-1 Gag localization,
virion biogenesis and maturation and infectivity [95]. Mutations that render NC
incompetent for zinc binding can destroy the capacity to recognize and package
genomic RNA [91, 96, 97]. Zinc finger interactions contribute to NC’s nucleic acid
chaperone activity by facilitating efficient minus- and plus-strand transfer and
nucleic acid annealing [71, 98, 99]. The conserved aromatic and hydrophobic
residues, including F16, I24, A25 of zinc finger 1 and W37, Q45, M46 of zinc
finger 2, are displayed on the protein surface and form a hydrophobic core that
could serve as the nucleic acid interactive site [89]. Besides interaction with viral
RNA, the zinc fingers are also found to directly interact with other proteins such
as Vpr [78]. The N-terminal zinc finger (F1 in Figure 1-3) is more conserved
among retroviruses and is proved more essential than the C-terminal zinc finger
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(F2 in Figure 1-3), whereas F2 serves an accessory role in NC’s chaperoning
activity [99-103].

(2) One important feature of NC domain or NCp7 is its high content of basic residues.
At neutral pH, NCp7 carries a net charge of +9. The basic residues in NC are
important for virus budding. The mutation of basic residues in NC can cause a
pronounced decrease in virus release from cultured cells [56]. The first zinc
finger of NC is flanked on both sides by a highly conserved and basic consensus
sequence, RXXRK, where X represents any amino acid residue. This motif is also
present in other retroviruses and many non-retroviral RNA-binding proteins and
is probably responsible for the unique hybridization properties of NC proteins,
which enhance RNA dimerization, tRNA annealing to the RNA primer binding and
the turnover rates of the interaction of a ribozyme with its RNA substrate [104,
105]. Basic residues in those motifs as well as the first zinc finger have been
shown to be required for speciﬁc binding of NC to HIV-1 RNA. In particular, R7,
R32 and K33 are the most essential basic residues for the interaction between
NCp7 and viral RNA [102, 104]. There’s an overall proportional relationship
between the basicity of NC mutants and their non-specific RNA binding activity
[104, 106]. Basic residues in NC domain are required for Gag-Gag interactions
and Gag multimerization. But the specific interaction between Gag and viral RNA
is more dependent on the protein tertiary structure than on the basic residues
[107, 108].
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(3) The linker region between the two zinc fingers has a highly conserved short basic
sequence, 29RAPRKKG35. Most notably, the proline residue at position 31 occurs
only in the trans conformation and induces a bend in the otherwise flexible
linker that is likely to bring the two fingers into close proximity. Mutations that
could destabilize the structure of the linker region are detrimental to the
infectivity of virion particles. Substitution of Pro31 by D-Pro31 causes spatial
rearrangement of the linker backbone, which leads to a severe reduction of viral
RNA dimerization in vitro [109]. The mutation P31L inhibits incorporation of GagPol polyprotein and tRNALys3 into virion particles and results in a total loss of RT
activity and the formation of non-infectious and immature viral particles [109,
110]. The overall structure, rather than the basicity, of the central globular
domain of NC, which consists of the two zinc fingers and the linker region, has
been shown to be critical to the structure and infectivity of virions [108].

(4) Another characteristic of NC is that it contains one and only one tryptophan
residue (Trp37), whose side chain resides in a hydrophobic core between the two
zinc motifs and is key to NC’s interaction with viral RNA. Tight and saturated
binding of RNA molecule onto NC can quench the natural fluorescence of Trp 37
by over 90%. Therefore the tryptophan fluorescence in NCp7 can be used to
monitor and measure the binding of viral RNA to NC in in vitro assays [111].
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Its multitude and significance in function and its sequence conservation and distinct
structure make the NC domain or mature NC protein an attractive target for anti-HIV
drug discovery. Even though there hasn’t been an approved NC inhibitor as anti-HIV
drug because of lack of selectivity and efficacy in drug candidates so far [112, 113],
researchers have been actively working on finding an effective anti-HIV drug that targets
NC domain or NCp7 [45, 86, 114-119]. Investigation of the structure-function
relationship in the interaction between NCp7 and viral RNA would shed light on the
rational design of anti-HIV drugs.

Mature NCp7 interacts with nucleic acids in vitro in a similar manner as NC domain does
in vivo [120, 121]. Synthetic or recombinant NCp7 protein has been widely used as a
model for structural and functional studies on NC and NC domain [57, 102, 104, 121124]. Therefore in this project I used recombinant NCp7 mutant and wild type proteins
over-expressed in E. coli as targets to investigate the interactions between them and
viral RNA in vitro.

1.4. SL3 Packaging Signal

The HIV-1 genome contains two copies of a 9.7-kb RNA molecule in a dimeric form,
which are coated with nucleocapsid proteins [125]. Besides serving as the HIV-1 genome,
the full length viral RNA also functions as an mRNA to encode the Gag and Gag-Pol
polyproteins [126]. Many functions of NC domain or NCp7 involve interactions between
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NC and the viral RNA. NC demonstrates both specific and non-specific interactions with
RNA. The non-specific interaction can be attributed largely to its high basicity, whereas
the specific interaction likely results from the structure of NC domain and/or the
sequence and structure of viral RNA, especially the 5’-untranslated region (5’-UTR) on
the viral RNA.

The 5’-untranslated region (5’-UTR) on the viral RNA is the most conserved part of the
HIV-1 genome and contains multiple distinct secondary structures, as shown in Figure 15 [57, 127-129], that can mediate several crucial steps in the viral replication cycle [130].
These structural elements include a trans-acting responsive (TAR) hairpin which binds
the transcriptional trans-activator protein Tat to regulate viral transcription [131, 132]; a
polyadenylation signal hairpin (poly(A)) which is inhibited by downstream splicing
signals [133, 134]; a primer binding site (PBS) domain where the tRNALys3 anneals to the
viral RNA as a primer to initiate reverse transcription [135, 136]; three stem-loops
containing the dimerization initiation site (DIS or SL1) [137, 138], the splice donor site
(SD or SL2) [139, 140] and the packaging signal (Ψ or SL3) domain [139, 141]; as well as
the start codon of the Gag polyprotein.

The NC domain or NCp7 can interact with many RNA motifs on the 5’-UTR region [53, 69,
98]. But NC bears the highest specificity and affinity for the major packaging signal SL3
[123, 142], which is considered as NC’s major RNA partner and primary recognition site
on HIV-1 genome. SL3 is highly conserved in sequences among different strains of HIV-1
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and well structured, which makes it of particular interest to many researchers [57, 61-66,
141, 143]. Inhibition of NC-SL3 interaction can significantly reduce the release of virus
particles from infected cells[144]. Deletion of the packaging signal causes loss of HIV-1
specific RNA from the virus-like particles being released from infected cells [141].
Disruption of the stem-loop structure of SL3 significantly diminishes both viral RNA
packaging and dimerization [145]. Further study of the interaction of NCp7 and SL3
could provide useful information that can facilitate rational design of anti-HIV drugs. To
investigate the interaction between NCp7 and SL3, De Guzman et al. (1998) constructed
a 20-nucleotide RNA molecule containing the 14-nt core sequence of SL3 (as shown in
Figure 1-5 inset) [57]. For consistency and convenience, in this study I used the same 20mer synthetic RNA molecule for affinity assays.

1.5. Interactions within the NCp7-SL3 complex

In 1998, the 3-D structure of the NCp7-SL3 complex (PDB 1A1T) was solved using
heteronuclear magnetic resonance spectroscopy by the Summers lab at University of
Maryland-Baltimore County, Baltimore, MD, with collaboration of the Borer lab at
Syracuse University, Syracuse, NY [57]. This structure revealed many details of the
interactions between NCp7 and SL3 RNA as summarized below, which served as a basis
for designing the mutation sites in this study.

- 15 -

(1) Overall structure: The stem nucleotides of SL3 RNA form an A helix and the tetra
loop bases project away from the stem and interact directly with NCp7. In NCp7,
the N-terminal residues from Lys3 to Arg10 form a 310 helix that binds within the
major groove of the RNA molecule. The two zinc fingers F1 and F2 are in close
proximity and interact with the G320 and G318 bases on the RNA tetra loop,
respectively, as shown in Figure 1-6.

(2) Hydrophobic interactions play a significant role in maintaining the protein
structure and contribute to the specific interactions between NC and SL3.
Hydrophobic interactions among Phe6 of the 310 helix, Val13 and Ile24 of F1 bring
the 310 helix tightly against the F1 knuckle, whereas the hydrophobic interactions
among Trp37of F2 and Phe16, Asn17, and Gly19 of F1 bring the two zinc fingers
tightly together. G320 binds to a hydrophobic cleft formed by the side chains of
Val13, Phe16, Ile24 and Ala25. G318 interacts with the F2 finger in a similar manner,
by fitting into a hydrophobic cleft formed by Trp37, Gln45 and Met46 side chains.
A319 makes hydrophobic contacts with the beta methyl or methylene groups of
Ala25, Phe16 and Asn17. A zoomed-in view of the hydrophobic clefts on the
surface model of the complex is shown in Figure 1-7.

(3) Hydrogen bonding is another important factor in the intra- and intermolecular
interactions within NCp7-SL3 complex. Phe16 forms a hydrogen bond with Trp37.
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Extensive hydrogen bonding between the side chain atoms of Asn17 to Cys28,
Pro31 and Lys33 stabilizes a single conformation of the linker region, which links
the two zinc fingers in close proximity. G320 forms hydrogen bonds with the
backbone atoms of Lys14, Phe16 and Ala25. G318 forms hydrogen bonds with the
backbone atoms of Trp37, Met46 and Gly35. A319 forms a hydrogen bond with the
side chain of Arg32. The side chain carbonyl of Asn5 forms a hydrogen bond with
the RNA stem and its NH2 group interacts with atoms of G320 and G321.

(4) Electrostatic interactions also contribute to maintaining the structure of the
NCp7-SL3 complex. Ten out of 15 basic residues are involved in intra- or
intermolecular interactions in the NC-SL3 complex. Most notably, three salt
bridges are formed between Lys14-Glu21, Lys33-Glu42 and Lys38-Glu51. The salt
bridges involving Lys14-Glu21 and Lys38-Glu51 are believed to stabilize the folding
of the F1 and F2 fingers, respectively. And the salt bridge between Lys33 and
Glu42 is thought to stabilize F2-linker interactions. Lys26 and Lys47 are responsible
for anchoring the zinc fingers to the RNA through electrostatic interactions.
Other basic residues are involved in non-specific electrostatic contacts with the
RNA.
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1.6. Previous mutational studies

The obvious significance and the unusual conservation of HIV-1 NC had invited extensive
mutational analysis on the protein. Deletion and replacement analysis indicated that
zinc finger F1 plays a more important role than F2 in NC’s functions [99, 102, 146, 147].
The intact CCHC motif of zinc finger F1 is required for the optimal target selectivity of
NCp7 [93]. The four conserved C-C-H-C residues involved in the zinc fingers were shown
to be critical for the functions of NC and infectivity of HIV-1 viral particles [76, 78, 95,
101, 103, 110, 148]. Random single mutations in the zinc motifs of NC resulted in more
relaxed RNA binding specificity of the protein [94]. Site-directed mutagenesis was
carried out on each residue in zinc finger F1 [148]. Five mutants, including F16A and
other four mutants on the C-C-H-C motif, showed no virus replication and significantly
lower viral RNA content in mutant viral particles. Replacing zinc finger F1 with F2 also
rendered similar adverse effects on virus replication and viral RNA content [148].
Binding assay using chemically synthesized mutants of NC protein showed that zinc
finger F1 and its flanking basic amino acid residues are sufficient for specific RNA binding.
Among those residues, F16 and T24 (a conserved variation of I24) and the arginine
residues, as well as the C-C-H-C motif, are essential for NC’s specific RNA binding [102].
Substitution of D-proline or leucine for Pro31 demonstrated reduced protein function
and viral infectivity [108-110]. Mutational analysis on the linker region between the two
zinc fingers indicated that the overall structure, rather than the basic nature, of the
linker region is critical for virion structure and infectivity [108]. Mutational analysis of
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basic residues in NCp7 suggested proportional relationship between the basicity of NC
mutants and their binding affinity for RNA or infectivity of mutant viruses. Nonetheless,
some basic amino acid residues, including R7, K14, R32 and K33, were proved to be
more critical than others for NC’s activity or the structure and infectivity of mutant
viruses [104, 149].

Some mutants reported in this dissertation, such as F16A and E21A, have been
previously studied by various binding or functional assays [82, 102, 146, 148]. Most in
vitro binding assays were carried out under different conditions than studied in this
thesis, and some of the findings weren’t consistent with each other (studies at low ionic
strength are largely irrelevant due to the dominance of non-sequence-specific
interactions [124]). Our work addresses these conflicts via a systematic and thorough
mutational and binding study on the effect of side chain contacts of NC residues on the
interactions between NC and SL3.

1.7. Specific Aims

The goal of this project was to locate the key residues in the NCp7-SL3 interaction that
are responsible for recognition and packaging of viral genomic RNA into nascent viral
particles. Based on previous studies and current knowledge of HIV-1 biology, the
following key hypotheses were proposed:
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(1) The RNA-nucleocapsid interaction is nearly the same in the NC-domain of the
Gag precursor as in the mature NCp7 protein.

(2) The NC-SL3 interaction is mainly defined by direct side chain contacts between
the protein and RNA.

(3) Important RNA-protein contacts that stabilize the NCp7-SL3 complex can be
probed by varying the protein sequence.

These hypotheses lead to the following specific aims:

A. Construct and express NCp7 variant proteins in which certain side chain contacts
are altered. Site-directed mutagenesis was used to construct the mutants. The
proteins were over-expressed in E. coli as recombinant proteins and used in in
vitro affinity assays for SL3 RNA.

B. Determine affinities of NCp7 variant proteins for SL3 RNA. Two types of affinity
assays were used in this study. The primary assay is a fluorescence spectroscopy
based assay, taking advantage of the natural fluorescence of Trp37. The
secondary assay is a direct thermodynamic assay and is used to confirm and
validate the data collected from the primary assay.
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C. Map the binding surface on NCp7 for SL3 RNA by comparing the affinity of NCp7
variants with wild type, so as to locate key residues in NCp7-SL3 interaction.

The methods and results are described and discussed in the following chapters.
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Figure 1-1. General features of HIV-1 replication cycle
Viral proteins labeled in the graph are: Gag, group-specific antigen protein; matrix (MA,
green), capsid (CA, red) and nucleocapsid (NC, blue); IN, integrase; Pol, polymerase; Rev,
regulator of viral protein expression; RT, reverse transcriptase; Vpr, viral propagation.
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Microbiology,
copyright 2005 (D’Souza and Summers [21]).
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Figure 1-2. Schematic representation of the HIV-1 genome and virion
(A) The location of the HIV-1 open reading frames is indicated. The RNA packaging signal,
ψ, is shown near the 5’-end of the genome. The gag open reading frame is enlarged.
(B) The HIV-1 virion, indicating the approximate location of Gag proteins, the Env
glycoproteins and the pol-encoded enzymes IN, RT, and PR
Reprinted from Virology, 251(1), Freed EO, pages 1-15, Copyright 1998, with permission
from Elsevier [36].
- 23 -

Figure 1-3. The amino acid sequence of HIV-1 NCp7 protein
Residues carrying a charge at neutral pH are shown in solid letters (positive = blue
capital letter, negative = red lower case); Zn2·NCp7 (1-55) carries a +9 charge at neutral
pH. The green outlined letter W indicates that the residue Trp 37 has natural fluorescence.
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Figure 1-4. Variation in 1700 NCp7 sequences
Open bars: conservative amino acid substitutions, closed bars: non-conservative.
Notation for RNA to protein side-chain interactions in the SL3-NCp7 complex: B = Hbonds or salt-bridges, S = steric contacts. Side-chain protein to protein contacts are also
noted: b = H-bonds or salt-bridges, s = steric contacts [57]. The consensus sequence is
shown, with different residues in the pNL4-3 isolate used in this work noted in
parentheses. CCHC in F1 and F2 are marked.
Reprinted with permission from Lin and Borer, unpublished data [87].
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Figure 1-5. Secondary RNA structure model of HIV-1 5' un-translated region
(5'-UTR)
Schematic illustration of a consensus hypothetical model of the HIV-1 5'-UTR showing
multiple stem-loop structures important for virus replication (from left to right): TAR
element, the poly(A) hairpin, the PBS domain, Stem-Loop 1 (DIS), Stem-Loop 2 (splice
donor, SD), Stem-Loop 3 (packaging signal, Ψ), and the Gag start codon, respectively.
Inset shows a 20-mer synthetic RNA molecule, which contains the core sequence of SL3
and is used in this study as a model for SL3. (Adapted from Russell et al. 2004 [127],
Paillart et al. 2004 [128], De Guzman et al. 1998 [57] and Watts et al. 2009 [129]).
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Figure 1-6. NMR structure of NCp7-SL3 complex
White ribbon: SL3 RNA; Stick model: backbone and base of G318 and G320; Magenta
ribbon: N-terminal 3-10 helix of NCp7; Yellow ribbon: N-terminal zinc finger (F1); Cyan
ribbon: linker region; Red ribbon: C-terminal zinc finger (F2); White sphere: zinc. Drawn
from PDB ID 1A1T using the UCSF Chimera package from the Resource for Biocomputing,
Visualization, and Informatics at the University of California, San Francisco (supported
by NIH P41 RR001081) [150].
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Figure 1-7. Hydrophobic cleft on NCp7-SL3 complex
White ribbon: SL3 RNA; Stick model: backbone and base of G318, A319 and G320; Surface
model: NCp7 protein; Magenta: N-terminal 3-10 helix of NCp7; Yellow: N-terminal zinc
finger (F1); Cyan: linker region; Red: C-terminal zinc finger (F2). Drawn from PDB ID 1A1T
using the UCSF Chimera package from the Resource for Biocomputing, Visualization, and
Informatics at the University of California, San Francisco (supported by NIH P41
RR001081) [150].
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Chapter 2. Construction, Expression,
Purification and Characterization of
Variants of NCp7 Protein
2.1. Introduction

2.1.1. Site-directed mutagenesis

Site-directed mutagenesis is a widely used technique in molecular biology to introduce
single point mutations or multiple mutations, insertions and deletions into a cloned DNA
fragment by polymerase chain reaction (PCR) [151]. As shown in Figure 2-1 (Stratagene,
2005 [152]), the desired mutation is designed and incorporated into a pair of mutagenic
primers. The primers are annealed to the circular dsDNA template (plasmid) and
extended by a high fidelity polymerase (PfuUltra).

DNA methylation is not essential but nonetheless universal in E. coli [153]. Many
laboratory strains of E. coli, including the XL1-blue and BL21(DE3)pLysS strains used in
this study, encode three sequence-specific methylases: the hsd (host-specificity), dam
(DNA adenine methylation), and dcm (DNA cytosine methylation) [153]. Foreign
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plasmids transformed into such E. coli strains will also become methylated if they
contain sequences recognized by those methylases [154, 155]. The dam methylase
specifically methylates the adenine residue in sequence GATC on both strands of the
duplex DNA. The Dpn I restriction enzyme cleaves on the 3’ side of methylated adenine
within the sequence GA*TC (* indicates methylation), which means all dam modified
dsDNA molecules are susceptible to Dpn I digestion [155, 156].

After sufficient thermal cycles, the mutagenesis PCR reaction produces a large number
of dsDNA molecules amplified by PfuUltra, which contain mutations introduced by the
primers and do not have dam methylation. The amplified PCR mixture is then subjected
to Dpn I digestion [152]. Because PCR synthesized products are not methylated, they
can survive the Dpn I digestion and stay intact, while the parental plasmid templates
containing dam methylation are degraded by Dpn I. Then the PCR synthesized DNA
containing the desired mutation is transformed into E. coli cells for preservation and
expression. Site-directed mutagenesis simplifies the process of gene manipulation and
has become an important tool in protein engineering, functional genomics and
structural biology.

Alanine scanning mutagenesis is probably the most common practice of site-directed
mutagenesis, in which the codon for one amino acid residue is substituted with a codon
for alanine [157]. Alanine was chosen as the substitution because it’s the simplest chiral
molecule of the 22 proteinogenic amino acids, with a chemically inert methyl group as
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its side chain. By substituting alanine for other amino acid residues, the side chain
contact on the mutated residue will be eliminated or greatly reduced whereas the
protein backbone remains unaltered. Thus the role of the side chain contact of the
mutated residue can be speculated from quantitative binding analysis of the alanine
scanning mutants.

2.1.2. Over-Expression and Purification of Recombinant NCp7

Over-expression of recombinant proteins in E. coli has been a routine technique in
modern biochemistry labs. Protocols for recombinant wild type NCp7 protein overexpression and purification have been well established and documented [111, 158, 159].
Because of the unusually high content of basic residues in NCp7, few proteins in E. coli
bear a higher charge than NCp7 does at neutral pH. Based on this fact, a two-part ion
exchange purification procedure was successfully used for the separation and
purification of NCp7. Because all mutants constructed in this study have the same or
even higher charge than wild type NCp7 at neutral pH, similar purification protocols can
be applied to the mutant proteins with only minimal modification.

In previously established protocols for purification of NCp7 protein, reducing agents
such as dithiothreitol (DTT) and beta-mercaptoethanol (BME) were used extensively in
order to protect the thiol group on the cysteine residues of the recombinant protein
from oxidation and forming disulfide bonds. DTT and BME are both widely used and
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very effective reducing agents. But UV background interference tends to be a problem
in accurate concentration determination of protein samples containing DTT or BME. The
oxidized forms of both DTT and BME have high absorption around the UV280 region.
Therefore they can interfere or even mask the UV absorption by a protein sample,
especially when the protein concentration is low. Air oxidation of DTT and BME makes it
difficult to avoid the interference by simply using a buffer blank.

Tris(2-Carboxyethyl) phosphine Hydrochloride (TCEP·HCl) is an attractive alternative to
DTT and BME [160]. It is a powerful reducing agent with a reducing potency comparable
to that of DTT. It is also non-volatile, odorless and resistant to air oxidation. More
importantly, it does not have absorption peak in the UV-Vis range so that it won’t
interfere with the measurement of protein concentration by UV absorption. All these
advantages make TCEP·HCl an ideal substitution for DTT and BME in the purification of
recombinant NCp7 proteins in this study. The results in this study demonstrated
satisfactory and reproducible purification of NCp7 with TCEP·HCl as the protective
reducing agent.

2.1.3. Protein characterization assays

SDS-PAGE was routinely used in this study to check the expression level of recombinant
NCp7 proteins and the purity of the purified proteins. Besides SDS-PAGE, two other
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assays were used in this study to identify and characterize the proteins before they are
subjected to affinity assays with SL3 RNA.

Mass spectrometry has been a preferred technology in protein identification for many
years [161]. Among different MS techniques, MALDI-TOF (Matrix-assisted laser
desorption/ionization (MALDI) in combination with time-of-flight (TOF) mass analyzers)
mass spectrometry is especially useful in protein and peptide analysis. MALDI-TOF mass
spectrometry is applicable to a wide range of biomacromolecules and is more tolerant
of common contaminants than other techniques. MALDI ionization preserves the
structural integrity of ionized biomacromolecules and extends the molecular weight and
polarity range of sample detection, allowing for easy sample preparation, large m/z
range and enhanced sensitivity [162, 163]. MALDI-TOF mass spectrometry was mainly
used in this study to determine the accurate molecular weight of the expressed and
purified protein. It also further confirmed the purity of the protein sample which was
checked on SDS-PAGE after purification.

Analytical ultracentrifugation is often used as a “gold standard” for monitoring
aggregation status of protein samples [164]. Protein oligomerization or aggregation can
affect the stoichiometry and apparent affinity of the studied protein for its ligands. So it
is important to determine the aggregation status of the protein of interest before
subjecting it to affinity assays. Our previous fluorescence titration model had assumed
that NCp7 is in monomer form and binds to SL3 RNA in a 1:1 ratio. The titration data
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fitted the model well [165]. But this assumption had never been directly proved by
experiment until now.

2.2. Materials and Methods

Unless otherwise noted, all chemicals and reagents were purchased from Sigma-Aldrich
(St. Louis, MO), Thermo Fisher (Waltham, MA) or Thermo Pierce (Rockford, IL). All E. coli
strains and site-directed mutagenesis kits were purchased from Stratagene (now Agilent
Genomics, Santa Clara, CA). All buffers and media were prepared with analytical grade
water produced from a Millipore Elix water purification system or ultrapure water
produced from a Millipore Milli-Q Biocel ultrapure water system (Millipore, Billerica,
MA).

Strains, plasmids and media. XL1-Blue E. coli strain was used for plasmid cloning and
preservation. BL21-(DE3)pLysS E. coli strain was used for the over-expression of NCp7
wild type and mutant proteins. The pRD2 plasmid containing the coding sequence of the
55-amino acid NCp7 from HIV-1 pNL4-3 strain[159] (a generous gift from Dr. Michael
Summers at University of Maryland, Baltimore County, referred to as “wild type” in the
following text. See plasmid map and sequence in appendix A) was used as template for
site-directed mutagenesis to construct all the NCp7 mutants characterized in this study.
The recombinant protein has methionine at position one of NCp7, coded by the AUG
start codon, rather than isoleucine, which occurs in wild type NCp7 from HIV-1 pNL4-3
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strain. Luria-Bertan (LB) medium was prepared according to Sambrook et al. [166] or
using pre-packed LB medium capsules (MP Biomedicals, Solon, OH). XL1-Blue strains
were grown in LB medium containing Ampicillin (Amp) (100μg/ml) as a selective
antibiotic. BL21-(DE3)pLysS strains were grown in presence of Amp (100μg/ml) and
Chloramphenicol (Cam) (34μg/ml). For protein over-expression, the LB-Amp-Cam media
were also supplemented with glucose (4g/L), MgSO4 (1mM), ZnCl2 (100μM), and M9
salts (NH4Cl (1g/L), Na2HPO4∙7H2O (3.2g/L) and KH2PO4 (3g/L) [111, 159, 167]. The sugar
and salt solutions were prepared as 10X, 100X or 1000X stock solutions, sterilized
separately and added to the media each time before starting culture.

Plasmid preparation. A single XL1-Blue colony picked from a freshly grown LB-Amp plate
was used to inoculate 5ml of LB-Amp media and grown at 37°C overnight, shaking at
200-250rpm. The overnight culture was harvested by centrifugation in a refrigerated
Eppendorf centrifuge Model 5804 (Eppendorf, Hauppauge, NY) for 5min at 3000rpm.
The plasmid was prepared from the harvested XL1-Blue cells using a QIAprep Spin
Miniprep kit (Qiagen, Valencia, CA) and eluted with 50µl of H2O or 1X TE (10mM TrisHCl, 1 mM EDTA, pH 8.0) [168] (also see appendix B-2). Plasmids are stored in 1X TE at 80°C for long term storage. The purity of the plasmid miniprep was confirmed by 1%
agarose gel electrophoresis and the concentration of the plasmid was determined using
a Nanodrop ND-1000 UV-Vis spectrophotometer (Thermo Nanodrop, Wilmington, DE).
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Site-directed mutagenesis. The Stratagene QuikChange® or QuikChange® II site-directed
mutagenesis kit was used to introduce site-specific mutations at positions listed in
Figure 2-2. Site-directed mutagenesis primers were designed using Stratagene
QuikChange Primer Design Program (http://www.genomics.agilent.com) or PrimerX
online tool (http://bioinformatics.org/primerx/) and synthesized by Integrated DNA
Technologies, Inc. (Coralville, IA). The mutagenesis PCR reactions were set up according
to the manufacturer’s instructions [152] (also see appendix B-3). After the PCR reactions
were finished, 0.5 μl of Dpn I restriction enzyme (provided in the site-directed
mutagenesis kit) was added into each reaction and incubated for 1 hr. The digested PCR
products were run on a 1% Agarose gel to check product size and estimate DNA
concentration. Then the digested PCR product was transformed into XL1-Blue E. coli
competent cells according to the manufacturer’s instructions [152] (also see appendix B4). XL1-Blue strains transformed with plasmids can be preserved in 15% glycerol (final
concentration) at -80°C for long term storage. Frozen stock of XL1-Blue strains should be
renewed every six months by remaking frozen stock from fresh overnight culture (also
see appendix B-6). Repeat the transformation if necessary. Plasmids containing the
desired mutations were prepared and stored as described above.

Sequencing. The prepared wild type and mutant plasmids were sequenced at the Core
Facility for DNA Sequencing & Flow Cytometry at State University of New York Upstate
Medical University, using a universal T7 promoter primer as sequencing primer. The
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sequences of mutants and wild type were aligned using the ClustalW2 online tool [169],
to confirm the position and sequence of the introduced mutation.

Transformation of BL21-(DE3)pLysS competent cells. The mutated and confirmed
plasmids were transformed into BL21-(DE3)pLysS E. coli competent cells according to
the manufacturer’s instruction [170] (also see appendix B-5). BL21-(DE3)pLysS strains
transformed with plasmids can be preserved in 15% glycerol (final concentration) at 80°C for long term storage. Frozen stock of BL21-(DE3)pLysS strains should be renewed
every six months by remaking frozen stock from fresh overnight culture (also see
appendix B-6). Repeat the transformation if necessary.

Over-expression of NCp7 Variants. The wild type and mutant NCp7 strains were grown in
LB media and the proteins were over-expressed using a revised protocol based on that
of Lee et al. [159] and Shubsda et al. [111] (also see appendix B-7). A Single BL21(DE3)pLysS colony was used to inoculate 5ml of supplemented LB-Amp-Cam media as
starter culture and grown at 37°C overnight, shaking at 200-250rpm. The overnight
starter culture was added to 1L of supplemented LB-Amp-Cam media and grown at 37°C,
shaking at 200-250rpm. The culture was induced with 400µM IPTG (isopropyl-β-Dthiogalactopyranoside) when its absorbance at 600nm reached 0.6-0.8. The induced
cells were grown for 4 more hours and harvested by centrifugation on an Avanti® J-E
centrifuge (Beckman Coulter, Brea, CA) using the JLA-10.5 rotor at 5000rpm for 15
minutes. The cell pellets were kept frozen at -20°C before subjected to cell lysis.
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Cell Lysis. Cell lysis was performed using a modified protocol based on that of Shubsda
et al. [111] (see also appendix B-8) Cell pellets from 1L culture were re-suspended on ice
in 30ml of lysis buffer (50mM Tris-HCl (pH 8.0), 10% (v/v) glycerol, 0.1M NaCl, 1µM ZnCl2,
5mM TCEP·HCl (Tris(2-Carboxyethyl) phosphine Hydrochloride, 60µg/ml Lysozyme,
53µM PMSF (phenylmethylsulfonyl fluoride), 1µg/ml Pepstatin A, 5mM sodium
deoxycholate). The mixture was left on ice for 20minutes before 4ml of B-PER II Protein
Extraction Reagent (Thermo Pierce) was added. The cells were then left on ice for 10
minutes before subjected to 4x 25 seconds of sonication using a Microson XL2000
Ultrasonic Liquid Processor (Misonix, now Qsonica, Newtown, CT) at an output power of
20-25 watts. 2ml of 4% PEI (polyethyleneimine) was then added to the mixture and
mixed thoroughly. The lysed cells were centrifuged at 17,000rpm for 30min at 4°C on an
Avanti® J-E centrifuge using the JA-25.5 rotor and the supernatant (lysate) was collected
for FPLC purification.

FPLC purification of NCp7 proteins. FPLC purification was carried out on an AKTA FPLC
system (Amersham, now GE Healthcare, Piscataway, NJ). Cell lysate was loaded onto a
HiPrep Q FF and a HiPrep SP FF column (GE Healthcare) connected in series and
previously equilibrated with at least 200ml of buffer A (50mM Tris-HCl (pH 8.0), 10%
(v/v) glycerol, 0.1M NaCl, 1µM ZnCl2, 1mM TCEP·HCl). After the A280 value returned to
baseline, the Q-column was disconnected and NCp7 protein was eluted using a onehour linear gradient from 20% to 50% buffer B (50mM Tris-HCl (pH 8.0), 10% (v/v)
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glycerol, 1.0M NaCl, 1µM ZnCl2, 1mM TCEP·HCl) (also see appendix B-9). Homogeneity
of the eluted protein was determined by SDS-PAGE. The purified NCp7 protein fractions
were then pooled and concentrated using a VIVASPIN 15ml Concentrator (5000 MWCO)
(GE Healthcare). The NCp7 concentration was determined by UV280 absorbance using a
molar extinction coefficient of ε280 = 6050 M-1∙cm-1 [171, 172]. Sample purity and
homogeneity was further confirmed by MALDI-TOF mass spectrometry and analytical
ultracentrifugation. Purified NCp7 protein was stored at -80°C both in aliquots (typically
in 100 µl aliquots at a concentration of 50 µM of protein in buffer A) and concentrate
stocks (usually range from 0.5-2mM in buffer A).

SDS-PAGE. Purity of the eluted protein was determined by SDS-PAGE [166]. Ten
microliters of each fraction was loaded and run on a 15% acrylamide/SDS Tris-Tricine gel
stacked with a 5% stacking gel. The gel was stained by Coomassie blue staining. The
fractions of the correct size and at least 95% purity are pooled and concentrated. Some
recent batches of over-expressed and purified protein were analyzed on precast
gradient gels purchased from Invitrogen (Carlsbad, CA), Bio-Rad (Hercules, CA) or Lonza
(Walkersville, MD) and stained using SimpleBlue™ SafeStain (Invitrogen).

Mass Spectrometry. Purified and concentrated protein samples were dialyzed against
MS buffer (5mM sodium phosphate, 0.2M NaCl, 1µM ZnCl2, 1mM TCEP·HCl, pH 7.0)
overnight. The concentrations of the dialyzed samples were determined by UV using MS
buffer as blank. The samples were then diluted to 20µM in 0.1% aqueous trifluoroacetic
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acid (TFA) solution. The dilute samples were then mixed in 1:1 ratio with freshly
prepared matrix solution (saturated Sinapinic Acid in Acetonitrile:0.1% aqueous TFA 1:2).
1µl of each sample mixture was spotted onto a MALDI sample plate and was allowed to
air dry. MALDI-TOF mass spectrometry was performed on an Autoflex III Smartbeam
MALDI-TOF system (Bruker Daltonics, Billerica, MA) at State University of New York
College of Environmental Science and Forestry, Syracuse, NY. The spectrometer was
operated in reflectron mode. Triplicate measurements were taken for each protein
sample.

Analytical Ultracentrifugation. Protein samples were dialyzed against NCp7 MS buffer
overnight. The concentrations of the dialyzed samples were determined by UV using MS
buffer as blank. Samples were then diluted in MS buffer to an absorbance of 1-1.5 at
280nm before being analyzed on a ProteomeLab™ XL-A Protein Characterization System
(Beckman Coulter). 400µl of sample was loaded each time. Sedimentation velocity
experiments were carried out at 50,000 rpm (200,000 x g) and 10°C overnight in 3-mm
two-sector charcoal-filled Epon centerpieces with quartz windows. Sedimentation data
were collected at 280nm and analyzed by the continuous sedimentation coefficient
distribution method using the program SEDFIT [173] (Acknowledgement: the AUC
sample run and data analysis were done by Dr. Anamika Patel (Laboratory of Prof.
Michael S. Cosgrove, Biology department, Syracuse University)).
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2.3. Results

Starting from the wild type pRD2 plasmid, sixteen mutants of NCp7 protein were made
as laid out in Figure 2-2. Thirteen out of the sixteen mutants are alanine scanning
mutants in which one non-alanine residue in the wild type protein sequence was
mutated into an alanine. These mutated residues were chosen because either they are
predicted to be involved in direct side chain contact with SL3 RNA or other parts of the
protein [57] (e.g. F16A) or they are structurally rigid (e.g. P31A) or flexible (e.g. G19A).
The other three mutants contain double mutations, which resulted in position switching
of the two residues involved in each of the three salt bridges in the wild type NCp7
structure. The mutant proteins were then over-expressed in E. coli and purified by ionexchange chromatography on FPLC.

Site-Directed Mutagenesis Primers. Designed mutagenesis primers are listed in table 2-1.
The primers were designed to have a melting temperature (Tm) between 75-85°C, a GC
content between 40-60% and a length between 30-55 bases [152]. The mutated codons
were designed to have minimal change from the template codon sequences in the wild
type and optimized for codon usage in E. coli [174, 175].

Sequence alignments. All 16 mutants and the wild type plasmids were sequenced and
the coding sequence regions on each plasmid were aligned and shown in Figure 2-3. The
sequencing results show that the desired mutations were introduced in the specific sites
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successfully. As reference, the plasmid map of pET-3a (on which pRD2 was constructed
[159]) was obtained from Novagen (now EMD4Biosciences, Gibbstown, NJ) [176] and
shown in appendix A-1. The full sequence of pRD2 is listed in appendix A-2.

FPLC chromatogram. A typical FPLC chromatogram is shown in Figure 2-4. Except for the
mutant E21A, all other NCp7 mutant proteins and wild type NCp7 were eluted off SP FF
column during the gradient from around 28% -42% Buffer B, with a peak at around 35%
Buffer B (the conductivity of sample at peak is around 27 mS/cm). E21A was eluted later
in the gradient because of its higher net charge than wild type.

SDS-PAGE. An example of SDS-PAGE gel image is shown in Figure 2-5. The gel clearly
shows that the recombinant NCp7 protein is expressed successfully and is a major
protein component in the crude lysate of the induced cells. Most of the NCp7 fractions
collected during the FPLC gradient elution are more than 95% pure. For the purpose of
affinity assays, this level of purity is acceptable. Precast gels produce excellent
resolution of NCp7 from other proteins. Representative gel images using precast gels
from three different suppliers are shown in Figure 2-6, 2-7 and 2-8. Invitrogen precast
gels have the best performance of the three. But in general all three kinds of precast
gels produce satisfactory results with good reproducibility and great convenience.

MALDI-TOF. An example of MALDI-TOF mass spectra of purified NCp7 protein is shown
in Figure 2-9. The spectrum shows that the observed mass of the highest peak (M+)
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agrees well with the calculated mass of the analyzed protein. The observed molecular
weight and calculated molecular weight of purified NCp7 wild type and all mutant NCp7
proteins are listed in table 2-2.

Analytical Ultracentrifugation. Two sets of AUC experiments were performed by Dr.
Anamika Patel using two different batches of NCp7 wild type protein samples. Results
from both experiments had only one single peak in the sedimentation velocity profile
with a calculated mass around 6.5 kDa, indicating that NCp7 is in the monomeric form in
the buffer conditions used in this study and is stable enough to be used in overnight
experiments. An example of the AUC profile of NCp7 wild type is shown in Figure 2-10.

2.4. Discussion

Protease inhibition. In cell lysis, the E. coli cells were homogenized by the concerted
efforts of lysozyme digestion, detergent dissolution and ultrasonic disruption. The
cellular proteins released after lysis were protected from endogenous proteases by
addition of protease inhibitors PMSF and Pepstatin A. Nonetheless, the protection from
protease inhibitors wears off soon due to their degradation in aqueous solution. For this
reason, the FPLC purification needs to be carried out on the same day of cell lysis to
avoid protein degradation.
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DNA contamination. Genomic DNA is a common contamination in recombinant protein
purification. NCp7 can bind DNA non-specifically because of its high basicity. So DNA
contamination is especially a problem for NCp7 purification. Polyethyleneimine (PEI) is a
basic cationic polymer which is positively charged at neutral pH. It can bind to negatively
charged macromolecules like nucleic acid and acidic protein molecules and precipitates
together with them. By addition of PEI and subsequent centrifugation, genomic DNA can
be removed from the lysate [177].

FPLC purification. The FPLC purification of NCp7 proteins involves two parts: removal of
negatively charged impurities by the Q FF column and separation of positively charged
NCp7 protein by the SP FF column. The purpose of flowing the cell lysate through the Q
FF column before SP FF column is to reduce the burden on the SP FF column and
increase the yield and purity of the separated NCp7 protein. SP FF column alone can be
used to separate NCp7 protein from the crude cell lysate. But the existence of negatively
charged cellular proteins can compete with the resin in the SP column for NCp7 protein,
and therefore reduce the binding capacity of the SP column. Moreover, the negatively
charged proteins might be co-eluted with NCp7 protein as a contaminant. So it is
necessary to include the Q FF column in the FPLC purification procedure.

Zinc concentration in media and buffers. The zinc concentration in the LB media used in
NCp7 over-expression was 100µM. But in the following purification and analysis process,
the zinc concentration used in all the buffers was reduced to 1µM. This was because of
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the instability of TCEP·HCl observed in presence of high concentration of zinc ions (data
not shown). The high concentration of zinc in the culture was to make sure that there
was enough zinc to be incorporated into the protein for the zinc finger structure to
correctly fold. Results from following affinity assays showed that NCp7 wild type protein
has similar Kd for SL3 RNA compared to reported Kd values of NCp7 wild type for SL3
RNA in the presence of higher zinc concentration (100 µM), which indicates that NCp7
protein maintains its zinc finger structure in the presence of lower zinc concentration in
the buffer (1µM).

MALDI-TOF peaks. Before we had ready access to the MALDI-TOF mass spectrometer
and worked out the optimal conditions for measuring NCp7 variants on MALDI, the most
reliable method for protein identification available to us was Sanger sequencing of the
plasmid being used for protein over-expression, which is indirect and often affected by
sequencing noise. SDS-PAGE gels give a good indication of the purity of protein but
don’t make accurate measurement of the molecular weight of protein and cannot
distinguish mutant proteins that are similar in size. Therefore MALDI-TOF and other
mass spectrometry techniques are powerful tools in protein chemistry. In fact, several
mutants which had exhibited unexpected binding patterns in preliminary experiments
were later found to contain unwanted mutations after being examined by MALDI-TOF.
For example, the original F6A mutant showed very weak binding affinity for SL3 RNA and
was later confirmed to be a double mutant, which contains both F6A and F16A
mutations. An early stop codon was introduced in the original P31A mutant because of a
- 45 -

shift in the reading frame, which resulted in a shorter translated product (31aa, mw.
3565). Those mutants were later re-constructed from scratch and confirmed to be the
correct ones by MALDI-TOF.

In the MALDI-TOF mass spectra of the NCp7 wild type and mutant proteins, the
molecular ion peak (M+) is the most abundant peak. In some cases, small peaks with
higher mass were observed. These peaks can be attributed to the zinc-bound protein
molecules. The most frequently observed small peak has a mass around M+65, which
can be attributed to the protein molecules coordinated with one zinc ion. Less
frequently, a peak around M+130 can be observed, indicating the NCp7 molecules
coordinated with two zinc ions. The low abundance of these peaks is probably because
the ionization condition of MALDI is too harsh for the zinc-bound protein to keep the
zinc ions upon the impact of laser. Using a milder ionization method such as
electrospray ionization (ESI) might help improve the abundance of zinc bound protein
peaks.
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Table 2-1. Site-directed mutagenesis primers for construction of NCp7 mutants
Primer
N5A
F6A
V13A
F16A
N17A
G19A
E21A
G22A
I24A
P31A
G40A
Q45A
M46A
K14E
K14E/
E21K
K33E
K33E/
E42K
K38E
K38E/
E51K

Primer Sequence

Length

Tm

Fw

5'-GGAGATATACATATGCAGAAAGGCGCATTTAGGAACCAAAGAAAGACTGTT-3'

51

78.5°C

Rv

5'-AACAGTCTTTCTTTGGTTCCTAAATGCGCCTTTCTGCATATGTATATCTCC-3'

51

78.5°C

Fw

5'-GAGATATACATATGCAGAAAGGCAATGCTAGGAACCAAAGAAAGACTGTTAA-3'

52

78.1°C

Rv

5'-TTAACAGTCTTTCTTTGGTTCCTTGCATTGCCTTTCTGCATATGTATATCTC-3'

52

78.1°C

Fw

5'-TTTTAGGAACCAAAGAAAGACTGCTAAGTGTTTCAATTGTGGCAAAG-3'

47

79.0°C

Rv

5'-CTTTGCCACAATTGAAACACTTAGCAGTCTTTCTTTGGTTCCTAAAA-3'

47

79.0°C

Fw

5'-CCAAAGAAAGACTGTTAAGTGTGCCAATTGTGGCAAAGAAGGGCAC-3'

46

79.4°C

Rv

5'-GTGCCCTTCTTTGCCACAATTGGCACACTTAACAGTCTTTCTTTGG-3'

46

79.4°C

Fw

5'-CAAAGAAAGACTGTTAAGTGTTTCGCATGTGGCAAAGAAGGGCACATAG-3'

49

79.2°C

Rv

5'-CTATGTGCCCTTCTTTGCCACATGCGAAACACTTAACAGTCTTTCTTTG-3'

49

79.2°C

Fw

5'-TGTTAAGTGTTTCAATTGTGCCAAAGAAGGGCACATAGC-3'

39

78.4°C

Rv

5'-GCTATGTGCCCTTCTTTGGCACAATTGAAACACTTAACA-3'

39

78.4°C

Fw

5'-GTTTCAATTGTGGCAAAGCAGGGCACATAGCCAAA-3'

35

78.1°C

Rv

5'-TTTGGCTATGTGCCCTGCTTTGCCACAATTGAAAC-3'

35

78.1°C

Fw

5'-TTCAATTGTGGCAAAGAAGCGCACATAGCCAAAAATTGC-3'

39

78.4°C

Rv

5'-GCAATTTTTGGCTATGTGCGCTTCTTTGCCACAATTGAA-3'

39

78.4°C

Fw

5'-TGGCAAAGAAGGGCACGCAGCCAAAAATTGCAGGG-3'

35

78.8°C

Rv

5'-CCCTGCAATTTTTGGCTGCGTGCCCTTCTTTGCCA-3'

35

78.8°C

Fw

5'-CAAAAATTGCAGGGCCGCTAGGAAAAAGGGCTGTT-3'

35

79.3°C

Rv

5'-AACAGCCCTTTTTCCTAGCGGCCCTGCAATTTTTG-3'

35

79.3°C

Fw

5'-GGGCTGTTGGAAATGTGCAAAGGAAGGACACCAAA-3'

35

79.3°C

Rv

5'-TTTGGTGTCCTTCCTTTGCACATTTCCAACAGCCC-3'

35

79.3°C

Fw

5'-TGTGGAAAGGAAGGACACGCAATGAAAGATTGTACTGAGAG-3'

41

78.2°C

Rv

5'-CTCTCAGTACAATCTTTCATTGCGTGTCCTTCCTTTCCACA-3'

41

78.2°C

Fw

5'-GTGGAAAGGAAGGACACCAAGCGAAAGATTGTACTGAGAGAC-3'

42

78.2°C

Rv

5'-GTCTCTCAGTACAATCTTTCGCTTGGTGTCCTTCCTTTCCAC-3'

42

78.2°C

Fw

5'-CCAAAGAAAGACTGTTGAGTGTTTCAATTGTGGC-3'

34

75.6°C

Rv

5'-GCCACAATTGAAACACTCAACAGTCTTTCTTTGG-3'

34

75.6°C

Fw

5'-GTTTCAATTGTGGCAAAAAAGGGCACATAGCCAA-3'

34

75.6°C

Rv

5'-TTGGCTATGTGCCCTTTTTTGCCACAATTGAAAC-3'

34

75.6°C

Fw

5'-TGCAGGGCCCCTAGGGAAAAGGGCTGTTGGAA-3'

32

81.6°C

Rv

5'-TTCCAACAGCCCTTTTCCCTAGGGGCCCTGCA-3'

32

81.6°C

Fw

5'-GCTGTTGGAAATGTGGAAAGAAAGGACACCAAATGAAAGA-3'

40

78.5°C

Rv

5'-TCTTTCATTTGGTGTCCTTTCTTTCCACATTTCCAACAGC-3'

40

78.5°C

Fw

5'-GAAAAAGGGCTGTTGGGAATGTGGAAAGGAAG-3'

32

76.5°C

Rv

5'-CTTCCTTTCCACATTCCCAACAGCCCTTTTTC-3'

32

76.5°C

Fw

5'-CACCAAATGAAAGATTGTACTAAGAGACAGGCTAATTGAATTC-3'

43

77.8°C

Rv

5'-GAATTCAATTAGCCTGTCTCTTAGTACAATCTTTCATTTGGTG-3'

43

77.8°C
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Table 2-2. Observed and calculated molecular weight of purified NCp7 proteins

#

Name

Observed Mr

Calculated Mr

Number of
Measurements

1

Wild Type

6369.7 ± 0.7

6369.4

11

2

N5A

6327.1 ± 0.4

6326.4

7

3

F6A

6293.0 ± 0.8

6293.3

6

4

V13A

6340.5 ± 2.0

6341.3

8

5

F16A

6293.2 ± 0.9

6293.3

9

6

N17A

6327.2 ± 1.3

6326.4

9

7

G19A

6383.4 ± 2.0

6383.4

8

8

E21A

6311.0 ± 1.9

6311.3

8

9

G22A

6385.0 ± 0.7

6383.4

6

10

I24A

6328.4 ± 0.4

6327.3

7

11

P31A

6344.3 ± 0.1

6343.3

6

12

G40A

6384.6 ± 0.5

6383.4

7

13

Q45A

6313.7 ± 0.6

6312.3

7

14

M46A

6310.3 ± 0.5

6309.3

4

15

K14E-E21K

6365.4 ± 0.2

6369.4

3

16

K33E-E42K

6369.4 ± 1.2

6369.4

4

17

K38E-E51K

6368.2 ± 0.1

6369.4

3
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Figure 2-1. Schematic procedure of site-directed mutagenesis
Circles indicate circular double stranded DNA templates and the nicked PCR amplified
products. Arc arrows indicate the mutagenesis PCR primers. Crosses indicate the
mutations being introduced via the primers. Dashed circles indicate the digested DNA
templates. © Agilent Technologies, Inc. 2005 [152]. Reproduced with permission,
courtesy of Agilent Technologies, Inc.
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Figure 2-2. HIV-1 NCp7 variants characterized in this study.
The amino acid sequence of wild-type NCp7 (pNL4-3 strain) is given at the top with
residue numbers labeled, followed by mutant sequences. The name of each mutant is
listed on the left. Identical residues to that of wild-type are indicated by dashes.
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WT
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WT
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K33E-E42K
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M Q K G N F R N Q R K T V K C F N C G K
ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA
ATGCAGAAAGGCGCATTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA
ATGCAGAAAGGCAATGCTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA
ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGCTAAGTGTTTCAATTGTGGCAAA
ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTGCCAATTGTGGCAAA
ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCGCATGTGGCAAA
ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGCCAAA
ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA
ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA
ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA
ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA
ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA
ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA
ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA
ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTGAGTGTTTCAATTGTGGCAAA
ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA
ATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAATTGTGGCAAA
************
******************** * ***** *
**** ****
E G H I A K N C R A P R K K G C W K C G
GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA
GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA
GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA
GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA
GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA
GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA
GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA
GCAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA
GAAGCGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA
GAAGGGCACGCAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA
GAAGGGCACATAGCCAAAAATTGCAGGGCCGCTAGGAAAAAGGGCTGTTGGAAATGTGGA
GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGCA
GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA
GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA
AAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGA
GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGGAAAAGGGCTGTTGGAAATGTGGA
GAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGGAATGTGGA
** **** ******************* ***** ************** ****** *
K E G H Q M K D C T E R Q A N X
AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168
AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168
AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168
AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168
AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168
AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168
AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168
AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168
AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168
AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168
AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168
AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168
AAGGAAGGACACGCAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168
AAGGAAGGACACCAAGCGAAAGATTGTACTGAGAGACAGGCTAATTAG 168
AAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168
AAGAAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAG 168
AAGGAAGGACACCAAATGAAAGATTGTACTAAGAGACAGGCTAATTAG 168
*** ******** * ************* *****************
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Figure 2-3. Sequence alignment of NCp7 wild type and mutants
The name of each mutant is listed on the left. The amino acid sequence of the wild type
is shown on top of the alignment. Mutated codons are indicated by underscored bold
red font. X indicates the stop codon.
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Figure 2-4. Typical FPLC chromatogram of NCp7 purification
Blue curve: UV absorption at 280nm; Brown curve: conductivity of sample; Green curve:
buffer gradient; Pink dashed line: Injection mark; Red tick marks: collected fractions.
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Figure 2-5. SDS-PAGE gel image of NCp7 protein sample (Tris-Tricine)
Lane 1: Protein mass ladder; lane 2: crude lysate of induced cells; lane 3-10: NCp7
sample fractions collected during FPLC gradient elution. Stacking gel: 5%. Separating gel:
15%. Gel thickness: 1.5mm. Running buffer: Tris-Tricine discontinuous buffer (see
appendix B-1). Run condition: 160V, 45 minutes.
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Figure 2-6. SDS-PAGE gel image of NCp7 protein sample (Invitrogen Precast Gel)
Lane 1: blank; lane 2: protein mass ladder; lane 3: blank; lane 4, 6, 9, 11: crude lysate of
un-induced cells; lane 5, 7, 10, 12: crude lysate of induced cells; lane 8 and 13-15: blank.
Gel: Invitrogen NuPAGE® Novex® 4-12% Bis-Tris Precast Gel. Gel thickness: 1.0mm.
Running buffer: 1X NuPAGE® MOPS SDS Running Buffer (Invitrogen). Run condition:
200V, 50 minutes.
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Figure 2-7. SDS-PAGE gel image of NCp7 protein sample (Bio-Rad Precast Gel)
Lane 1: blank; lane 2: protein mass ladder; lane 3: blank; lane 4 and 6: crude lysate of
un-induced cells; lane 5 and 7: crude lysate of induced cells; lane 8: blank; lane 9-14:
purified protein samples; lane 15: blank. Gel: Bio-Rad 4-20% Mini-Protean® TGX™
Precast Gel. Running buffer: 1X Tris-Glycine buffer (Bio-Rad). Run condition: 100V, 90
minutes.
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Figure 2-8. SDS-PAGE gel image of NCp7 protein sample (Lonza Precast Gel)
Lane 1: protein mass ladder; lane 2: blank; lane 3: crude lysate of induced cells; lane 4:
blank; lane 5-15: NCp7 sample fractions collected during FPLC gradient elution; lane 16:
blank. Gel: Lonza PAGEr® 4-20%T-G Precast Gel. Running buffer: 1X Tris-Glycine buffer
(Bio-Rad). Run condition: 125V, 6 minutes.
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Figure 2-9. Sample MALDI-TOF spectrum of NCp7 protein variants
Sample MALDI-TOF mass spectrum acquired on a Bruker Daltonics Autoflex III
Smartbeam MALDI-TOF system. Analyzed protein sample shown in this spectrum is F16A.
Spectrum was acquired in reflectron mode and recorded in the mass range between
4000 and 22500 m/z.
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Figure 2-10. Sedimentation velocity profile for NCp7 wild type
Diffusion-free sedimentation coefficient distributions (c(s)) derived from sedimentation
velocity data of NCp7 in MS buffer. Sedimentation data were collected at 280nm,
centrifuging at 50,000rpm and 10°C overnight. Sedimentation velocity profile for NCp7
wild type was fitted to a distribution of Lamm equation solutions using the SEDFIT
software [173].
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Chapter 3. Quantitative Binding
Analysis of NCp7 Variant Proteins with
SL3 RNA
3.1. Introduction
After sufficient amounts (>1 mg) of pure NCp7 wild type and mutant proteins were
acquired and identified, the proteins were subjected to quantitative binding analysis to
determine their affinity for SL3 RNA. Two kinds of affinity assays, tryptophan
fluorescence titration and isothermal titration calorimetry (ITC), were used in this study
to measure the affinity of the proteins for HIV-1 SL3 RNA, as described below.

3.1.1. Tryptophan fluorescence titration

Tryptophan is the primary contributor of the intrinsic fluorescence of proteins [178]. The
fluorescence emission of tryptophan is always dominant over that of other fluorescent
residues such as tyrosine and phenylalanine. Fluorescence of phenylalanine is much
weaker than that of tryptophan and tyrosine and can only be observed in the absence of
those two stronger fluorescent residues. Tryptophan fluorescence is very sensitive to its
microenvironment, which makes it especially useful as an intrinsic fluorescence probe in
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gathering information about protein structures and conformational transitions. Changes
of tryptophan fluorescence upon such transitions as protein unfolding, ligand binding or
protein-protein association allow for acquisition of thermodynamic and kinetic
information about these processes.

As mentioned in Chapter 1, the NCp7 protein contains one and only one tryptophan
residue (Trp37), two phenylalanine residues (Phe6 and Phe16) and no tyrosine residue.
Therefore the W37 residue accounts for most of the intrinsic fluorescence of NCp7
protein. The NMR structure of NCp7-SL3 complex revealed that the G318 base of SL3 RNA
stacks tightly on the side chain of Trp37 upon binding [57]. This kind of stacking
effectively quenches the fluorescence of tryptophan by nearly 100%, which is the
underlying mechanism of the fluorescence titration assay used in this study. The assay
can be conveniently conducted with 0.6 nmoles (~ 3.8 µg) of NCp7 protein and 2 nmoles
(~ 13 µg) of SL3 RNA.

In the tryptophan fluorescence titration assay, SL3 RNA was added in small aliquots into
a protein solution under constant stirring in a quartz cuvette. After each addition, the
solution is excited at 290nm and emission is recorded at 350nm. NMR structures
showed that except for the zinc fingers, NCp7 is largely disordered in the absence of
RNA [159], and the Trp37 residue is almost fully exposed to the solvent. Therefore an
emission maximum at around 350nm is expected in the fluorescence emission spectrum
of the NCp7 protein [179, 180]. By monitoring fluorescence emission at 350nm, the
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highest sensitivity and signal-to-noise ratio can be achieved in the titration. Upon
increasing concentration of SL3, the fluorescence emission was observed to drop
following a quadratic curve with the 1:1 molar ratio trend line and the x axis as its
tangent lines, and can be fitted using a simple 1:1 binding model of NCp7 and SL3 RNA
[165].

3.1.2. Isothermal titration calorimetry

Isothermal titration calorimetry (ITC) is a thermodynamic technique for probing
interactions between biomolecules. It directly measures the heat change upon binding
of two or more species of molecules. This method is label-free and does not require the
sample to have optical characteristics that change in response to a structural change,
such as in fluorescence or UV spectrophotometry. ITC also doesn’t require sample
immobilization as in surface plasma resonance (SPR) and doesn’t have a limitation on
molecular weight. It can simultaneously determine multiple binding parameters such as
the binding constant (K), enthalpy (ΔH), entropy (ΔS) and the binding stoichiometry (n).
All of these make ITC a powerful and universal method to study biomolecular
interactions [181]. A typical ITC assay requires 30 nmoles (~190 µg) of NCp7 protein and
10 nmoles (~65 µg) of SL3 RNA.

A schematic representation of isothermal titration calorimetry is shown in Figure 3-1
(Freyer et al. 2008 [182]). In an ITC instrument (a calorimeter), a pair of identical coin
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shaped cells made of highly efficient thermal conducting alloy are enclosed in an
adiabatic shield. Both cells are filled with liquid during experiments. During a typical ITC
experiment, the reference cell is filled with water and the sample cell is filled with one
reactant (sample) in titration buffer. A spinning syringe is filled with the other reactant
(titrant) in the same buffer and used for injecting and subsequent mixing of the two
reactants. The reference cell is maintained at a user-defined constant temperature by
applying a small constant power to it. The temperature difference between the sample
and reference cells (ΔT) is kept at a constant value by increase or decrease of power
being applied to the sample cell, as appropriate, using a feedback circuit. When
precisely known aliquots of titrant are titrated into the sample cell through the syringe,
heat gets released or absorbed, resulting in the increase or decrease of the sample cell’s
temperature. This change activates the feedback circuit, causing the power being
applied to the sample well to decrease or increase, in order to keep ΔT constant. This
change in the power is recorded and used to calculate the thermodynamic parameters
using preset or user-defined fitting models in Origin software [183].

ITC has its limitations, as well. It usually requires significantly higher amounts of sample
than other binding assays do. The reason for that is to generate large enough heat
change to be accurately measured by the calorimeter. The concentration of the sample
is usually set between 1 and 1000 times of the estimated or expected K d of the sample
for the titrant [184]. The concentration of the titrant is set so that the final molar ratio
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of titrant to sample is above 2 or higher, ensuring the sample to be saturated by titrant
toward the end of titration.

3.2. Materials and Methods

SL3 RNA. Desalted SL3 RNA (rGrGrArCrUrArGrCrGrGrArGrGrCrUrArGrUrCrC) was
purchased from Integrated DNA Technologies, Inc. (Coralville, IA) and used without
further purification. SL3 RNA was reconstituted in NCp7 titration buffer (5mM sodium
phosphate, 0.2M NaCl, 1µM ZnCl2, 1mM TCEP·HCl, 0.1% PEG 8000, pH 7.0). The
concentration of SL3 RNA was determined by UV260 absorbance using a molar extinction
coefficient of ε260 = 160,000 M-1∙cm-1 as described previously [111]. Purity of SL3 RNA
was examined by ion exchange HPLC using a DNAPac® PA200 4X250mm column (Dionex,
Sunnyvale, CA) on an Agilent 1200 HPLC system. SL3 was heat denatured at 95°C and
snap cooled on ice before being loaded onto HPLC. Ten microliters of ~30µM SL3 RNA
was injected onto the PA200 column and eluted with a gradient from 0-65% B over 10
minutes (solvent A=0.01M Tris-HClO4, 20% acetonitrile, pH 8.0; solvent B=0.01M TrisHClO4, 20% acetonitrile, 0.33M NaClO4, pH 8.0).

Tryptophan Fluorescence Titration Assay. NCp7 wild type and mutant proteins were
titrated with SL3 RNA using conditions similar to those described previously [111]. NCp7
wild type protein was titrated every time as a positive control along with the mutant
proteins. Fluorescence emission was measured at 350nm with a QuantaMaster QM- 63 -

4/2005SE fluorometer (Photon Technology International, Birmingham, NJ) in the
laboratory of Prof. Bruce Hudson at Chemistry Department, Syracuse University,
Syracuse, NY, using a 290-nm excitation wavelength, a 4-nm excitation band-pass and a
1.5-nm emission band pass. The fluorescence reading was acquired 2 minutes after each
oligo aliquot using Felix 5.1 software. The titration curves were fitted to a model
assuming 1:1 stoichiometry for the molar ratio of NCp7 to bound SL3 RNA as described
by Paoletti et al. [165]. The titration curves were fitted to the following equation:



I  I   / I 0   Rt  Pt  K d   Rt  Pt  K d 2  4Pt K d 

1/ 2

/ 2P

t

(3-1)

where Rt and Pt are the total RNA and protein concentrations, respectively, I0 is the
intensity at Rt =0, and I∞ is the limiting intensity at saturation. In this study I∞ was set to
zero, leaving Kd as the only adjustable fitting parameter. The NCp7 concentration was
fixed at 0.3 μM, and titrations were extended to Rt/Pt ≈3.0. Kd values were fitted using
the above model in Origin 7.0 software (OriginLab, Northampton, MA).

Isothermal Titration Calorimetry. Isothermal Titration Calorimetry (ITC) experiments
were performed on a Microcal VP-ITC Micro Calorimeter (Microcal, now GE Healthcare)
at State University of New York Upstate Medical University, Syracuse, NY, in the
laboratory of Prof. Stephan Wilkens. Origin 7.0 software was used for data collection
and analysis. The sample cell has a volume of 1.4 ml and the total available injection
volume in the syringe is 300µl. The sample and titrant were degassed for 5 minutes
before being loaded into the sample cell and syringe. Each time around 2ml of 5µM SL3
RNA dissolved in NCp7 titration buffer was used to load the sample cell and the
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overflow was removed by a syringe. About 500µl of NCp7 protein at a concentration
around 60µM was needed for filling the syringe in each titration. Binding reactions were
carried out at 30°C. Reference power was set to 5µcal/sec. The first injection volume
was set to 2µL, 4sec, followed by 29 injections of 10µl, 20sec. The last injection volume
was set to 8µL, 16sec. Interval between each injection was set to 240 sec. Syringe
stirring speed was set at 295 rpm. The feedback gain was set at high and equilibrium set
at fast, auto. The above-mentioned concentrations of sample and titrant were chosen so
that the titration would reach saturation at least 5-10 data points before the last
injection. A baseline was drawn by linear extrapolation using the data points collected
under saturation conditions and subtracted from the whole data set to correct for the
heat of dilution [185, 186]. Binding isotherms were then fitted to a one-binding-site
model using the supplied manufacturer’s ITC add-on for Origin 7.0 software, with Kd and
the binding stoichiometry, n, as adjustable parameters.

3.3. Results

SL3 RNA purity. The HPLC chromatogram of SL3 RNA is shown in Figure 3-2. The RNA
sample shows no sign of degradation and the purity is higher than 90% as judged by
integrals of the peaks in the HPLC chromatogram. This level of purity is acceptable for
the purpose of the binding affinity assays used in this study. Therefore the SL3 RNA was
used without further purification.
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Tryptophan Fluorescence Titration Assay. Seven of the seventeen protein-SL3 titration
curves are shown in Figure 3-3 covering the wide range of Kd values of the wild-type and
mutant NCp7 proteins for SL3. All seventeen Kd values calculated from Trp titration data
are compiled in Table 3-1 as well as in Appendix C-1, ranging from 9 nM to 720 nM.
Pictorial summaries are displayed in Figures 3-4, 3-5 and 3-7. All individual Trp titration
curves are shown in Appendix C-2. The Kd value for binding of the wild type NCp7 with
SL3 was calculated to be 29 nM, which agreed with our previous experimental data
[124, 165] and served as a good positive control for the mutant proteins. Dissociation
constants were calculated by non-linear regression to get the best fit titration curves,
assuming a 1:1 complex. No evidence for other stoichiometries was indicated by the
data at 0.2 M NaCl [111, 124]. The binding isotherms for low-affinity complexes (e.g.
F16A) were not extended to saturation because the nature of the complex may change
in the presence of a large excess of RNA [165]. I∞ was set at zero because in the range of
the Kd values for these titration curves, very little effect of the residual fluorescence was
observed [165].

Isothermal Titration Calorimetry. Due to limitations of material and time, only 8 mutant
NCp7 proteins and NCp7 wild type protein and were examined using ITC assay. A set of
ITC titration curves for all 9 proteins are shown in Figure 3-6. The Kd values and other
binding parameters calculated from ITC experiments are compiled in table 3-2 as well as
in Appendix C-1. All individual ITC titration curves are shown in Appendix C-3. The Kd
values calculated from the ITC assays (termed KdITC) were compared with the ones
- 66 -

calculated from the tryptophan fluorescence titration assay (termed KdTrp) in Figure 3-5.
Taking into account that ITC experiments were carried out at 30°C, the Kd values
calculated from the ITC data were converted to equivalents at room temperature (22°C)
using the van’t Hoff equation as shown in equations (3-2), assuming the ΔH0 is constant
over the limited temperature range of eight degrees. The Kd values calculated and
converted from ITC data were generally larger than their counterparts calculated from
tryptophan fluorescence titration data. But the overall trend of the changes in KdITC
values agrees well with the trend observed in KdTrp values, as demonstrated in Figure 35. The average number of binding sites determined by ITC also suggested that NC-SL3
binding follows a 1:1 binding model. These observations confirmed the validity of the
tryptophan fluorescence titration as a good affinity assay for NCp7 proteins and SL3.
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3.4. Discussion
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(3-2)

For the convenience of discussion, the mutants are divided into groups based on their Kd
values calculated from the tryptophan titration data. The factor (F) by which Kd change
was calculated and is listed in Table 3-1 for each mutant protein by dividing its Kd value
by the Kd value of wild type NCp7 (29nM). Mutants with a change factor less than 2 are
considered as mutants with little or no change in affinity. Those with a change factor
between 2 to 10 are considered to have moderate change in affinity. Those with an F
value greater than 10 are considered as mutants with significant change in affinity. The
observed changes from the fluorescence titrations are summarized in Figure 3-4 and 3-5
and will be further discussed in the following section. A set of ITC data for the wild-type
and eight mutants are displayed in Figure 3-6.

3.4.1. Single mutants

Mutants having little change in affinity. Most of the single mutants have a Kd value close
to that of wild type NCp7. These mutants include N5A, F6A, V13A, N17A, G19A, E21A,
G22A, P31A and G40A.

In the case of F6A, this observation is not surprising because Phe6 does not participate in
any RNA-protein or protein-protein side chain contacts and therefore may not
contribute much in stabilizing the structure of the protein or protein-RNA complex.
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Considering the position and structure of Gly19, Gly22 and Gly40 (each reside in similar
positions in the two zinc finger motifs), we hypothesized that substitution of alanine for
those residues might give rise to unwanted side chain contacts between NC and RNA or
within the NC protein, or to a loss in flexibility in the zinc fingers, which would result in
loss of affinity of NCp7 for SL3 RNA. The observations however indicated the opposite,
that substitutions of alanine for glycine on these positions do not cause unfavorable
effects.

Pro31 itself does not have any RNA-protein or protein-protein side chain contact. But
given its unique structural rigidity and high conservation, we expected that the P31A
mutation might affect its affinity for SL3 RNA. In fact, it’s reported that Pro31 helps
determine the spatial proximity of the two zinc fingers [109]. Substitution of Pro31 would
result in significant impairment of viral RNA dimerization, virion formation and
infectivity [108, 109]. So the observation that P31A only shows a slight change in affinity
for SL3 RNA was surprising. This observation indicates that the affinity of NCp7 for SL3
RNA doesn’t require specific spatial orientation of the zinc fingers.

Val13 does participate in NCp7-SL3 interaction by forming a hydrophobic cleft, which
interacts with G317 of SL3 RNA, with neighboring residues Phe16, Ile24 and Ala25. When
NCp7 is bound to SL3 RNA, Val13 also contributes to intra-protein hydrophobic
interactions between the 310 helix and zinc finger 1 [57]. Molecular dynamics study
suggests that Val13 resides within a hydrophobic core with Phe16, Ile24, Ala25, Trp37, Gln45
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and Met46 [53, 89]. Substitution of Val13 with alanine shortened the side chain but still
maintained similar polarity and hydrophobicity with those of valine. The observation
that V13A mutation resulted in a smaller change in affinity than the other mutants in
the same hydrophobic core suggests that Val13 contributes little to the RNA binding
function of NCp7, except by maintaining the hydrophobic core. The fact that Val13 is
among the residues with a higher frequency of natural variation with hydrophobic
residues (see Figure 1-4) also suggests that the specific side chain of Val13 is less
important to maintaining the hydrophobic core than some of the other residues.

Asn5 and Asn17, especially Asn5, were thought to play a more significant role in NCp7’s
RNA recognition. Asn5 is part of the 310 helix that binds the major groove of SL3 RNA and
is also the only NC residue that forms specific hydrogen-bonds with the RNA stem.
Moreover, Asn5 is one of the most conserved residues in NCp7. Asn17 is part of the F1
knuckle and makes hydrophobic contacts with the SL3-tetraloop. It also stabilizes the
protein structure through multiple hydrogen-bonding and hydrophobic interactions [57].
The observation that both N5A and N17A displayed no significant change in affinity for
SL3 was unexpected. This may indicate that either these two residues are not essential
in NCp7-SL3 binding or that conformational changes in the mutants could compensate
for the loss of H-bonds that should be caused by these mutations.

Another interesting mutant in this group is E21A. Glu21 forms a salt bridge with Lys14,
which appears to stabilize the folding of the F1 knuckle [57]. Mutating Glu21 into Alanine
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effectively destroys the above mentioned salt bridge. One would expect such a change
might result in a noticeable loss in the mutant protein’s affinity for SL3 RNA. However,
the affinity of E21A for SL3 RNA turned out to be even higher than that of wild-type
NCp7. The Kd of E21A is calculated to be 9nM vs. 29nM for the NCp7 wild type. One
explanation could be that although the mutation from Glu21 to alanine destroyed the
salt bridge between Glu21 to Lys14, it also resulted in an increase of the mutated
protein’s net charge from +9 to +10, which helps the protein to attract the negatively
charged RNA. Also the zinc finger’s structure is stabilized by many forces including the
salt bridge. While the loss of the salt bridge may destabilize the structure to some
extent, other forces such as hydrophobic interaction could be enough to keep the
structure of the zinc finger intact. Also the bound RNA might play a role to keep the
protein correctly folded. Moreover, nucleic acid binding studies suggest that binding
affinity of NC for RNA is strongly dependent on the net charge of the protein [104, 187,
188].

Mutants with moderately change in affinity. I24A, Q45A and M46A show a moderately
lower affinity with Kd values ranging from 2 to 10 times of that of wild-type NCp7. As
shown in Figure 3-7, these residues occupy positions on the same side of the two fingers,
with Ile24 and Gln45 in equivalent positions.

Ile24, Gln45 and Met46 are members of the hydrophobic core described above. They all
show certain steric interactions with the RNA molecule in the NMR structure [57]. The
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loss of affinity caused by these mutations indicates that these interactions may
contribute more to the stabilization of the complex than the residues in the first group.

Mutant with significant change in affinity. F16A has a much larger Kd value than wildtype NCp7 (approximately 25-fold). This observation also agrees with previously
reported northwestern blot (meaning protein-RNA blotting) data and molecular
dynamics analysis [148, 189]. Phe16 forms a hydrophobic cleft with several other amino
acid residues and closely interacts with Trp37, for which fluorescence is monitored in the
binding assay to determine the affinity of the binding. The mutation from Phe 16 to
alanine could result in relocation of Trp37 in the protein-RNA complex so that the
binding of SL3 may no longer quench its fluorescence efficiently.

3.4.2. Salt-bridge switching double mutants

Two of the three double mutants, K33E-E42K and K38E-E51K, do not produce large
changes in their affinity for SL3 RNA. But the other double mutant, K14E-E21K, which
contains mutations within the F1 knuckle, showed a moderate change in its affinity for
SL3. The Kd value of this double mutant for SL3 was calculated to be 140 nM. Compared
to the other two double mutants, this observation indicated that structure of F1 knuckle
is more susceptible to mutations and/or more crucial to NC’s affinity for SL3 RNA. The
tryptophan titration curve of K14E-E21K doesn’t fit well with the model described by
equation (3-1), as shown in Figure 3-8. One explanation could be that this mutant might
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bind to SL3 RNA differently than the wild type NCp7 does. Its interaction with SL3 RNA
might involve a tight binding phase and a weak binding phase, giving rise to the unique
shape of the titration curve.

The structure of NCp7-SL3 complex may offer a clearer explanation of the differences in
the affinity of the three salt-bridge switching mutants for SL3. As shown in Figure 3-9,
the salt bridge between Lys33 and Glu42 and the one between Lys38 and Glu51 are both
directly exposed to solvent, while the one between Lys14 and Glu21 is partially buried
inside the complex, especially residue Lys14. Salt bridges exposed to the solvent may not
contribute to stabilizing protein structures because of the interference of solvent. But
semi-buried salt bridges like the one between Lys14 and Glu21 can be a strong stabilizing
force [190]. The moderate change of this double mutant’s affinity indicates that even
though the switched residues are still in close proximity, their ability to form salt bridges
might be modified.

3.4.3. Comparison of Trp titration and ITC titration results

The Kd values calculated from ITC titration data don’t match exactly with those
calculated from Trp titration data for the same mutant. But overall they show the same
trend. The same criterion (the change factor of Kd value, F) used to categorize the
mutants based on their Trp titration data can be used on their ITC titration data and the
mutants can be grouped exactly the same way (see Table 3-1, 3-2 and Figure 3-5). This
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shows that ITC is a good alternative assay for measuring NCp7-SL3 RNA binding
isotherms.

Some of the differences in the Kd values calculated from the two methods may be
attributed to the different nature of the assays. Tryptophan fluorescence titration relies
on the direct interaction of Trp37 and the bases in the bound RNA, while ITC experiments
directly measure the heat change upon binding, which is not dependent on the
structure of protein or RNA. The ITC experiment can be more accurate than Trp titration,
but this is only true at much higher concentrations than are practical for NC-SL3
titrations. The ITC data, especially for the weakly bound complexes with F16A, I24A,
K14E-E21K, are noisy or have unusual shape (See Figure 3-6). This causes more
uncertainty in Kd. Trp titration has the advantage of being a convenient and
straightforward assay with much higher sensitivity than ITC. The observation that ITC
data follow the same trends for Trp titration data also endorses the validity of Trp
titration assay for measuring the affinity of NCp7 for SL3 RNA.

The order of titration in the two assays is also different in this work. In tryptophan
fluorescence titrations, SL3 RNA is being titrated into NCp7 protein because it’s a well
established and convenient way of titration and lots of titration data had already been
collected before the ITC assay came into play. Our lab has recently worked out the
conditions and fitting model for the AddPro approach of tryptophan fluorescence
titration, in which NCp7 protein aliquots were added into a large excess of SL3 RNA
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solution. Excellent agreement in Kd values was found at the nearly physiological salt
concentrations used in the present work [124].

While in ITC titrations, NCp7 protein is loaded into syringe and titrated into SL3 RNA
solution in the cell. The amount of titrant (syringe sample) in ITC experiments needs to
be at least two to three times of that of sample (cell sample). Considering the cost
efficiency, it was reasonable to use SL3 RNA as the cell sample which requires smaller
amount of the two binding partners, because SL3 RNA is the most expensive material
needed in this assay.

3.4.4. ITC data analysis

Origin software defines the "ligand" as the species with only one site and calls the
species with n greater than 1.0 the "macromolecule", irrespective of their molecular
weights [191]. In theory, when two binding partners follow a 1:1 binding stoichiometry
and have only one binding site, as in the case of NCp7 and SL3, it shouldn’t matter which
one is defined as “ligand” and which one is loaded into syringe, because the system
would be symmetrical. But in reality, systematic errors and other factors would prevent
one from acquiring perfect data that produces an exact n=1 stoichiometry. So it’s
important to be consistent in the ITC experiment setup and data analysis for the same
set of samples. In this study, the SL3 RNA was defined as “ligand” and was loaded into
the cell in all the experiments.
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One should note that the order of titration in ITC experiments, i.e. whether the “ligand”
is in the syringe or in the cell, needs to be specified under the “ITC” menu in the Origin
software before data analysis. The default option in the software is the “ligand-insyringe” mode. The second option is the “ligand-in-cell” mode. It has been observed
that the same set of data can produce similar shape of fitted curve but very different
binding parameters. The binding stoichiometry n calculated in one mode is normally the
reciprocal of the n value calculated from the same set of data in the other mode. But the
Kd and ΔH values are less straightforward, thus much more difficult, to convert between
the two modes. So it’s necessary to choose the appropriate mode for the data being
analyzed. All the ITC data in this study were fitted in the “ligand-in-cell” mode because
SL3 was the loaded in the cell in all experiments.

Before fitting the ITC titration data, it’s necessary to subtract from the data set the
baseline or background heat signal, which is largely due to the heat change generated
from dilution of the injected titrant. There are two approaches to establish the baseline
for ITC data analysis [186]. One is to run a separate background titration by injecting the
same titrant into buffer only. The other is to include extra data points at the end of
titration when the sample in the cell has already been saturated by the titrant. The heat
change in this phase is mainly because of dilution of the titrant. I have tried both
approaches of background correction and found that overall the two approaches
demonstrated good agreement with each other. When there is discrepancy in data
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analyzed with different approaches, the ones corrected with terminal injection data
generate a better fit (see Appendix C-3).

3.5. Conclusion

Overall, most of the mutations did not result in significant loss of affinity for SL3 RNA in
the mutant NC proteins. This indicates that the side chain contacts of those involved
residues in wild type NCp7 either contribute little to its stability or can be compensated
by new contacts in the mutants. On the other hand, conservation of many of these
residues could arise from NC’s interactions with other proteins or in other aspects of its
many roles in HIV infection.

The F16A mutant exhibits a profound loss of affinity for SL3 RNA and is confirmed by
both fluorescence titration and ITC assay. This observation agrees with previously
reported NMR structure and molecular dynamics analysis [57, 189]. All of these indicate
that Phe16 is a key site in the NCp7-SL3 interaction and warrant further structural and
functional study focusing on Phe16. Other interesting mutants include I24A and K14EE21K.

Tolerance to alanine mutagenesis mutation in some structurally important sites, such as
Asn5, Gly19, Pro31 and Gly40, indicates the key interactions between NCp7 and SL3 might
be confined in a small locale on protein surface and is not sensitive to the overall
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protein structure. Yet the high conservation of those residues suggests that they have
important roles in other functions of NCp7, if not in the NCp7-SL3 interactions.

Fluorescence titration and ITC are complementary methods, both of which have their
own flaws and advantages. Both assays make reliable and reproducible measurements
of the Kd value. Both methods have good agreement with each other’s data and have
confirmed an n=1 stoichiometry for NCp7-SL3 binding, which is shown in the complexes
used in previous NMR study [57].

The Trp titration assay is robust, sensitive and straightforward. It also doesn’t require
large amount of sample. But the Trp titration assay requires that the protein has
intrinsic fluorescence and the fluorescent residue has to be directly involved in the
binding site, which limit the application of this assay for other proteins and one NCp7
mutant of great interest, W37A. Also because Trp titration measures the fluorescence
signal of protein, it can distinguish complexes with R1P1 (complexes consist of one
molecule of RNA and one molecule of protein) from R1P2 (complexes consist of one
molecule of RNA and two molecule of protein), R1P3, etc., but not R1P1 from R2P1, R3P1,
etc. (See Athavale et al., 2010 [124]).

ITC can distinguish those different stoichiometries of complexes, because it measures
the heat change of the binding reaction, which is independent from species and optical
characteristics. The nature of ITC assay makes it a universal and direct method for
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measuring parameters in a binding reaction. But ITC experiments require a much larger
amount of sample and much longer time to finish than Trp titrations. And ITC
experiments are more susceptible to background noises, thus more difficult to be
optimized with the experimental conditions. The data analysis of ITC is also trickier than
Trp titration. Different titration mode can affect fitted data as mentioned earlier. There
are also more variables that cannot be fixed when fitting ITC data, such as the binding
stoichiometry n. This can produce more accurate fit of data but on the other hand also
makes the fitted data more difficult to interpret.

3.6. Suggestions for future work

The discoveries in this study shed light on some promising projects for future work.
Since ITC has been confirmed as a good alternative assay for measuring Kd value of
NCp7-SL3 interactions, the mutant W37A, which was not able to be measured by the
Trp titration assay, can now be subjected to ITC assay. One would expect to see K d
changes in W37A similar to the level of F16A, if not greater, given its key position in the
binding site and direct involvement in the binding as demonstrated in the Trp titration
assays.

There are other interesting mutants that can be constructed and subjected to either Trp
titration or ITC assay. These include G43A, for its similar position in F2 finger as Gly22 in
F1 finger; K14A, K33A, K38A, E42A, E51A and combinations of these mutations, to
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further investigate the stabilizing effect of salt bridges for the zinc finger structures;
F16W, W37F and F16W-W37F, to investigate the involvement of Phe16 and Trp37 in the
interaction between NCp7 and SL3.

Some interesting mutants such as N5A and F16A should also be studied with NMR.
Solving the structures of these mutant proteins in complex with SL3 RNA can lead to
better understanding of the mechanism underlying the NCp7-SL3 recognition and
interactions and further decipher the roles of NCp7 in HIV-1 biology.

Mutants with moderate to significant Kd changes, such as F16A, I24A and K14E-E21K,
should be further studied by functional assays such as viral infectivity assay in human
cell lines to determine the relationship of the affinity for SL3 RNA and the viability of
mutant viruses.

The findings of this project will also benefit drug screening for anti-HIV drugs or
aptamers. Prior work done by Dr. Chris DeCiantis has identified about 20 drug leads
from over 2000 compounds in the NCI diversity set [192]. Because the similarity of F16A
and NCp7 WT in sequence and basicity, we can use F16A to eliminate the non-specific
hits from those drug leads or from an aptamer library.
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Table 3-1. Trp titration results of NCp7 wild type and mutant proteins

#

Mutant
Name

KdTrp (nM)
Avg.

SD

SD%

Fa

mb

1

WT

29

± 4.5

± 15%

1.0

8

2

N5A

29

± 5.6

± 19%

1.0

5

3

F6A

33

± 3.3

± 10%

1.1

3

4

V13A

31

± 6.9

± 22%

1.1

3

5

F16A

720

± 26

± 4%

25

3

6

N17A

32

± 1.4

± 4%

1.1

3

7

G19A

45

± 2.6

± 6%

1.5

3

8

E21A

8.6

± 2.3

± 26%

0.3

3

9

G22A

45

± 6.7

± 15%

1.6

3

10

I24A

170

± 29

± 17%

5.8

5

11

P31A

23

± 5.8

± 25%

0.8

3

12

G40A

33

± 6.5

± 20%

1.1

3

13

Q45A

73

± 14

± 20%

2.5

4

14

M46A

62

± 10

± 16%

2.1

3

15

K14E-E21K

140

± 5.1

± 4%

4.8

7

16

K33E-E42K

40

± 11

± 27%

1.4

3

17

K38E-E51K

33

± 5.1

± 15%

1.1

3

a.

F is the change factor for the Kd of a mutant NC compared with that of wild type
NC. F = (Kd of mutant)/(Kd of WT).

b.

m is the number of measurements.
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Table 3-2. ITC titration results of NCp7 wild type and mutant proteins
Mutant
Name

#

Kd

ITC

30°C

RT

a

(nM)

Nb

ΔH (kcal/mol)
mc

SD

SD%

F

Avg.

SD

Avg.

SD

1

WT

69

42

± 5.0

± 12%

1.0

1.1

± 0.034

-11E+03

± 600

4

2

N5A

124

80

± 26

± 33%

1.9

1.1

± 0.082

-9.8E+03

± 1500

4

3

F6A

97

58

± 23

± 40%

1.4

0.87

± 0.041

-12E+03

± 690

3

4

F16A

1790

1200

± 540

± 45%

28

1.4

± 0.13

-9.0E+03

± 2500

3

5

I24A

483

310

± 130

± 42%

7.3

1.4

± 0.18

-9.0E+03

± 910

4

6

P31A

81

46

± 5.6

± 12%

1.1

1.1

± 0.044

-13E+03

± 320

3

7

Q45A

177

120

± 12

± 10%

2.8

1.2

± 0.087

-8.2E+03

± 360

3

8

K14E-E21K

195

150

± 14

± 9%

3.5

0.79

± 0.021

-6.3E+03

± 430

3

9

K33E-E42K

75

43

± 4.1

± 9%

1.0

1.1

± 0.049

-12E+03

± 1100

3

a.

Kd values measured at 30°C were converted to equivalents at room temperature
(22°C) using van‘t Hoff equation. The Kd values at 22°C are rounded to two
significant digits.

b.

N is the average number of binding sites determined by ITC.

c.

m is the number of measurements.
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Figure 3-1. Schematic representation of isothermal titration calorimetry (ITC)
Major features of ITC instrument such as the reference and sample cells, sample
injection syringe and the adiabatic shield are noted in the figure. This schematic diagram
shows how the power applied by the instrument to maintain constant temperature
between the reference and sample cells is measured resulting in the instrument signal.
Reprinted from Methods in Cell Biology, vol. 84, Freyer MW & Lewis EA, Pages 79-113,
Copyright 2008 [182], with permission from Elsevier.

- 83 -

Figure 3-2. HPLC chromatogram of SL3 RNA
SL3 RNA sample purchased from IDT was run on an ion-exchange column on Agilent
1200 HPLC system. UV absorption signal was monitored and recorded at 260nm.
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Figure 3-3. Tryptophan fluorescence titration curves of NCp7 wild type and mutant
proteins with SL3 RNA
Compilation of tryptophan fluorescence titration curves of NCp7 wild type and mutant
proteins with SL3 RNA. Only 7 sample curves are shown for clear presentation. Molar
ratio of total RNA to total protein, Rt/Pt, increases from left to right. Colored curves are
fitted curves using the data points of the same color coding. Data point sets are as
following: green square, NCp7 wild type; pink circle, N5A; red triangle, F16A; blue
triangle, E21A; brown diamond, I24A; orange triangle, Q45A; teal circle, K14E-E21K. The
black line is the trend line for a 1:1 complex with an infinite binding constant (Kd-1). See
all calculated Kd values in table 3-1.
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Figure 3-4. The effect of site-directed mutagenesis on the Kd values of NCp7 mutant
proteins for SL3 RNA
Kd values of NCp7 mutants for SL3 RNA calculated from the tryptophan titration data
were taken from table 3-1 and shown in the above bar chart as change relative to the Kd
value of wild type NCp7. Y axis is the change factor F. F = (Kd of mutant)/(Kd of WT). The
three mutants with highest Kd values are: F16A, I24A and K14E-E21K.
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Figure 3-5. Comparison of the Trp Titration and ITC Data
Kd values of NCp7 mutants for SL3 RNA calculated from the tryptophan titration data
(orange bar) and ITC data (blue bar) were taken from table 3-1 and 3-2 and shown in the
above bar chart as change relative to the Kd value of wild type NCp7. Y axis is the change
factor F. F = (Kd of mutant)/(Kd of WT).
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Figure 3-6. Representative ITC titration curves of NCp7 WT and mutant proteins
Note that the vertical axis scales are not constant.
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Figure 3-7. Comparison of the changes in NCp7 protein’s affinity for SL3 RNA by
alanine mutations on different residues
The highly conserved residues are shown in larger fonts and the residues in smaller
fonts are more tolerant to variations. The red solid letters indicate residues with RNAProtein steric contact. Black solid letters indicate residues with protein to protein steric
contact. The red hollow letters are the residues with both protein-to-protein and RNAto-protein steric contacts. The black hollow letters are the ones with no steric contacts
at all. The green boxes mark the salt bridge switch mutants. The blue ovals indicate
alanine scanning mutants. Yellow background is used to highlight the mutants with
moderate to significant change in affinity, with the Kd change factor (F) shown next to
the residue(s) (See Table 3-1).
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Figure 3-8. Tryptophan fluorescence titration curve of K14E-E21K for SL3 RNA
K14E-E21K titrated with SL3 RNA. The fitted titration curve does not provide a good fit
for the data points, indicating a different binding model might play a role in K14E-E21K’s
binding with SL3 RNA.
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Figure 3-9. Positions of the three salt bridges in NC-SL3 complex

White ribbon: SL3 RNA; Colored ribbon: NCp7 protein; Stick model: side chain atoms of
Lys14, Glu21, Lys33, Lys38, Glu42 and Glu51; Surface model: NCp7 protein; Magenta: Nterminal 3-10 helix of NCp7; Yellow: N-terminal zinc finger (F1); Cyan: linker region; Red:
C-terminal zinc finger (F2). Surface is shown in 60% transparency. Drawn from PDB ID
1A1T using the UCSF Chimera package from the Resource for Biocomputing,
Visualization, and Informatics at the University of California, San Francisco (supported
by NIH P41 RR001081) [150].
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Part II. Methods Development for
Aptamer Discovery

Chapter 4. Introduction
For decades after the elucidation of the genetic code [193] and the articulation of the
central dogma of molecular biology [194], nucleic acids had been envisioned mainly as
carriers of genetic information through their sequences. Nonetheless, extensive studies
on the relationship between the structure and function of nucleic acids had indicated
that the structure of nucleic acids is equally, if not more, important than their sequence.
The stem-loop structure has been shown to be critical for the recognition of HIV-1
packaging signal by NCp7 [145]. Single stranded nucleic acids can carry out various
biological functions such as enzymatic activities and specific target binding [195-198].
The secondary and tertiary structure of a DNA or RNA molecule can be affected by the
sequence of the molecule, by the ionic strength of the buffer or by the ligand bound to
it. Because of the vast diversity in the secondary and tertiary structure of nucleic acids,
researchers have begun to explore a new application of nucleic acids as, other than the
genetic material, affinity ligands.

4.1. Aptamers
Aptamers (termed from the Latin aptus, meaning “to fit” [199]) are synthetic RNA or
ssDNA molecules with stable three-dimensional structures and high affinity and
specificity for certain target molecules. Since first described in 1990 [199, 200],
aptamers have been developed over the past two decades to be a powerful tool for
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drug discovery, biosensors, diagnosis and therapy [201-219]. They are now widely used
in place of antibodies, especially in diagnostic applications [220].

Aptamers can be composed of naturally occurring nucleotide bases or chemically
synthesized or modified derivatives. By incorporation of unnatural nucleotides or postselection modifications, aptamer molecules can withstand hydrolysis or enzymatic
degradation. The length of aptamers ranges from 15 nt to about 100 nt long. After
modification, the size of aptamer molecules can range from 6kDa to 40kDa, most
commonly be seen around 10kDa [220]. Because of the small size of aptamers, they
usually penetrate or diffuse in biological tissues better than antibodies do. There also
has been no evidence of aptamers’ immunogenicity [221].

Aptamers usually have well-defined three-dimensional structures, especially when
complexed with target molecules. Their structures result from a combination of WatsonCrick and non-canonical interactions. Common structural motifs seen in aptamers
include G-quartets [222], non-canonical base pairs, in particular, purine-purine base
pairs like G-G base pairs [223], and the GNRA tetra-loop (N is any nucleotide and R is a
purine) [224, 225]. RNA aptamers usually can adopt a greater variety of complex tertiary
structures than DNA aptamers can. This is because RNA molecules are more lenient in
allowing non-Watson-Crick base pairs and have great rotational freedom in the
backbone of their non-base-paired regions[226]. In addition, the 2’-hydroxyl groups on
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the riboses of RNA molecules are potential hydrogen bond donors in intermolecular
interactions [227].

The affinity of aptamers for their targets can vary a lot from target to target. They
usually have affinities for small molecules in the micro-molar range, nano-molar level
affinities for nucleic acid binding molecules and affinities in the nano-molar to subnanomolar range for proteins. Targets that have high affinity aptamers also tend to have
measurable non-specific affinity for nucleic acids [220].

Nonetheless, aptamers can show significant specificity for their target molecules.
Aptamers can distinguish different enzymes with similar activity, enantiomers of small
molecules or minor sequence variants of macromolecules with several orders of
magnitude difference in Kd values between the two similar species of molecules being
distinguished by the aptamers. The targets of aptamers can be as small as metal ions or
as big as large glycoproteins. The targets of aptamers are also chemically diverse,
including organic dyes, neutral disaccharides, aminoglycoside antibiotics, dopamine, etc.
[220].

To sum it up, aptamers are interesting because they are:

1) Synthetic molecules. The manufacturing cost of aptamers therefore is
considerably lower than that of antibodies, which requires much longer time and
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much more expensive animals to produce the desired antibodies. They are also
easy to make, modify and label.
2) Structurally diverse and stable. The diverse structure allows for selection of
aptamers for a large variety of target molecules, making aptamers good
candidates in a wide range of applications. Assisted with unnatural nucleotides
and chemical modifications, aptamers can have a much longer shelf life than
antibodies.
3) Ligands with high affinity and specificity for their targets. Comparable affinities
and specificities as antibodies make aptamers good substitutes for antibodies.
Low immunogenicity and smaller size also make them attractive as therapeutic
agents.

4.2. SELEX

Aptamers are usually selected from a large pool of random DNA or RNA sequences by an
iterative in vitro process termed SELEX (systematic evolution of ligands by exponential
enrichment) [200]. The name “SELEX” was coined two decades ago, but the history of in
vitro selection for RNA ligands goes back much further.

In 1974, Sol Spiegelman and his colleagues reported an in vitro evolutionary method to
select an RNA ligand that has specificity for Qβ phage RNA polymerase [228]. This
experiment and other work by Spiegelman and his co-workers are considered as
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pioneering work to SELEX and aptamer science[197]. These experiments and SELEX
share the same rationale. These methods consisted of rounds of replication and
selection procedures and enabled selection of specific RNA ligands from a random pool
of RNA sequences, which is in essence an in vitro Darwinian evolutionary process.

A schematic representation of SELEX procedure is shown in Figure 4-1 [229]. SELEX is a
cyclic combinatorial procedure. Each round of SELEX involves three major steps:

1. Binding. Target molecules are added to and incubated with a pool of DNA/RNA
sequences which have a completely random sequence region with flanking
defined primer binding sites required in the following PCR amplification. The
starting DNA/RNA pool usually contains 1013 - 1015 molecules and each one is a
unique sequence. By mixing this DNA/RNA library with target molecules,
potential aptamer molecules will bind tightly to the target molecules, while most
sequences will remain unbound or loosely bound to the target molecules.
2. Partitioning. In this step, the bound and unbound species of DNA/RNA sequences
are partitioned to remove the sequences with no or low affinities for the target.
This is a critical step in the SELEX procedure. Partitioning can be achieved by
affinity chromatography, magnetic beads, electrophoresis or microfluidics. After
partitioning, most unbound or loosely bound DNA/RNA sequences will be
washed off the target molecules and removed from the library.
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3. Regeneration by amplification. The bound DNA/RNA molecules are eluted off the
target molecules and used as PCR template to amplify and regenerate a new
library which contains only the surviving members of the original library. But
each sequence remaining in the new library now has multiple copies. This newly
generated library is then used as starting library for the next round of SELEX.

A single round of selection is not sufficient to recover a tight binding aptamer sequence
from a large random pool. Usually it takes multiple (10 to 15) rounds of SELEX runs
before a successful aptamer sequence is enriched to the extent that it accounts for a
significant portion of the final DNA/RNA library. At that point, a small number (1-100) of
survivors will be cloned and sequenced to identify the potential aptamer sequence.

SELEX has its advantages. It is an in vitro process, which makes it easy for optimization
and manipulation. The complexity of the starting pool is much greater than other
combinatorial methods. And the selection does not require any prior knowledge about
the structure of the target or the library.

However, SELEX also has its limitations. The multiple cycles of amplification and
partitioning could make SELEX time consuming, labor intensive and require substantial
amounts of purified target. A typical SELEX process may take several weeks before an
aptamer sequence is identified. Repetitive PCR amplifications tend to produce a higher
background in identifying the final aptamer sequences, making it difficult to tell a tight
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binding aptamer from sequences with moderate affinities. More importantly, PCR
amplifications might produce cycling artifacts, in which case some sequences are
favored because they are easier to amplify, not because they have higher affinity for the
target molecules.

4.3. Acyclic identification of aptamers

Many of the limitations of SELEX are intrinsic to repetitive cycling. To overcome these
limitations, our lab proposed and validated a method for acyclic identification of
aptamers (AIA) [230]. A schematic comparison between SELEX and AIA is shown in
Figure 4-2 (McPike, M.P., 2011 [231]). This method eliminates the need for cycling by
utilizing guided library design and the large sequencing capacity of next generation
sequencing (NGS) technology. The overall screening time for AIA is shortened to less
than a week compared with several weeks for SELEX. One successful AIA run can turn
out millions of sequences while SELEX usually produces less than 100 sequences each
time.

A typical AIA procedure includes the following steps:

1. Binding. Similar to SELEX, a random library of 1014 molecules is used to incubate
with the target molecules in this step. The key difference is the design of the
library. Even though an AIA library can contain a number of molecules similar to
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SELEX libraries, the variable region of the AIA library is usually shorter (22nt or
less) than that of SELEX libraries (often 40nt or more). This design ensures that
the complexity of AIA library is lower than that of SELEX library so that each
unique sequence in the AIA library is represented multiple times in the library.
This kind of over-representation is essential for the acyclic selection to be able to
obtain a meaningful signal-to-noise ratio in the final sequencing results.
2. Partitioning. This step is basically the same as the partitioning step in SELEX,
where unbound and loosely bound sequences are separated from the tight
binding sequences and removed from the library by stringent washing.
3. Sequencing and counting. After elution from the target, the tightly bound
molecules are directly subjected to sequencing without going through iterative
steps of amplification and partitioning. The partitioned library is linked to two
universal adapters and sequenced on a next generation sequencer such as an
Illumina GAII sequencer. The final sequences are analyzed using a Perl script and
the good reads (sequences with intact flanking sequences) are counted. The
count number of each sequence should be proportional to its affinity for the
target molecules. So the sequence with highest count number is also in theory
the sequence with highest affinity for the target.

As described so far, AIA overcomes the main bottleneck in SELEX by eliminating cyclic
enrichment. But it has its own limitation of low complexity in the library. However, for
libraries with high complexity and low representation, a pre-selection step can be added
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before the AIA procedure to increase the sample representation level to a suitable level
for AIA experiments [232]. Twenty years of research on SELEX can also be used to guide
the design of AIA libraries to focus on regions of sequence and fold-space that are
especially productive for aptamer discovery. AIA can be used to further refine the
structure and sequence of aptamers selected using SELEX.

AIA also has great multiplexing potential. Multiplexing is limited with SELEX because an
especially high affinity aptamer for one target can take over the evolving pool. While in
AIA, multiple targets can be screened in parallel and aptamers with different level of
affinities can be selected at the same time because the aptamers with lower affinity are
not suppressed by evolutional selection.

4.4. Next-generation sequencing (NGS) technologies

The success of AIA relies in large part on the commercial realization of next generation
sequencing (NGS) technologies. Ever since next-generation sequencing instruments
became commercially available in 2004, these fast-paced technologies have already
made a significant impact in many fields of biological sciences, such as genome-wide
association studies, transcriptome analysis, synthetic biology and systems biology.

Next-generation sequencing technologies generate fragment libraries by ligating
platform-specific linkers to DNA fragments, amplify single strands of this library and
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perform sequencing reactions on amplified strands. Next-generation sequencing
technologies are highly streamlined, high throughput and high yield. Each NGS run can
generate from several hundred thousand to tens of millions of reads [233].

Most imaging equipment used in modern sequencing systems cannot detect single
fluorescent events, therefore in many cases templates need to be amplified before they
can be sequenced. Based on the strategies used for template preparation, current
commercially available NGS technologies can be divided into two major categories,
which I’ll briefly describe below [234]:

4.4.1. Bridge amplification based NGS technology (Illumina)

Illumina (San Diego, CA) is currently the market leader and the most widely used
platform in the NGS industry. The Illumina technology generates DNA clusters by bridge
amplification as shown in figure 4-3-a (adapted from Metzker, M.L. 2010) [234]. Each
cluster contains thousands of copies of one single DNA fragment, ensuring sufficient
signal intensity for detection during sequencing. There are 8 lanes on an Illumina sample
slide. Each lane can produce 10-40 million sample reads. The clusters are sequenced
using the sequence-by-synthesis approach.

4.4.2. Emulsion PCR based NGS technology (454/SOLiD/Polonator)
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Emulsion PCR is commonly used for preparing sequencing templates in several types of
NGS technologies (Roche/454, Life/APG (SOLiD) and Polonator). Emulsion PCR was
originally designed to analyze rare gene mutations in a large pool of gene templates
[235, 236]. In emulsion PCR, each emulsion droplet contains only one template, as
shown in figure 4-3-b (adapted from Metzker, M.L. 2010) [234]. After amplification,
each droplet contains thousands of copies of the single starting template sequence.
Thus high signal to noise ratio can be achieved. Millions of droplets can be formed in
one emulsion and make high throughput screening possible. The homogeneity and
multiplexing nature of emulsion PCR makes it an ideal method for aptamer screening.
The amplified sequences on the emulsion beads are sequenced using either the
sequence-by-ligation or pyrosequencing approach, depending on the platform of choice.

4.5. Potential of NGS in aptamer discovery

A typical sequencing run on an Illumina GAII sequencer can generate over 100 million
sample reads per slide and similar output can be expected from an ABI SOLiD sequencer.
We prefer to get 5-15 million reads from each partitioned AIA library sample. This huge
difference between the sequencing capability and the multitude of sample necessitates
multiplexing of samples.

Besides multiplexing of samples, there’s another way that we can utilize the full capacity
of next generation sequencing technology. I call it the sequence-and-screen approach.
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Compared to this approach, the traditional SELEX and AIA method can both be
attributed as screen-and-sequence approaches. In screen-and-sequence approaches,
the initial library is partitioned by incubating with target molecules, the partitioned
library is subjected to sequencing and the resulting sequences are aligned and counted
to generate the final aptamer candidate sequences. Whereas in sequence-and-screen
approaches, the initial library is directly subjected to next generation sequencing to get
the full coverage of every possible sequence in the library. The sequenced library should
have formed small clusters of single sequences on the slide that was used in earlier
sequencing. We propose that these clusters can be detected and screened by ds-DNA
binding fluorescent dyes, fluorescently labeled complementary DNA probes or
fluorescently labeled targets to generate hits in the clusters. The sequence of those hit
clusters would then be tracked and pulled out of the sequence file and tested for
affinities and specificities for the probes used.

The advantages of sequence-and-screen approach are as below:

1. There is no partitioning step, which could save time and resources.
2. Target molecules are not immobilized on the slide except by binding to
aptamers, which are attached to the surface. This might be beneficial for the
target to retain its natural structure or activity.
3. Multiplexing of target molecules is easy and convenient, parallel or subsequent
screening is possible.
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4. The library will get full coverage after screening. Effect of PCR artifacts would be
minimal.

4.6. Specific aims

When the idea of the sequence-and-screen approach was first brought up by Dr. Mark
McPike and I around 2007, next-generation sequencing technologies and instruments
were much more expensive than they are as of today. Without easy access to a high
capacity next-generation sequencer, we decided to create our own prototype sequenceand-screen platform based on known principles of commercialized next generation
sequencers at that time. What we were trying to accomplish are listed as below:

A. Establish prototype sample preparation platforms similar in principle as
commercialized next-generation sequencers.
B. Develop sensitive and efficient detection and screening methods on the
established prototype platforms.
C. Develop multiplexed screening protocols using the above-mentioned platforms
and methods.
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Figure 4-1. Schematic SELEX (Systematic Evolution of Ligands by Exponential
Enrichment) procedure
Adapted from http://www.molgen.mpg.de/~nabt/background.html [229]. See
description in text.
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AIA

Figure 4-2. Comparison of SELEX and AIA
Reproduced from McPike, M.P. 2011 [231] with permission. See description in text.
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Figure 4-3. Template preparation strategies in NGS
Adapted by permission from Macmillan Publishers Ltd: Nature Review Genetics [234], copyright 2010. See description in text.

- 108 -

Chapter 5. Experimental Design and
Preliminary Data
5.1. Experimental design

At the time these preliminary experiments began, our lab was planning to purchase a
high-throughput DNA sequencer. Under consideration were the Illumina/Solexa GAIIx
(using bridge amplification) and the Life Technologies (formerly Applied Biosystems)
SOLiD or Dover Systems Polonator(both the SOLiD and Polonator use emulsion PCR for
amplification). We decided to investigate strategies to utilize both bridge amplification
and emulsion PCR for aptamer discovery.

In 1992, Bock et al. reported a 15-nt long DNA sequence (5′-GGTTGGTGTGGTTGG-3′) for
human alpha thrombin, which was later named thrombin binding aptamer (TBA) [201].
Thrombin has high affinity for TBA (Kd ≈ 100 nM) but not for a similar sequence (5′GGTGGTTGTTGTGGT-3′) (TBA scrambled, or TBA-S) (Kd > 1 µM) [237]. Because of this
distinction, TBA and TBA scrambled sequences have often been used with thrombin as a
model system in aptamer application development experiments to examine the validity
and efficiency of the applications being developed [238-240]. In this project, I also chose
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to use TBA and TBA scrambled sequences with thrombin in a set of proof-of-concept
experiments for the proved robustness and convenience of this model system.

5.1.1. Bridge amplification

In this proof-of-concept experiment, I tried to create DNA clusters consisting of either
positive control sequence (TBA sequence) or negative control sequence (TBA scrambled
sequence) by bridge amplification on a glass slide, as depicted in figure 5-1. A lawn of a
universal primer is attached onto a glass slide by tight binding between the streptavidin
coating on the slide and the dual biotin label on the 5’-end of the primer. Also attached
onto the slide is a template sequence with a stem-loop structure. The stem region of the
template contains an identical sequence to the universal primer and its complementary
sequence. The loop region contains the target sequence, in this case, either TBA or TBA
scrambled sequence. Sequences and secondary structures of the two templates are
shown in figures 5-2 and 5-3. The template sequences are attached to the slide in a
small ratio to the primer sequences. Then bridge amplification reaction is carried out on
the surface of the slide. If the amplification is successful, clusters containing the target
sequence and its complimentary sequence should be formed on a background of the
primer lawn, which would look like bacteria colonies on a LB-plate. These colonies could
be detected by different probes such as DNA stain, labeled complementary DNA probe
or labeled protein affinity ligand, as represented in figure 5-4.
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5.1.2. Emulsion PCR

At the beginning of emulsion PCR, each emulsion bead is in an isolated compartment
containing no more than one copy of the starting template sequence. Therefore each
amplified bead should be equivalent to a DNA cluster containing a single DNA sequence
and its complementary sequence. These beads are magnetic and can be harvested using
a magnetic separator. The harvested beads are attached onto a glass slide and then
subjected to detection and screening.

To successfully attach the emulsion PCR beads onto the glass slide, a capping oligo and a
bridging oligo sequence are adopted according to the Polonator chemistry which is also
based on emulsion PCR [241]. The capping oligo has 5’-phosphate and 3’-amine
modification. The bridging oligo is partly complementary to the 3’-end of amplified
sequence and partly complementary to the capping oligo. The capping oligo is ligated by
T4 DNA ligase onto the 3’-end of the amplified sequences on emulsion PCR beads via
splinted ligation guided by the bridging oligo [242]. Two set of capping oligos and
bridging oligos were used to attach both control beads and sample beads onto the slide.
The processed beads are then covalently attached onto a glass slide pretreated with
aminosilane. A schematic setup for emulsion PCR process is shown in figure 5-5.
Uniformly dispersed beads containing the successfully amplified sequences can then be
detected and screened in a similar manner as shown in figure 5-4.
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5.2. Methods and Materials

Primers and templates. The primers and templates used in this study are listed in table
5-1. All oligos were purchased from Integrated DNA Technologies, Inc. (Coralville, IA) in
desalted form and used without further purification.

5.2.1. Methods for bridge amplification based detection

Sample coating. Dissolve biotinylated primer and template oligos in Micro Spotting
Solution Plus (ArrayIt, Sunnyvale, CA) at designed final concentration. Mix the primer
and template oligos in designed ratio. Attach a 25-µl frame-seal incubation chamber
(Bio-Rad) onto a SuperStreptavidin Substrates slide (ArrayIt, Sunnyvale, CA). Spot mixed
DNA samples inside the chamber using a micropipette. Hybridize the sample at room
temperature for 30 minutes.

Slide Blocking. Block the slide with 25 µl SuperStreptavidin blocking buffer (ArrayIt,
Sunnyvale, CA). Incubate the slide at room temperature for 1 hour. Wash the slide twice
in 1x PBST (NaCl 8g/L, KCl 0.2g/L, Na2HPO4 1.44g/L, KH2PO4 0.24g/L, Tween-20 0.05%,
MgCl2 5mM, pH 7.4) for 5 minutes each. Spin dry the slide.

Bridge Amplification. Prepare PCR mix 25ul: Turbo Pfu 2ul (2.5U/µl), dNTP 0.25mM
each, 1x Pfu buffer. Fill the chamber with the PCR mix. Seal the chamber with a plastic
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cover slip. Run PCR in DNA Engine Dyad Thermocycler or Thermo PX2 Thermocycler. PCR
cycles were set up as the following: 92°C, 1 minute; (92°C, 30 seconds; 55°C, 30 seconds;
72°C, 30 seconds) x 40 cycles; 72°C, 1 minute; 4°C hold.

Sample staining. After amplification, remove the cover slip and rinse the slide twice with
1X PBST for 5 minutes each time. Stain the slide with 20 µl of Sybr555 DNA stain
(Invitrogen) in 27ml of 1X PBST at room temperature for 5 minutes. Wash the slide twice
with 1X PBST for 5 minutes each time. Spin dry the slide (optional).

Imaging. Stained slides were scanned in a GenePix 4400A microarray scanner (Axon™
Instruments, Union City, CA, USA). Images were taken using GENEPIX PRO 5.0 software
(Axon).

5.2.2. Methods for emulsion PCR based detection

Bead loading. Re-suspend Dynabeads MyOne streptavidin C1 beads (10mg/ml) in stock
vial by vortexing. Take 100 µl of suspended beads and transfer into a 1.5 ml eppendorf
microcentrifuge tube. Add 100 µl of Bind and Wash buffer (5mM Tris-HCl, 0.5mM EDTA,
1.0M NaCl, pH 7.5). Mix by vortexing and remove all liquid on a magnetic particle
concentrator (Dynal MPC-S magnet). Wash 2 more times in 200 µl Bind and Wash
buffer, and re-suspend in 198 µl Bind and Wash buffer. Add 2 µl of 1mM forward primer
with 5’ dual-biotin label. Mix well by pipetting and incubate the mixture at room
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temperature on a Dynabeads rotary mixer for 20 minutes. Remove all liquid, and wash
twice in 200 µl of Bind and Wash buffer, then once in 200 µl of 1X TE (10mM Tris-HCl, 1
mM EDTA, pH 8.0). Remove all liquid and re-suspend beads in 200 µl of 1X TE. These
beads should now be around 5x10^9 beads/ml.

Emulsion PCR. Prepare the aqueous and oil phase according to the protocols established
by Church lab at Harvard [241, 243] (also described in Appendix D-3), scale up or down
when necessary. Mix oil and aqueous phase, vortex well for 5 minutes, distribute into
PCR tubes or 96-well plate for approximately 50 µl per tube/well. PCR amplify for 120
cycles.

Breaking emulsion. Add 100 µl isopropanol to each tube or well containing the amplified
PCR mixture, mix well by pipetting. Pool the mixture into a 15 ml polypropylene falcon
tube, vortex for 1 minute. Spin down the beads for 30 seconds at 4000 rpm. Remove
supernatant by decanting. Add 2 ml isopropanol and re-suspend the pellet by pipetting.
Add 1 ml of isopropanol, vortex for 30 seconds. Spin down the beads for 30 seconds at
4000 rpm. Remove supernatant as much as possible. Re-suspend the pellet in 3 ml of
NXS (10mM Tris pH 7.5, 1mM EDTA pH 8.0, 100mM NaCl, 1% (v/v) Triton X-100, 1%
(w/v) SDS) and mix well by vortexing. Split the suspension into two 1.5ml siliconized
microcentrifuge tubes, spin down the beads for 30 seconds at 3000 rpm. Remove the
supernatant on a magnet. Wash the pellet in 1 ml of NXS once and then in 1 ml of 1X TE
twice. Re-suspend the beads in 500 µL 0.1 M NaOH. Incubate the suspension at room
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temperature on a Dynabeads rotary mixer for 5 minutes. Wash the beads once with 500
µl of 0.1 M NaOH, then twice with 500 µl of 1X TE. Re-suspend and combine the beads
in 30 µl of 1X TE.

Bead capping. Prepare the hybridization mixture by adding 1.8 µl 1mM bridging oligo 1
and 1.8 µl 1mM bridging oligo 2 into 90 µl 6X SSPE with 0.01% Triton X-100. Re-suspend
amplified emulsion PCR beads in this solution and mix well by vortexing. Incubate the
mixture at 56°C for 10 minutes. Mix well again and then incubate the mixture at room
temperature on a Dynabeads rotary mixer for 10 more minutes. Wash the beads twice
with 200 µl of 1X TE. Prepare ligation mix by mixing the following: 84 µl dH2O; 10 µl 10x
T4 Ligase Buffer; 2 µl 1mM Capping oligo 1; 2 µl 1mM Capping oligo 2; 2 µl T4 DNA ligase
(3U/µl). Remove all liquid from beads and re-suspend them in the ligation mix solution.
Incubate the mixture at room temperature on a Dynabeads rotary mixer for 1 hour.
Remove ligation mixture solution on a magnet. Wash beads once with 200 µl of 1X TE,
once with 200 µl of NX (10mM Tris pH 7.5, 1mM EDTA pH 8.0, 100mM NaCl, 1% (v/v)
Triton X-100), then twice with 200 µl of 1X TE. Transfer the beads to a new tube, wash
once with 200 µl of 1X TE, then re-suspend the beads in 30 µl of 1X TE.

Aminosilane treatment of glass slide. Load slides (Erie Scientific, Portsmouth, New
Hampshire) into a glass rack. Wash the slides by immersing the loaded rack in solution
of 0.5% Triton X-100 in dH2O and manually agitating the rack for ~1 minute. Drain all the
liquid and wash slides thoroughly under running water to remove all detergent, then
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rinse slides with dH2O. Drain all the liquid and rinse the slides in 100% EtOH, then let air
dry. Use glass pipettes to prepare 2% aminopropyl triethoxysilane (Pierce) solution in
dry acetone in a glass beaker. Immerse the rack with completely dry (and ethanol-free)
slides in the silane solution for 30 seconds. Manually agitate the rack. Remove and
immediately immerse in fresh dry acetone, rinse for 1 minute. Remove rack and blowdry partially with compressed air (to remove the bulk of the acetone). Let the slides
completely air dry and store them under vacuum at room temperature.

Bead attachment. Wash beads three times in 50 µl 1x PBS (NaCl 8g/L, KCl 0.2g/L,
Na2HPO4 1.44g/L, KH2PO4 0.24g/L, pH 7.4). Quickly re-suspend beads in 35 µl fresh BS3
(Bis(Sulfosuccinimidyl) suberate) solution in 1x PBS (2.86 mg BS3 in 1 ml 1x PBS). Add
the beads onto the aminosilane treated center circle on a Teflon coated glass slide,
apply the cover slip. Incubate the slide at room temperature for 1 hour. Wash the slide
twice with 1x TE for 5 minutes each time to remove any unattached beads.

Staining the beads. Add 35 µl of 6x SSPE (0.9M NaCl, 60mM NaH2PO4, 60mM EDTA, pH
7.4) with 0.01% Triton X-100 to each circle, cover with a cover slip. Incubate at 56°C for
10 minutes. Wash immediately with 1x TE twice for 2 minutes on labquake. Add 35 µl of
6.7 µM 6-FAM labeled probe dissolved in 6x SSPE w/ 0.01% Triton X-100 to each slide,
cover with a cover slip. Incubate at 56°C for 2 minutes, then 40°C for 10 minutes and
25°C for 10 minutes. Wash twice with 1x TE for 5minutes each time on a labquake. Spin
dry the slide. Add 25ul 1x self seal reagent (Bio-Rad) in 1X TE, cover with a cover slip. In
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the case of thrombin staining, stain the slide overnight at room temperature using Cy3
or Cy5 labeled thrombin in 1X PBST (thrombin concentration 500nM). Keep the slide
covered throughout the staining procedure. Wash the stained slide with 1X PBST twice
and twice with 1X PBS for 10 minutes each time. Add 25 µl of 1x self-seal reagent in 1X
PBS, cover with a cover slip.

Visualization. Stained slides were visualized using epifluorescence microscopy on a
Nikon TE2000 microscope (Nikon, Tokyo, Japan) equipped with a CCD camera, a 100X,
1.4 numerical aperture objective and standard FITC-Texas Red dichroic filter sets. Snap
images were taken by the CCD camera using SPOT software (Diagnostic Instruments,
Sterling Heights, MI), in both bright field mode and fluorescence mode. Bright field
images and the fluorescent images were superimposed using Adobe Photoshop
software.

5.3. Preliminary Results

5.3.1. Bridge amplification

Figure 5-6 shows the preliminary result from bridge amplification approach. 0.5 µM
template (TBA 55mer) was spotted on the slide as a positive control. The initial sample
spotting solution contained 0.5 µM primer (BA primer) and 0.01 pM template (TBA
55mer). The negative control spotting solution contained 0.5 µM primer (BA primer) and
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1 pM template (TBA 55mer) but no polymerase was added in the PCR mix for negative
control. The slides were subjected to bridge amplification and subsequent staining with
Sybr555 DNA stain.

Both positive control and sample spots were stained by Sybr555. Negative control spots
weren’t visible. Sample spots were much brighter than the positive control spots. This
could be considered as a sign of successful amplification. But the bridge amplification
slides suffered from uneven staining and high background problems. The staining results
were not consistent and at times the staining results for controls and samples were not
distinguishable. I also tried staining with Cy5-labeled thrombin. The staining results
weren’t satisfactory with very high background issues (data not shown).

I also used an open loop template design (TBA and TBA-S 63mer as templates and BA
fwd and rev primers in table 5-1) as shown in figure 5-7 and tried to repeat in situ
polony PCR in gel pads as Mitra et al. reported in 1999 [244]. The open loop template
design was to make the template more accessible to primers and thus make the
amplification more efficient. The polony PCR protocol was adopted also to increase PCR
efficiency. The gel pad was supposed to hold the PCR mixture within and create a
solution-like environment for the reaction while holding the amplified DNA clusters in
place. However, both approaches did not help solve the high background problem. In
fact, the background was worse in the gel pads (data not shown). The possible reason
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might be that the gel monomers and/or APS and TEMED inhibited the enzyme activity
and the probes were difficult to diffuse into or to be washed out of the gel pad.

5.3.2. Emulsion PCR

One set of the initial emulsion PCR experiment results is shown in Figure 5-8. In this
experiment, the results show that the control beads (no template added) and sample
beads (using TBA 89mer as template) were both attached to the silane-treated glass
slide. But only the sample slide was stained by 6-FAM labeled TBA probe. Successful
amplification on the sample beads was indicated by the staining result. Logically, the
next step was to see whether the sample beads could be stained by fluorophore-labeled
thrombin.

As can be seen in Figure 5-9, the emulsion PCR beads were stained with Cy3-labeled
thrombin. But to our disappointment, both control slide and sample slide were stained
by Cy3-thrombin. And there weren’t distinct differences between the fluorescence
signal intensity of the two slides, which suggested non-specific binding between
thrombin and the control beads.

To reduce this kind of non-specific binding, 10mg/ml casein was added into the block
solution and 2mg/ml casein was added into the staining solution. And one more set of
negative control (where no forward primers were loaded onto the beads) was
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examined. But the staining result still show signs of non-specific binding of thrombin to
the control beads, as shown in figure 5-10. It suggested that casein did not provide
sufficient blocking in this experimental setup.

To determine the source of the non-specific binding, another set of control experiments
was carried out. Beads loaded with forward primers but not stained were used as
negative control 1. Unloaded beads were used as negative control 2. Positive control
beads are loaded with a 5′-dual biotin labeled DNA 35mer consisting 20 T’s on the 5′end and the 15mer TBA sequence on the 3′-end (T20TBA). Both negative control 2 and
the positive control beads were stained with Cy5-labeled thrombin in eppendorf tubes
for overnight instead of 30 minutes on slide. The staining results showed clear
distinction between the negative and positive control beads, as shown in Figure 5-11.
This suggests that the non-specific binding was not between thrombin and the bead
surface. Also the beads or the primers did not have background fluorescence. The
positive control had very satisfactory staining result. The contributing factors might be
the overnight staining in tubes and the TBA sequence being at the far end of the
attached oligos.

To examine the effect of staining conditions, a set of experiments similar to that shown
in Figure 5-9, except that the beads were stained overnight in tubes instead of 30
minutes on slide. The results showed that the fluorescence signal on sample beads did
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improve compared with the control beads, as shown in Figure 5-12. But the improved
signals were not as bright as the positive sample in Figure 5-11.

To test the hypothesis that the TBA sequence binds thrombin better on the free end of
the sequence than in the middle, a new emulsion PCR template (Temp-AloI) was
designed as shown in Table 5-1 and Figure 5-13. A restriction enzyme recognition site
was designed into the template to the 5′-end of the TBA region. After amplification, the
beads were digested with the restriction enzyme AloI to expose the TBA sequences so as
to allow easy access for thrombin binding. The control (no template) and sample beads
were digested and stained with 6-FAM labeled TBA probe (Figure 5-14) or Cy5-labeled
thrombin (Figure 5-15) in parallel. The results showed that AloI digestion increased the
Cy5 signal but decreases the 6-FAM signal. And non-specific binding between thrombin
and the control beads are still noticeable.

5.4. Discussion

Amplification efficiency. It has been reported that PCR amplifications on a solid surface
has much lower efficiency than solution-phase PCR reactions [245, 246], which might
explain the considerably greater difficulties in establishing a prototype bridge
amplification platform than an emulsion PCR platform. The close proximity of the
clustered complementary DNA strands makes them not able to freely move inside the
reaction chamber and results in low efficiency of bridge amplification. The low
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amplification efficiency made it difficult to distinguish between samples and controls,
therefore the high background issues. The amplicon length also has a negative
correlation with the efficiency of the emulsion PCR [247]. The in-gel polony PCR
approach was supposed to improve the amplification efficiency and help with polony
formation [244]. But the less-than-satisfactory results called for more optimization
before an ideal condition for bridge amplification could be worked out.

Staining efficiency. Staining of the amplicons also works better in solution phase than on
a solid surface, as demonstrated in Figure 5-11 and previously stained images. This is
probably because the probes, especially the protein probes, have less steric hindrance
staining the amplicons floating in solution than staining the ones being attached onto a
planar solid surface. Also, the on-slide staining for emulsion PCR beads was performed
in a small chamber, which usually has smaller volume than tubes and is less efficient for
the staining solution and/or the PCR mix to reach the beads. When comparing different
probes, the performance can be listed from the best to the worst as: thrombin (Cy5) >
thrombin (Cy3) > TBA probe (6-FAM) > Sybr555. The sybr555 DNA dye is a non-specific
DNA dye and prefers double stranded DNA over single stranded DNA. The clusters
formed by bridge amplification have only partial double stranded stem region near the
surface of the slide, so the staining efficiency was not good in the case of Sybr555. The
TBA probe and thrombin are both specific probes. The fact that thrombin stained better
than the TBA probe indicated that the TBA sequence might have higher affinity for
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thrombin than for the complementary TBA probe sequence. The structural stability of a
G-quadruplex makes it easier to bind thrombin than the TBA probe sequence.

Background issue. In the whole slide staining and washing steps, the slides were stained
in a plastic tube filled with appropriate solutions and incubated on a lab rocker. It’s
observed that slides stained and washed in this manner tend to have weaker signals on
both ends of the slides and a streaky pattern in background can often be seen. Using a
larger tray and enough solutions to cover the slide throughout the time of incubation on
the lab rocker might improve this issue of uneven staining. The catch is that more
probes would be needed as the volume would be larger in this staining setup. But that
should be a small price to pay. Other factors contribute to high or uneven backgrounds
include insufficient blocking, air bubbles in the staining chamber, and slides drying out
before wash. Non-specific binding could result from residual components from the PCR
mixture, which contribute to the high background as well as false positive signal. It was
also observed that Cy3- or Cy5-labeled thrombin has reduced affinity for TBA sequence,
which indicates possible structure change or denaturation of thrombin due to the
fluorophore labeling [248]. This fact might also contribute to the staining/background
issues.

5.5. Conclusions and suggestions for future work
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5.5.1. Bridge amplification

The bridge amplification platform did not work as planned, mostly because of the low
amplification efficiency and staining issues. Initial data did show signs of successful
amplification but the results weren’t consistent.

With the recent acquirement of an Illumina GAII sequencer in our lab, the need to
create a prototype bridge amplification platform is not as significant as before. We are
planning to work on screening protocols using actual Illumina sample slides, which could
be an extension of this project.

5.5.2. Emulsion PCR

The emulsion PCR platform can be considered as partly accomplished. There was clear
sign that template sequences were successfully amplified on magnetic beads using
emulsion PCR. The results were reproducible and the detection methods worked well.

But there are still issues with non-specific binding and detection sensitivity. One should
be able to improve or solve these issues given more time and resources. But without
access to an NGS sequencer based on emulsion PCR, this project currently remains at
the prototype stage.
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Emulsion PCR

Bridge Amp

Table 5-1. Template and primer sequences used in aptamer discovery method development
Name
TBA
TBA Scrambled
TBA 55mer
TBA-S 55mer
BA Primer
TBA 63mer
TBA-S 63mer
BA Fwd Primer
BA Rev Primer

Length
15
15
55
55
20
63
63
24
24

modification
5'-dual biotin
5'-dual biotin
5'-dual biotin
5'-dual biotin
5'-dual biotin
5'-dual biotin
5'-dual biotin

TBA 89mer

89

Fwd primer
Rev primer
Bridging oligo 1
Bridging oligo 2

TBA Probe
T20TBA

29 5'-dual biotin
21
24
28
5'-phosphate,
10
3'-amine
5'-phosphate,
11
3'-amine
12 5'-6-FAM
35 5'- dual biotin

Temp-AloI

77

Rev primer AloI
Fwd primer AloI

21
21 5'-biotin

Capping oligo 1
Capping oligo 2

-

-

Sequence (5'->3')
GGTTGGTGTGGTTGG
GGTGGTTGTTGTGGT
CGGTTGCGTTTACTGCCGTCGGTTGGTGTGGTTGGGACGGCAGTAAACGCAACCG
CGGTTGCGTTTACTGCCGTCGGTGGTTGTTGTGGTGACGGCAGTAAACGCAACCG
CGGTTGCGTTTACTGCCGTC
AGAAGGAGAAGGAAAGGGAAAGGGGGTTGGTGTGGTTGGGGTTTGGGTTGGTTTGGGTTGGTG
AGAAGGAGAAGGAAAGGGAAAGGGGGTGGTTGTTGTGGTGGTTTGGGTTGGTTTGGGTTGGTG
AGAAGGAGAAGGAAAGGGAAAGGG
CACCAACCCAAACCAACCCAAACC
AACTGCCCCGGGTTCCTCATTCTCTACGCCAACCACACCAACCCGTATCACCGACTGCCCATA
GAGAGGAAAGCGGAGGCGTAGTGGTT
CCACTACGCCTCCGCTTTCCTCTCTATGG
CTGCCCCGGGTTCCTCATTCT
GTGAGCTTCGTCTGCCCCGGGTTC
GTGAGCTTCGTCCATAGAGAGGAAAGCG
CGAAGCTCAC
ACGAAGCTCAC
CCAACCACACCA
TTTTTTTTTTTTTTTTTTTTGGTTGGTGTGGTTGG
AAGTCAGCTATGCCGCTACGGACCCGGGGTTCTCAGATCCCAACCACACCAACCTCCAAACAC
CTCCGCATCACCTT
GTCAGCTATGCCGCTACGGAC
GGTGATGCGGAGGTGTTTGGA

- 125 -

Figure 5-1. Formation of DNA clusters by bridge amplification
Red: universal primer; green: complementary region to the universal primer; Black: TBA
sequence; gray: complementary sequence of TBA; blue: TBA scrambled sequence; light
blue: complementary sequence of TBA scrambled; dotted arrow indicates the bridge
amplification reaction and its extension direction.
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Figure 5-2. TBA 55mer
Drawn with mfold web server online tool at http://mfold.rna.albany.edu/?q=mfold
[249].
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Figure 5-3. TBA scrambled 55mer
Drawn with mfold web server online tool at http://mfold.rna.albany.edu/?q=mfold
[249].
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Figure 5-4. Detection of DNA clusters after bridge amplification
Black: TBA cluster; blue: TBA scrambled cluster; gold: DNA clusters stained with Sybr555
DNA stain; green: DNA clusters stained with labeled thrombin; red: DNA clusters stained
with labeled TBA scrambled probe.
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Figure 5-5. Schematic setup of emulsion PCR
Grey circle: magnetic emulsion beads; green bar: forward primer; purple bar: reverse
primer; the three-part bar: template; light green bar: capping oligo; the two-part bar:
bridging oligo; arrows: extension direction.
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Figure 5-6. TBA clusters formed by bridge amplification
Positive control: 0.5 µM template (TBA 55mer); Negative control: 0.5 µM primer (BA
primer) + 1 pM template (TBA 55mer), no polymerase; Sample: 0.5 µM primer (BA
primer) + 0.01 pM template (TBA 55mer). Controls and sample were stained with
Sybr555 DNA stain for 5 minutes. All chambers went through the same thermo cycling
and staining procedure.
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Figure 5-7. Open loop template design
Two set of non-complementary primers are attached on the solid surface. The 5′-region
and 3′-region of the template match the two primers, respectively. The template does
not have stable secondary structure by design.
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Figure 5-8. Detection of emulsion PCR beads by TBA probe (6-FAM)
Panel A: bright field images. Panel B: fluorescent images. Control beads did not contain
template in the PCR mixture. Both control beads and sample beads went through the
same thermo cycling and were stained with 6-FAM labeled TBA probe.
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Figure 5-9. Detection of emulsion PCR beads by Thrombin (Cy3)
Panel A: bright field images. Panel B: fluorescent images. Control beads did not contain
template in the PCR mixture. Both control beads and sample beads went through the
same thermo cycling and were stained by thrombin labeled with Cy3.
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Figure 5-10. Detection of emulsion PCR beads by Thrombin (Cy5)
Panel A: bright field images. Panel B: fluorescent images. Control 1: no template; control
2: no forward primers. Both control beads and sample beads were blocked in the
presence of 10mg/ml casein for 1 hour and went through the same thermo cycling. All
beads were stained with Cy5-labeled thrombin in the presence of 2mg/ml casein in the
staining solution.
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Figure 5-11. Detection of control beads by Thrombin (Cy5)
Panel A: bright field images. Panel B: fluorescent images. Negative control 1: beads
loaded with forward primers but not stained; negative control 2: unloaded beads;
positive control: beads loaded with T20TBA. Both negative control 2 and positive control
were stained with Cy5-labeled thrombin overnight in eppendorf tubes.
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Figure 5-12. Detection of emulsion PCR beads by Thrombin (Cy3)
Panel A: bright field images. Panel B: fluorescent images. Control beads did not contain
template in the PCR mixture. Both control beads and sample beads went through the
same thermo cycling and were stained by thrombin labeled with Cy3 overnight in
eppendorf tubes.
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Figure 5-13. New emulsion PCR template design
Gray circle: magnetic emulsion beads; scissor: restriction enzyme (AloI); green bar:
forward primer; purple bar: reverse primer; the three-part bar: template; arrows:
extension direction.
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Figure 5-14. Detection of emulsion PCR beads by TBA probe (6-FAM)
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Figure 5-15. Detection of emulsion PCR beads by Thrombin (Cy5)
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Appendices
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Appendix A. NCp7 Site-Mutagenesis
Sequence information
A-1. Map of pET-3a plasmid
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A-2. Full sequence of the pRD2 construct (from HIV-1 pNL4-3 strain)
> pRD2
TTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAAT
AATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTG
TTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAAT
GCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTAT
TCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGT
AAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAG
CGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAA
AGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCG
CCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCT
TACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACAC
TGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCA
CAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCAT
ACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACT
ATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGC
GGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGA
TAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGG
TAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACG
AAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCA
AGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTA
GGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCA
CTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCG
CGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGA
TCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAA
TACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCC
TACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTG
TCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAAC
GGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCT
ACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCC
GGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTG
GTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATG
CTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCT
GGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGA
TAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCG
CAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCTGATGCGGTATTTTCTCCTTACGCA
TCTGTGCGGTATTTCACACCGCATATATGGTGCACTCTCAGTACAATCTGCTCTGATGCC
GCATAGTTAAGCCAGTATACACTCCGCTATCGCTACGTGACTGGGTCATGGCTGCGCCCC
GACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTT
ACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCAC
CGAAACGCGCGAGGCAGCTGCGGTAAAGCTCATCAGCGTGGTCGTGAAGCGATTCACAGA
TGTCTGCCTGTTCATCCGCGTCCAGCTCGTTGAGTTTCTCCAGAAGCGTTAATGTCTGGC
TTCTGATAAAGCGGGCCATGTTAAGGGCGGTTTTTTCCTGTTTGGTCACTGATGCCTCCG
TGTAAGGGGGATTTCTGTTCATGGGGGTAATGATACCGATGAAACGAGAGAGGATGCTCA
CGATACGGGTTACTGATGATGAACATGCCCGGTTACTGGAACGTTGTGAGGGTAAACAAC
TGGCGGTATGGATGCGGCGGGACCAGAGAAAAATCACTCAGGGTCAATGCCAGCGCTTCG
TTAATACAGATGTAGGTGTTCCACAGGGTAGCCAGCAGCATCCTGCGATGCAGATCCGGA
ACATAATGGTGCAGGGCGCTGACTTCCGCGTTTCCAGACTTTACGAAACACGGAAACCGA
AGACCATTCATGTTGTTGCTCAGGTCGCAGACGTTTTGCAGCAGCAGTCGCTTCACGTTC
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GCTCGCGTATCGGTGATTCATTCTGCTAACCAGTAAGGCAACCCCGCCAGCCTAGCCGGG
TCCTCAACGACAGGAGCACGATCATGCGCACCCGTGGCCAGGACCCAACGCTGCCCGAGA
TGCGCCGCGTGCGGCTGCTGGAGATGGCGGACGCGATGGATATGTTCTGCCAAGGGTTGG
TTTGCGCATTCACAGTTCTCCGCAAGAATTGATTGGCTCCAATTCTTGGAGTGGTGAATC
CGTTAGCGAGGTGCCGCCGGCTTCCATTCAGGTCGAGGTGGCCCGGCTCCATGCACCGCG
ACGCAACGCGGGGAGGCAGACAAGGTATAGGGCGGCGCCTACAATCCATGCCAACCCGTT
CCATGTGCTCGCCGAGGCGGCATAAATCGCCGTGACGATCAGCGGTCCAGTGATCGAAGT
TAGGCTGGTAAGAGCCGCGAGCGATCCTTGAAGCTGTCCCTGATGGTCGTCATCTACCTG
CCTGGACAGCATGGCCTGCAACGCGGGCATCCCGATGCCGCCGGAAGCGAGAAGAATCAT
AATGGGGAAGGCCATCCAGCCTCGCGTCGCGAACGCCAGCAAGACGTAGCCCAGCGCGTC
GGCCGCCATGCCGGCGATAATGGCCTGCTTCTCGCCGAAACGTTTGGTGGCGGGACCAGT
GACGAAGGCTTGAGCGAGGGCGTGCAAGATTCCGAATACCGCAAGCGACAGGCCGATCAT
CGTCGCGCTCCAGCGAAAGCGGTCCTCGCCGAAAATGACCCAGAGCGCTGCCGGCACCTG
TCCTACGAGTTGCATGATAAAGAAGACAGTCATAAGTGCGGCGACGATAGTCATGCCCCG
CGCCCACCGGAAGGAGCTGACTGGGTTGAAGGCTCTCAAGGGCATCGGTCGACGCTCTCC
CTTATGCGACTCCTGCATTAGGAAGCAGCCCAGTAGTAGGTTGAGGCCGTTGAGCACCGC
CGCCGCAAGGAATGGTGCATGCAAGGAGATGGCGCCCAACAGTCCCCCGGCCACGGGGCC
TGCCACCATACCCACGCCGAAACAAGCGCTCATGAGCCCGAAGTGGCGAGCCCGATCTTC
CCCATCGGTGATGTCGGCGATATAGGCGCCAGCAACCGCACCTGTGGCGCCGGTGATGCC
GGCCACGATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTC
ACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGA
NdeI
GATATACATATGCAGAAAGGCAATTTTAGGAACCAAAGAAAGACTGTTAAGTGTTTCAAT
TGTGGCAAAGAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGG
AAATGTGGAAAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTAGTTA
BamHI
GGGAGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTG
AGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGA
AAGGAGGAACTATATCCGGATATCCACAGGACGGGTGTGGTCGCCATGATCGCGTAGTCG
ATAGTGGCTCCAAGTAGCGAAGCGAGCAGGACTGGGCGGCGGCCAAAGCGGTCGGACAGT
GCTCCGAGAACGGGTGCGCATAGAAATTGCATCAACGCATATAGCGCTAGCAGCACGCCA
TAGTGACTGGCGATGCTGTCGGAATGGACGATATCCCGCAAGAGGCCCGGCAGTACCGGC
ATAACCAAGCCTATGCCTACAGCATCCAGGGTGACGGTGCCGAGGATGACGATGAGCGCA
TTGTTAGATTTCATACACGGTGCCTGACTGCGTTAGCAATTTAACTGTGATAAACTACCG
CATTAAAGCTTATCGATGATAAGCTGTCAAACATGAGAA
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Appendix B. Recipes and Protocols
Used in NCp7 Mutagenesis

B-1. Recipes for medium, buffers and solutions

LB Medium
Per liter:
Tryptone

10g

Yeast extract

5g

NaCl

10g

Or use the premixed capsules (MP Biomedicals, Solon, OH), 4 capsules per liter
Sterilize by autoclaving
Store media at room temperature (RT)

Antibiotics
Chloramphenicol: 34mg/ml in ethanol, filtered, store at -20°C.
Ampicillin: 100mg/ml in ddH2O, filtered, store at -20°C.

1X TE
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Tris-HCl

10mM

EDTA

1 mM

pH 8.0

10x M9 Salts
Per liter:
NH4Cl

10g

KH2PO4

30g

Na2HPO4∙7H2O

32g

Filtered sterile, store at RT

ZnCl2 (200mM)
Weigh 1.363g of ZnCl2, dissolve in 50ml ddH2O, filtered, store at 4°C

MgSO4 (1M)
Weigh 6.02g of MgSO4, dissolve in 50ml ddH2O, filtered, store at 4°C

40% Glucose (w/v)
Weigh 80g of Glucose, dissolve in 200ml ddH2O, filtered, store at 4°C

10mg/ml Lysozyme
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Weigh 10mg Lysozyme, dissolve in 1ml filtered ddH2O. Prepare fresh solution
each time immediately before use.

1mg/ml Pepstatin A
Pepstatin A comes in 5mg/bottle package (Sigma P4265). Dissolve the content in
5ml of methanol. Store at 4°C

10mM PMSF(Phenylmethylsulfonyl Fluoride)
Weigh 87.1mg PMSF, dissolve in 50ml of ethanol, filtered, store at 4°C

1% Deoxycholate
Weigh 0.5g of sodium deoxycholate monohydrate, dissolve in 50ml ddH2O,
filtered, store at 4°C

1M TCEP·HCl (Tris(2-Carboxyethyl) phosphine Hydrochloride)
Weigh 5.733g of TCEP·HCl, dissolve in 20ml ddH2O, filtered, make 1ml aliquots,
store at -20°C

4% PEI (polyethyleneimine)
Take 4ml of 50 % (w/v in water) Poly(ethyleneimine) solution (Sigma P3143), add
ddH2O to a total volume of 50ml, filtered, store at 4°C
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2M NaCl
Weigh 116.88g of NaCl, dissolve in 1 L of ddH2O, filtered, store at 4°C

1M NaOH
Weigh 40g of NaOH, dissolve in 1 L of ddH2O, filtered, store at 4°C

NCp7 FPLC Buffers
Buffer A (1 Liter)
Tris-Base

6.06g

(final 50mM)

Glycerol

100ml

(final 10%)

NaCl

5.8g

(final 100mM)

200mM ZnCl2

500μl

(final 100μM)

1M TCEP·HCl

1ml

(final 1mM)

Adjust to pH8.0 with HCl
Filtered sterile, store at 4°C
Buffer B (1 Liter)
Tris-Base

6.06g

(final 50mM)

Glycerol

100ml

(final 10%)

NaCl

58.4g

(final 1M)

200mM ZnCl2

500μl

(final 100μM)

1M TCEP·HCl

1ml

(final 1mM)

Adjust to pH8.0 with HCl
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Filtered sterile, store at 4°C
Note: The FPLC buffers were made and stored without TCEP·HCl. TCEP·HCl was
only added immediately prior to use.

10X TBE

Per liter:
Tris-Base

108g

(final 890mM)

Boric Acid

55g

(final 890mM)

0.5M EDTA pH8.0

40ml

(final 20mM)

Add ddH2O to 1 liter, filter and store at RT.
Note: Do not adjust pH. pH of the stock solution should be around 8.3. Filtering is
optional and can delay precipitation.

SDS PAGE Gel
15% Separating Gel (10ml)
H2O

3.55ml

40% Gel concentrate

3.75ml

1.5M Tris (pH 8.8)

2.5ml

10% SDS

0.1ml

10% Ammonium Persulfate

0.1ml

TEMED

4µl
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5% Stacking Gel (4ml)
H2O

2.92ml

40% Gel concentrate

0.5ml

1.5M Tris (pH 8.8)

0.5ml

10% SDS

0.04ml

10% Ammonium Persulfate

0.04ml

TEMED

4µl

Note: This recipe is enough for making one 7mm x 8mm x 1.5mm gel or two 7mm
x 8mm x 0.75mm gel (regular gel size for Bio-Rad mini-protean tetra cell
system). Scale up or down if necessary.

SDS PAGE Running Buffer
Anode Buffer (10X): 2.0M Tris HCl (pH8.9)
Dissolve 121.1 g of Tris base in 400ml ddH2O, adjust pH to 8.9 with HCl,
and add ddH2O to final volume of 500ml. Store at RT.
Cathode Buffer (10X): 1.0M Tris HCl, 1.0M Tricine, SDS (pH8.25)
Dissolve 60.55 g of Tris base, 89.58g of Tricine and 5g of SDS in 400ml
ddH2O, adjust pH to 8.25 with HCl, and add ddH2O to final volume of
500ml. Store at RT.
Note: Cathode Buffer goes to upper chamber; Anode Buffer goes to the bottom
chamber.
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SDS 2X Loading Buffer
1M Tris-HCl pH 6.8

1 ml

10% SDS

4 ml

Glycerol

2 ml

Bromophenol blue

0.02 g

1M DTT

2 ml

Adjust volume to 10 ml, divide into 1 ml aliquots, and store at -20°C

Gel Staining and Destaining Solution
Coomassie Brilliant Blue staining solution
PhastGel Blue R

1 tablet

Methanol

450ml

ddH2O

450ml

Glacial acetic acid

100ml

Filter and store at RT

Destaining solution
Methanol

450ml

ddH2O

450ml

Glacial acetic acid

100ml

Store at RT
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10X NCp7 MS Buffer*
Per liter:
NaH2PO4

6g

(final 50mM)

NaCl

116.8g

(final 2M)

200mM ZnCl2

50µl

(final 10µM)

Adjust pH to 7.0 with HCl. Filter and store at RT.
*Dilute with ddH2O to 1X and add TCEP·HCl to 1mM final concentration before
use.

10X NCp7 Titration Buffer*
Per liter:
NaH2PO4

6g

(final 50mM)

NaCl

116.8g

(final 2M)

200mM ZnCl2

50µl

(final 10µM)

PEG 8000

10g

(final 1%)

Adjust pH to 7.0 with HCl. Filter and store at RT.
*Dilute with ddH2O to 1X and add TCEP·HCl to 1mM final concentration before
use.
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B-2. Protocol for plasmid preparation

Materials:



XL1-Blue strain or other endA- strain containing the needed plasmid



LB-Amp medium



QIAprep Spin Miniprep kit

Procedure:

1. Streak the frozen culture of XL1-Blue cells onto a LB agar plate containing
100μg/ml Ampicillin. Incubate the streaked plate at 37°C overnight.
2. Pick a single colony from the overnight grown plate to inoculate 5ml of LB-Amp
medium. Incubate the liquid culture at 37°C overnight, shaking at 200~250rpm.
3. Harvest the overnight culture by spinning the cells for 5 minutes at 3000rpm in a
tabletop centrifuge. Remove all the supernatant.
4. Re-suspend pelleted bacterial cells in 250 µl of Buffer P1 and transfer the
suspension to a microcentrifuge tube.
5. Add 250 µl of Buffer P2 and mix thoroughly by inverting the tube 4–6 times.
6. Add 350 µl of Buffer N3 and mix immediately and thoroughly by inverting the
tube 4–6 times.
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7. Centrifuge for 10 minutes at 13,000 rpm (~17,900 x g) in a table-top
microcentrifuge.
8. Apply the supernatant (from step 7) to the QIAprep spin column by decanting or
pipetting.
9. Centrifuge for 1 minute. Discard the flow-through.
10. Wash QIAprep spin column by adding 0.75 ml of Buffer PE and centrifuging for 1
minute.
11. Discard the flow-through, and centrifuge for an additional 1 minute to remove
residual wash buffer.
12. To elute DNA, place the QIAprep column in a clean 1.5 ml microcentrifuge tube.
Add 50 µl of nuclease-free water to the center of each QIAprep spin column, let
stand for 1 minute, and centrifuge for 1 minute.
13. Check the purity and integrity of the miniprep by agarose gel electrophoresis.
Measure the concentration of the prepared plasmid DNA by UV absorption at
260nm.
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B-3. Protocol for site-directed mutagenesis

Materials:



Stratagene® QuikChange® II Site-Directed Mutagenesis Kit (Stored at -20°C)



Plasmid DNA template: dilute to 10ng/μl



Primers: dilute to 10μM (100~150ng/μl)

Procedure:

1. Prepare PCR mix as below:

10× reaction buffer

2.5 μl

dsDNA template (10ng/μl)*

0.5 μl

Forward primer (10 μM)

0.5 μl

Reverse primer (10 μM)

0.5 μl

dNTP mix (10mM)

0.5 μl

PfuUltra polymerase (2.5 U/μl)

0.5 μl

Nuclease free H2O

20 μl

Final volume:

25 μl

* Nuclease free H2O was added instead of DNA template as a negative control.
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2. Set up and run mutagenesis PCR reactions as below:

1) 95°C

30 seconds

2) 95°C

30 seconds

3) 55°C

1 minute

4) 68°C

6 minutes

5) go to step 2) for a total of 16 cycles
6) hold at 4°C

3. Add 0.5µl of DpnI restriction enzyme into each PCR reaction. Mix well and
incubate the mixture at 37°C for 1 hour.
4. Check product size and integrity on agarose gel. Load 5 µl of each digested PCR
reaction per well on a 1% agarose gel. Use 1X TBE as running buffer. Run the gel
at 160V for 40 minutes. Stain with ethidium bromide and take gel image on a
Kodak Gel Imager equipped with UV transilluminator.
5. Transform mutated DNA product into XL1-Blue competent cells (See appendix B4 for detailed protocol).
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B-4. Protocol for transformation into XL1-Blue competent cells

Materials:



XL-1 Blue competent cells(Stratagene), stored at -80°C



Digested PCR mix



LB+0.4% glucose



LB/AMP plates

Procedure:

1. Estimate concentration of PCR product based on the agarose gel. (UV absorption
at this time is not reliable because of interference by dNTPs and free primers.)
2. Use ~5ng of DNA (DNA volume should not exceed 10% of reaction volume, in this
case, 2μl) for each transformation. Add the DNA into a 200μl PCR tube, let it chill
on ice. Use 1 μl of pUC18 control DNA (0.1ng/μl, included in the kit) as positive
control. Use 1 μl of nuclease free H2O as negative control.
3. Thaw a tube of XL-1 Blue competent cells on ice. Add 20 μl of competent cells
into each tube.
4. Incubate the mixture on ice for 30 minutes. In the mean time, warm up a tube of
LB+0.4% glucose at 42°C.
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5. Heat-shock the cell mixture at 42°C for 45 seconds on a pre-warmed thermal
cycler.
6. Immediately put tubes back on ice, incubate for 2 minutes.
7. Add 100 μl of pre-warmed LB+0.4% glucose (42°C), gently mix.
8. Pool the tubes in a 15ml falcon tube, shake at 250rpm in a 37°C incubator for 1
hour. Warm up a few LB/AMP plates during this time.
9. Spread 50 μl of the recovered cells onto each LB/AMP plate. Grow plates at 37°C
overnight.
10. Pick single colony from plate, inoculate a 5-ml LB/AMP liquid culture, grow at
37°C overnight, shaking at 220~250rpm.
11. Make permanent glycerol storage culture (see appendix B-6). Store the frozen
stocks at -80°C.
12. Do plasmid miniprep using QIAprep Spin Miniprep kit. Elute plasmid with 50 μl of
nuclease free H2O.
13. Measure plasmid concentration by UV absorption. Use 200-800ng of each
plasmid as Sanger sequencing template. Store the rest of plasmid at -80°C.
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B-5. Protocol for transformation into BL21 competent cells

Materials:



BL21-(DE3)pLysS competent cells (Stratagene), stored at -80°C



Mutant plasmid DNA, dilute to 10ng/μl



LB+0.4% glucose



LB/AMP/Chl plates

Procedure:

1. Add 1 μl of plasmid (10 ng) to a 200 μl PCR tube, let it chill on ice. Use 1 μl of
pUC18 control DNA (0.1 ng/μl) as positive control. Use 1 μl of nuclease free H2O
as negative control.
2. Thaw a tube of BL21 competent cells on ice. Add 20ul of BL21 competent cells to
each tube.
3. Incubate the mixture on ice for 30 minutes. In the mean time, warm up a tube of
LB+0.4% glucose at 42°C.
4. Heat-shock the cell mixture at 42°C for 20 seconds on a pre-warmed thermal
cycler.
5. Immediately put tubes back on ice, incubate for 2 minutes.
6. Add 100 μl of pre-warmed LB+0.4% glucose (42°C), gently mix.
- 159 -

7. Pool the tubes in a 15ml falcon tube, shake at 250rpm in a 37°C incubator for 1
hour. Warm up a few LB/AMP/Chl plates during this time.
8. Spread 50 μl of the recovered cells onto each LB/AMP/Chl plate. Grow plates at
37°C overnight.
9. Pick single colony from plate, inoculate a 5-ml LB/AMP/Chl liquid culture
supplemented with Zinc, M9 salts and glucose (see recipe for starter culture in
appendix B-5), grow at 37°C overnight, shaking at 220~250rpm.
10. Make permanent glycerol storage culture (see appendix B-6). Store the frozen
culture at -80°C.
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B-6. Protocol for making or renewing frozen stock of E. coli strains

Materials:



Fresh LB plates with healthy colonies of E. coli cells (plated with freshly
transformed cells or streaked from previous frozen stock)



LB medium



Antibiotics of choice/Glucose/M9 salts



50% glycerol (sterilized by autoclave)



Dry ice

Procedure:

1. Prepare 5 ml of fresh LB media, add appropriate antibiotic(s) and nutrients at
desired concentration.
2. Pick a single colony from the LB plate, inoculate the above 5-ml LB media with
this colony, mix well and grow cells overnight.
3. Aliquot 150 µl of 50% glycerol to microcentrifuge tubes or cryo-vials.
4. Add 350 µl of fresh overnight culture to each tube containing glycerol, mix well.
5. Immediately put tubes on dry ice. Transfer tubes into -80°C freezer after the
mixture is completely frozen.
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B-7. Protocol for NCp7 protein over-expression

Materials:



BL21-(DE3)pLysS cells containing the needed plasmid



LB-Amp-Chl medium



Supplements: 10X M9 salts, 200mM ZnCl2, 1M MgSO4, 40% Glucose



1M IPTG

Procedure:

1. Streak the frozen culture of BL21-(DE3)pLysS cells onto a LB-Amp-Chl plate.
Incubate the streaked plate at 37°C overnight.
2. Pick a single colony from the overnight grown plate to inoculate 5ml of starter
culture as described below:
Starter culture media
LB media

4.45ml

10X M9 salts*

500μl

(final conc. 1X)

34mg/ml Chloramphenicol

5μl

(final conc. 34μg/ml)

100mg/ml Ampicillin

5μl

(final conc. 100μg/ml)

200mM ZnCl2

2.5μl

(final conc. 100μM)

1M MgSO4

5μl

(final conc. 1mM)
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40% Glucose

50μl

Final Volume:

5ml

(final conc. 0.4%)

*See appendix B-1 for recipe.
3. Grow the inoculated starter culture overnight at 37°C, shaking at 200-250rpm.
4. Transfer the overnight starter culture to 1 liter of fresh media as described below:
NCp7 expression media (1 Liter)
LB media

890ml

10X M9 salts*

100ml

(final conc. 1X)

34mg/ml Chloramphenicol

1ml

(final conc. 34μg/ml)

100mg/ml Ampicillin

1ml

(final conc. 100μg/ml)

200mM ZnCl2

0.5ml

(final conc. 100μM)

1M MgSO4

1ml

(final conc. 1mM)

40% Glucose

10ml

(final conc. 0.4%)

Final Volume:

1L

*See appendix B-1 for recipe.
5. Incubate the 1L culture at 37°C, shaking at 200-250rpm. Monitor cell density by
measuring the culture’s absorbance at 600nm every half hour until OD600
reaches 0.6-0.8, which usually takes 4-5 hours after inoculation.
6. Induce the culture with 400μl of 1M IPTG (final conc. 400μM) when the culture’s
OD600 is between 0.6-0.8. Incubate the culture at 37°C, shaking at 200-250rpm,
for 4 more hours after induction.
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7. Harvest cells by centrifuging the culture on an Avanti® J-E centrifuge (Beckman
Coulter) using the JLA-10.5 rotor, spinning at 5000rpm for 15 minutes. Dump the
clear supernatant and keep the cell pellet.
8. Use the cell pellet for cell lysis or freeze the cell pellet at -20°C.
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B-8. Protocol for cell lysis

Materials:



Cell pellets from over-expression (see appendix B-6)



Lysis buffer (see procedure below for recipe)



B-PER II Protein Extraction Reagent (Thermo Pierce)



4% PEI (polyethyleneimine)

Procedure:

1. Re-suspend fresh or frozen cell pellet in ~30ml of ice-cold lysis buffer as
described here:
NCp7 Lysis Buffer (for pellets from 1L culture)
NCp7 FPLC Buffer A w/o TCEP* 30ml
10mg/ml freshly made Lysozyme

200μl (final 60μg/ml)

1mg/ml Pepstatin A

30μl

10mM PMSF

172μl (final 53μM)

1% Deoxycholate

2.1ml (final 5mM)

1M TCEP

150μl (final 5mM)

*See appendix B-1 for recipe.
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(final 0.9μg/ml)

2. Transfer the re-suspended cells into a pre-chilled 50ml conical tube and left on
ice for 20 minutes.
3. Add 4ml of B-PER Protein Extraction Reagents (Thermo Pierce), mix well and
leave the lysate on ice for additional 10 minutes.
4. Further disrupt the cells using a Microson XL2000 Ultrasonic Liquid Processor
(Misonix, now Qsonica) for 4 times, 25 seconds each time, at an output power
setting of 20-25 watts, with 1-minute intervals in between pulses.
5. Add 2ml of 4% PEI (Sigma-Aldrich), mix well and transfer the lysate into a prechilled 50ml Oakridge tube.
6. Spin down the lysed cells on an Avanti® J-E centrifuge (Beckman Coulter) using
the JA-25.5 rotor, spinning at 17,000rpm for 30 minutes at 4°C.
7. Transfer supernatant into a clean conical tube, filter with 0.45μm syringe filter
when necessary. Load the collected lysate onto FPLC immediately for purification.
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B-9. Protocol for FPLC purification of NCp7

Materials:



Fresh cell lysate (see appendix B-7)



NCp7 FPLC buffer A and B (see appendix B-1)



SP FF and Q FF FPLC columns

Procedure:

1. Wash and equilibrate a 20ml HiPrep Q FF column (GE Healthcare) and a 20ml
HiPrep SP FF column (GE Healthcare) connected in series with at least 200ml of
NCp7 FPLC Buffer A, at a flow rate of 3ml/min.
2. Set flow rate to 2ml/min and load cell lysate onto the Q FF column (a strong
anion exchange column).
3. After loading, set the flow rate back to 3ml/min. When the flow through peak is
washed off and the UV absorbance decreases to ~15mAU, quickly take the Q FF
column off the system and keep washing the SP FF column until the UV
absorbance reaches a stable base line.
4. Start a 5-min linear gradient from 0% to 20% NCp7 FPLC Buffer B. Wash SP FF
column with 20% NCp7 FPLC Buffer B until the UV absorbance reaches a stable
base line again.
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5. Start a one-hour linear gradient from 20% to 50% NCp7 FPLC Buffer B. Collect
peak fractions for further analysis.
6. Start a 5-min linear gradient from 50% to 100% NCp7 FPLC Buffer B. Wash the
column with 100% NCp7 FPLC Buffer B until the UV absorbance reaches a stable
baseline.
7. Start a 5-min linear gradient from 100% to 0% NCp7 FPLC Buffer B. Wash the
column with 100% NCp7 FPLC Buffer A until the UV absorbance reaches a stable
baseline.
8. Clean the columns separately with 2M NaCl solution and ddH2O before the next
FPLC run. Clean and store the columns appropriately following the
manufacturer’s protocol (also see appendix B-10).
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B-10. Protocols for cleaning and storing FPLC columns

Materials:



FPLC columns



ddH2O



2M NaCl



1M NaOH



70% Ethanol



20% Ethanol or 20% Ethanol with 0.2 M sodium acetate

Procedure:

Regular cleaning

1. Wash the column with 2 column volumes of 2M NaCl at a flow rate of 5 ml/min
after each run to elute material still bound to the column, followed by 2 column
volumes of ddH2O.
2. Re-equilibrate the column before use with at least 5 column volumes of start
buffer or until the UV base-line and pH/conductivity values are stable.

More rigorous cleaning
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1. Reverse the flow direction and run at a flow rate of 5 ml/min at room
temperature the following sequence of solutions.
1) 4 column volumes of a 2 M NaCl solution (removes ionically bound
proteins from the column) followed by 3 column volumes of ddH2O.
2) 4 column volumes of a 1 M NaOH solution (removes precipitated proteins,
hydrophobically bound proteins and lipoproteins from the column)
followed by 3 column volumes of ddH2O.
3) 4 column volumes of 70% ethanol (removes proteins, lipoproteins and
lipids that are strongly hydrophobically bound to the column) followed by
3 column volumes of ddH2O.
2. Re-equilibrate the column before use with at least 5 column volumes of start
buffer in the normal flow direction.

Storage

If the column is to be stored for more than two days after use, clean the column
according to the procedure described above. Then equilibrate with at least 5
column volumes of 20% ethanol (for Q FF column) or 20% ethanol with 0.2 M
sodium acetate (for SP FF column) at a flow rate of 5 ml/min. Cap the outlet
tubings and store the columns at 4°C.
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B-11. Protocol for FPLC column packing

Materials:



SP FF resin or Q FF resin, 25ml/bottle



20% Ethanol



XK 16 column



ddH2O



FPLC buffer

Procedure:

1. Disassemble the column following the column’s manual, use the right tools.
Remember to loosen the adjusting knob before pulling out the plungers.
2. Clean the parts thoroughly. Autoclave the chromatographic glass tube without
the thermostat jacket and tubings.
3. Re-assemble the column. Put an end piece to the bottom.
4. Add 20% ethanol into column, use a syringe to pull ethanol through the tubing to
get rid of air bubbles. Let the ethanol dripping into a clean beaker.
5. Shake the resin well, pour down the column, let it settle, add more till
appropriate height.
6. Draw ethanol through the top end piece to get rid of air bubbles.
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7. Insert top end piece at an angle to avoid trapping air bubbles. Assemble the
column.
8. Let the resin settle overnight.
9. Adjust adaptor until it touches the surface of resin. Tighten the O-ring to lock the
adaptor in position.
10. Connect the column to FPLC, wash column with 3 column volumes of ddH2O
then 3 column volumes of buffer A at regular flow rate. Re-adjust adaptor
position if necessary.
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Appendix C. NC-SL3 Titration Data
C-1. Compilation of NCp7-SL3 Trp titration data

#

1

Mutant

WT

Titration Date

Kd(nM)

10/29/2010
11/7/2010
11/17/2010
11/18/2010
11/19/2010
11/22/2010
11/23/2010
11/29/2010

23.72
21.81
32.98
34.06
31.13
32.39
27.32
29.34

0.999
0.999
0.999
0.999
0.998
0.999
0.999
0.999

4.54%
3.21%
5.47%
5.56%
5.88%
5.09%
3.96%
5.82%

10/18/2010
10/20/2010
10/28/2010
11/17/2010

63.69
65.79
65.36
80.97

Fitting
Error
11%
15%
21%
13%

Avg. Kd=
SD=
SD%=

29
4.5
15%

M=
F=

8
1.0

Avg. Kd=
SD=
SD%=

69
8.1
12%

Avg. N =
SD=
SD%=

KdRT=
SD=
SD%=

42
5.0
12%

R

2

Endpoint

ITC Date

Kd(nM)

Analyzed w/ separate blank titration
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N

Memo

ΔH0

1.09
1.14
1.17
1.15

-1.162E+04
-1.081E+04
-1.030E+04
-1.041E+04

1.1
0.034
3%

Avg. ΔH0=
-1.079E+04
SD= 598.2474404
SD%=
6%
ln(K1/K2)=
M=
F=

0.4857564
4
1.0

2

N5A

10/18/2010
10/20/2010
10/28/2010
11/17/2010

79.37
71.94
33.67
90.09

14%
14%
48%
11%

0.928
0.886
0.835
0.879

-1.325E+04
-1.279E+04
-1.094E+04
-1.246E+04

Avg. Kd=
SD=
SD%=

69
25
36%

Avg. N =
SD=
SD%=

0.88
0.038
4%

Avg. ΔH0=
-1.236E+04
SD= 1000.566506
SD%=
8%

KdRT=
SD=
SD%=

39
14
36%

ln(K1/K2)=
M=
F=

0.5566944
4
1.0

10/20/2010
10/29/2010
11/9/2010
11/15/2010
11/18/2010

33.01
23.66
22.75
33.45
33.86

0.999
0.997
0.993
0.995
0.994

4.75%
5.86%
6.81%
6.84%
7.57%

10/28/2010
11/11/2010
11/15/2010
11/17/2010

72.99
169.78
138.12
116.55

16%
31%
14%
13%

0.993
1.18
1.04
1.03

-1.077E+04
-7.615E+03
-1.042E+04
-1.034E+04

Avg. Kd=
SD=
SD%=

29
5.6
19%

M=
F=

5
1.0

Avg. Kd=
SD=
SD%=

124
41
33%

Avg. N =
SD=
SD%=

1.1
0.082
8%

Avg. ΔH0=
-9.786E+03
SD= 1459.494062
SD%=
15%

KdRT=
SD=
SD%=

80
26
33%
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ln(K1/K2)=
M=
F=

0.4407727
4
1.9

3

4

5

F6A

V13A

7/26/2010
10/12/2010
11/15/2010

29.63
32.73
36.17

0.999
0.987
0.988

Avg. Kd=
SD=
SD%=

33
3.3
10%

M=
F=

5.81% 10/22/2010
10.60% 10/28/2010
10.26% 11/15/2010

70.92
78.74
142.25

20%
18%
21%

0.884
0.824
0.902

-1.097E+04
-1.125E+04
-1.228E+04

Avg. Kd=
SD=
SD%=

97
39
40%

Avg. N =
SD=
SD%=

0.87
0.041
5%

Avg. ΔH0=
-1.150E+04
SD= 689.8550572
SD%=
6%

KdRT=
SD=
SD%=

58
23
40%

50.00% 9/29/2010
50.51% 10/4/2010
50.22% 11/19/2010

1701
2639
1031

7%
7%
27%

1790
808
45%

Avg. N =
SD=
SD%=

3
1.1

11/7/2010
6/8/2011
6/9/2011

38.79
25.32
29.13

0.992
0.969
0.976

9.60%
8.95%
8.65%

Avg. Kd=
SD=
SD%=

31
6.9
22%

M=
F=

3
1.1

10/12/2010
11/19/2010
11/23/2010

686.35
732.30
730.75

0.986
0.994
0.987

Avg. Kd=
SD=
SD%=

720
26
4%

M=
F=

ln(K1/K2)=
M=
F=

1.26 12 uM
1.33 19 uM
1.51 5uM

0.51796
3
1.4

-1.051E+04
-1.036E+04
-6.121E+03

F16A
3
25

Avg. Kd=
SD=
SD%=
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1.4
0.13
9%

Avg. ΔH0=
-8.997E+03
SD= 2491.818011
SD%=
28%

KdRT=
SD=
SD%=

1200
540
45%

ln(K1/K2)=
M=
F=

0.40522488
3
28

Analyzed w/ separate blank titration

6

N17A

11/7/2010
6/8/2011
6/9/2011

30.39
32.55
32.98

0.992
0.990
0.984

7.73%
9.96%
9.38%

Avg. Kd=
SD=
SD%=

32
1.4
4%

M=
F=

3
1.1

9/29/2010
10/4/2010
11/19/2010

667
592
2262

33%
65%
21%

Avg. Kd=
SD=
SD%=

1174
943
80%

Avg. N =
SD=
SD%=

KdRT=
SD=
SD%=

703
565
80%
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0.77 12 uM
0.71 19 uM
0.68 5uM
0.72
0.046
6%

-8.673E+03
-1.026E+04
-1.517E+04

Avg. ΔH0=
-1.137E+04
SD= 3387.173797
SD%=
30%
ln(K1/K2)= 0.511999707
M=
3
F=
17.8

7

8

9

10

G19A

E21A

G22A

I24A

11/3/2010
11/23/2010
6/8/2011

41.78
44.87
46.96

0.999
0.999
0.997

7.32%
7.67%
9.55%

Avg. Kd=
SD=
SD%=

45
2.6
6%

M=
F=

3
1.5

11/23/2010
6/8/2011
6/9/2011

10.25
6.04
9.55

0.984
0.968
0.980

5.90%
5.16%
5.92%

Avg. Kd=
SD=
SD%=

8.6
2.3
26%

M=
F=

3
0.3

11/23/2010
6/8/2011
6/9/2011

48.84
37.68
49.72

0.988
0.969
0.952

11.37%
9.89%
14.42%

Avg. Kd=
SD=
SD%=

45
6.7
15%

M=
F=

3
1.6

10/30/2010
11/4/2010
11/9/2010
11/12/2010

141.42
140.32
168.53
161.24

0.997
0.999
0.996
0.998

16.89% 10/30/2010
16.71% 11/4/2010
21.32% 11/11/2010
21.50% 11/15/2010
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359.7
366.3
787.4
416.7

20%
22%
23%
23%

1.19
1.13
1.49
1.32

-1.000E+04
-8.347E+03
-1.037E+04
-9.117E+03

11

11/15/2010

211.09

0.999

23.29%

Avg. Kd=
SD=
SD%=

170
29
17%

M=
F=

5
5.8

10/18/2010
10/30/2010
6/9/2011

17.02
28.69
22.97

0.999
1.000
0.998

Avg. Kd=
SD=
SD%=

23
5.8
25%

M=
F=

483
205
42%

KdRT=
SD=
SD%=

310
130
42%

3.31% 10/18/2010
4.82% 10/18/2010
6.02% 10/30/2010

69.93
87.72
86.21

9%
9%
10%

1.06
1.13
1.14

-1.304E+04
-1.240E+04
-1.279E+04

Avg. Kd=
SD=
SD%=

81
10
12%

Avg. N =
SD=
SD%=

1.1
0.044
4%

Avg. ΔH0=
-1.274E+04
SD= 322.5419869
SD%=
3%

KdRT=
SD=
SD%=

46
5.6
12%

3
0.8

P31A

Avg. N =
SD=
SD%=

1.3
0.16
12%

Avg. ΔH0=
-9.459E+03
SD= 908.4985782
SD%=
10%

Avg. Kd=
SD=
SD%=

ln(K1/K2)=
M=
F=

0.42601084
4
7.3

ln(K1/K2)= 0.573959733
M=
3
F=
1.1

Analyzed w/ separate blank titration
10/18/2010
10/18/2010
10/30/2010
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74.63
93.46
84.03

8%
9%
10%

0.95
0.89
0.88

-1.399E+04
-1.446E+04
-1.486E+04

12

13

G40A

Q45A

84
9
11%

KdRT=
SD=
SD%=

44
4.9
11%

10.17% 11/1/2010
10.25% 11/4/2010
10.59% 11/22/2010
12.54%

163.93
169.78
198.02

29%
21%
11%

1.18
1.16
1.32

-8.250E+03
-8.463E+03
-7.753E+03

Avg. Kd=
SD=
SD%=

177
18
10%

Avg. N =
SD=
SD%=

1.2
0.087
7%

Avg. ΔH0=
-8.155E+03
SD= 364.3437022
SD%=
4%

KdRT=

120

11/3/2010
11/23/2010
6/9/2011

30.03
39.97
27.74

0.996
0.998
0.995

5.57%
6.70%
7.06%

Avg. Kd=
SD=
SD%=

33
6.5
20%

M=
F=

3
1.1

10/13/2010
11/1/2010
11/4/2010
11/22/2010

69.80
58.18
71.02
92.65

1.000
0.995
0.999
0.999

Avg. Kd=
SD=
SD%=

73
14
20%

M=
F=

4
2.5
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Avg. N =
SD=
SD%=

0.9
0.038
4%

Avg. ΔH0=
-1.444E+04
SD= 435.4690957
SD%=
3%

Avg. Kd=
SD=
SD%=

ln(K1/K2)= 0.650227467
M=
3
F=
1.1

ln(K1/K2)= 0.367316213

14

15

M46A

K14EE21K

SD=
SD%=

12
10%

23.83% 11/1/2010
21.92% 11/4/2010
25.32% 11/22/2010
22.71%
17.11%
16.72%
16.72%

184.2
184.5
215.5

38%
43%
38%

0.774
0.814
0.784

-6.162E+03
-6.804E+03
-6.000E+03

Avg. Kd=
SD=
SD%=

195
18
9%

Avg. N =
SD=
SD%=

0.79
0.021
3%

Avg. ΔH0=
-6.322E+03
SD= 425.2105361
SD%=
7%

KdRT=
SD=
SD%=

150
14
9%

11/23/2010
6/8/2011
6/9/2011

72.46
52.28
61.16

0.991
0.994
0.995

13.54%
7.43%
11.32%

Avg. Kd=
SD=
SD%=

62
10
16%

M=
F=

3
2.1

10/12/2010
11/1/2010
11/4/2010
11/22/2010
11/29/2010
11/29/2010
11/29/2010

146.74
131.91
142.90
137.51
138.46
144.02
136.74

0.967
0.972
0.944
0.971
0.939
0.960
0.936

Avg. Kd=
SD=
SD%=

140
5.1
4%

M=
F=

7
4.8
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M=
F=

ln(K1/K2)=
M=
F=

3
2.8

0.28474288
3
3.5

16

17

K33EE42K

K38EE51K

11/1/2010
11/18/2010
11/22/2010

30.17
51.36
38.84

0.999
0.999
0.998

Avg. Kd=
SD=
SD%=

40
11
27%

M=
F=

6.40% 11/1/2010
8.49% 11/17/2010
8.47% 11/22/2010
3
1.4

11/7/2010
11/23/2010
6/9/2011

27.80
37.96
33.72

0.950
0.963
0.938

10.80%
11.34%
12.17%

Avg. Kd=
SD=
SD%=

33
5.1
15%

M=
F=

3
1.1

68.49
75.19
82.64

10%
10%
12%

1.04
1.12
1.13

-1.356E+04
-1.158E+04
-1.192E+04

Avg. Kd=
SD=
SD%=

75
7.1
9%

Avg. N. =
SD=
SD%=

1.1
0.049
4%

Avg. ΔH0=
-1.235E+04
SD= 1058.741391
SD%=
9%

KdRT=
SD=
SD%=

43
4.1
9%

*M = number of measurements
F = Change factor of Kd
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ln(K1/K2)= 0.556394133
M=
3
F=
1.0

C-2. Individual NCp7-SL3 Trp Titration Curves

Individual curves start from the next page.
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10/29/2010 WT

11/7/2010 WT
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11/17/2010 WT

11/18/2010 WT
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11/19/2010 WT

11/22/2010 WT
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11/23/2010 WT

11/29/2010 WT
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11/29/2010 WT (SL3+10%)

11/29/2010 WT (SL3-10%)
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10/20/2010 N5A

10/29/2010 N5A
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11/9/2010 N5A

11/15/2010 N5A
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11/18/2010 N5A
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7/26/2010 F6A

10/12/2010 F6A
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11/15/2010 F6A
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11/7/2010 V13A

6/8/2011 V13A
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6/9/2011 V13A
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10/12/2010 F16A

11/19/2010 F16A
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11/23/2010 F16A
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11/7/2010 N17A

6/8/2011 N17A
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6/9/2011 N17A
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11/3/2010 G19A

11/23/2010 G19A

- 199 -

6/8/2011 G19A
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11/23/2010 E21A

6/8/2011 E21A
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6/9/2011 E21A
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11/23/2010 G22A

6/8/2011 G22A
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6/9/2011 G22A
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10/30/2010 I24A

11/4/2010 I24A
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11/9/2010 I24A

11/12/2010 I24A
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11/15/2010 I24A
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10/18/2010 P31A

10/30/2010 P31A
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6/9/2011 P31A
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11/3/2010 G40A

11/23/2010 G40A
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6/9/2011 G40A
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10/13/2010 Q45A

11/1/2010 Q45A
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11/4/2010 Q45A

11/22/2010 Q45A
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11/23/2010 M46A

6/8/2011 M46A
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6/9/2011 M46A
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10/12/2010 K14E-E21K

11/1/2010 K14E-E21K
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11/4/2010 K14E-E21K

11/22/2010 K14E-E21K
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11/29/2010 K14E-E21K-1

11/29/2010 K14E-E21K-2
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11/29/2010 K14E-E21K-3
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11/1/2010 K33E-E42K

11/18/2010 K33E-E42K
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11/22/2010 K33E-E42K
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11/7/2010 K38E-E51K

11/23/2010 K38E-E51K
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6/9/2011 K38E-E51K
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C-3. Individual NCp7-SL3 ITC Curves
6/9/2011 WT blank titration
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6/9/2011 F16A blank titration
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6/12/2011 P31A blank titration
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10/18/2010 WT (Use endpoints data as baseline)
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10/18/2010 WT (Use blank titration data as baseline)
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10/20/2010 WT (Use endpoints data as baseline)
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10/20/2010 WT (Use blank titration data as baseline)
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10/28/2010 WT (Use endpoints data as baseline)
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10/28/2010 WT (Use blank titration data as baseline)
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11/17/2010 WT (Use endpoints data as baseline)
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11/17/2010 WT (Use blank titration data as baseline)
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10/28/2010 N5A
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11/11/2010 N5A
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11/15/2010 N5A
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11/17/2010 N5A
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10/22/2010 F6A

- 239 -

10/28/2010 F6A
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11/15/2010 F6A
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9/29/2010 F16A (Use endpoints data as baseline)
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9/29/2010 F16A (Use blank titration data as baseline)

- 243 -

10/4/2010 F16A (Use endpoints data as baseline)
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10/4/2010 F16A (Use blank titration data as baseline)
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11/19/2010 F16A (Use endpoints data as baseline)
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11/19/2010 F16A (Use blank titration data as baseline)
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10/30/2010 I24A

- 248 -

11/4/2010 I24A
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11/11/2010 I24A
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11/15/2010 I24A
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10/18/2010 P31A-1 (Use endpoints data as baseline)

- 252 -

10/18/2010 P31A-1 (Use blank titration data as baseline)
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10/18/2010 P31A-2 (Use endpoints data as baseline)
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10/18/2010 P31A-2 (Use blank titration data as baseline)
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10/30/2010 P31A (Use endpoints data as baseline)
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10/30/2010 P31A (Use blank titration data as baseline)
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11/1/2010 Q45A
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11/4/2010 Q45A
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11/22/2010 Q45A
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11/1/2010 K14E-E21K

- 261 -

11/4/2010 K14E-E21K
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11/22/2010 K14E-E21K
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11/1/2010 K33E-E42K
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11/17/2010 K33E-E42K
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11/22/2010 K33E-E42K
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Appendix D. Recipes and Protocols
Used in the Development of Methods
for Aptamer Discovery
D-1. Recipes for buffers and solutions

5X PBS
Per liter:
NaCl

40g

KCl

1g

Na2HPO4

7.2g

KH2PO4

1.2g

Adjust pH to 7.4 with HCl. Filter and store at RT.

1X PBST
PBS

1X

Tween-20

0.05%

MgCl2

5mM
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Bind and Wash buffer (for MyOne beads)
Tris-HCl

5mM

EDTA

0.5mM

NaCl

1.0M

pH 7.5

1X TE
Tris-HCl

10mM

EDTA

1 mM

pH 8.0

NXS
Tris-HCl

10mM, pH 7.5

EDTA

1mM, pH 8.0

NaCl

100mM

Triton X-100

1% (v/v)

SDS

1% (w/v)

Tris-HCl

10mM, pH 7.5

EDTA

1mM, pH 8.0

NaCl

100mM

NX
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Triton X-100

1% (v/v)

0.1 M NaOH
Per liter:
NaOH

4g

Filtered sterilize and store air tight at room temperature.

20x SSPE
Per liter:
NaCl

175.3g

NaH2PO4∙H2O

27.6g

EDTA

7.4g

Dissolve in 800ml of H2O, adjust pH to 7.4 with NaOH, adjust volume to 1 liter.
Filtered sterilize. Store at RT.

6X SSPE w. Triton X-100
Adjust 20X SSPE stock solution to 6X with dH2O.
Add Triton X-100 to 0.01%

10X Sodium Borate Buffer (0.5M)
Per liter:
Boric Acid

30.92g
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Dissolved in 800ml of ddH2O, adjust pH to 8.5 using NaOH
Filtered sterilize and store at room temperature.
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D-2. Protocol for bridge amplification and detection

Materials:



SuperStreptavidin substrates slide (ArrayIt)



Micro Spotting Solution Plus (ArrayIt)



SuperStreptavidin blocking buffer (ArrayIt)



25ul Frame-seal incubation chambers (Bio-Rad)



1X PBST



Templates and primers (biotinylated)



dNTP, TurboPfu, 10X Pfu buffer



Sybr555 DNA stain (Invitrogen)

Procedure:

1. Dissolve biotinylated primer and template oligos in Micro Spotting Solution Plus
at desired final concentration. Mix the primer and template oligos in designed
ratio.
2. Attach a 25-µl frame-seal incubation chamber (Bio-Rad) onto a SuperStreptavidin
Substrates slide (ArrayIt, Sunnyvale, CA).
3. Spot DNA samples inside the incubation chamber by pipetting. Let the sample
hybridize with the substrates for 30 minutes at room temperature.
- 271 -

4. Block with 25 µl SuperStreptavidin blocking buffer for 1 hour at room
temperature.
5. Wash twice with 1x PBST for 5 minutes each time. Spin dry the slide.
6. Prepare PCR mix as below:
Turbo Pfu, 2.5 U/µL

2 µL

10mM dNTP

2.5 µL

10X Pfu Buffer

2.5 µL

Nuclease free H2O

18 µL

Final Volume:

25 µL

7. Fill the chamber with the PCR mix. Seal the chamber with a plastic cover slip.
8. Run PCR thermal cycles as below:
1) 92°C

1 minute

2) 92°C

30 seconds

3) 55°C

30 seconds

4) 72°C

30 seconds

5) Go back to 2) for a total of 40 cycles
6) 72°C

1 minute

7) Hold at 4°C
9. After amplification, remove the cover slip rinse the slide twice with 1X PBST for 5
minutes each time.
10. Stain the slide with 20 µl of Sybr555 DNA stain (Invitrogen) in 27ml of 1X PBST at
room temperature for 5 minutes.
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11. Wash the slide twice with 1X PBST for 5 minutes each time.
12. Spin dry the slide (optional).
13. Scan the stained slides in a GenePix 4400A microarray scanner (Axon™
Instruments, Union City, CA, USA). Record images using GENEPIX PRO 5.0
software (Axon).
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D-3. Protocol for emulsion PCR and detection

Materials:



Dynal MyOne streptavidin C1 beads



Bind and Wash buffer



Dynal MPC-S magnet



1X TE, NXS, NX, 0.1 M NaOH, 1X PBS, 1X PBST, 6x SSPE w/ 0.01% Triton X-100



Templates and primers, capping and bridging oligos



dNTP, 10X Taq buffer without MgCl2, 50mM MgCl2 (Invitrogen)



hot-start Taq (5U/µl, Denville)



Tegosoft DEC (Degussa)



light mineral oil (Sigma #5904-500ml)



ABIL WE09 (Degussa)



Bis(Sulfosuccinimidyl) suberate (BS3)



Teflon coated glass slide (Erie Scientific) (pre-treated with aminosilane)



2X Self-seal reagent (Bio-Rad)



SuperStreptavidin blocking buffer (ArrayIt)

Procedure:

1. Bead-loading
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1) Take 100 µl of Dynal MyOne paramagnetic streptavidin beads (10mg/ml)
from stock vial, transfer into a 1.5ml eppendorf tube.
2) Add 100ul Bind and Wash buffer into the beads. Mix and remove all liquid on
a magnetic particle concentrator (Dynal MPC-S magnet).
3) Wash twice in 200 µl of Bind and Wash buffer, and re-suspend in 198 µl of
Bind and Wash buffer.
4) Add 2ul 1mM 5’-dual-biotin labeled forward primer. Mix well by pipetting
and incubate the mixture at room temperature for 20 minutes on a
Dynabeads rotary mixer, or periodically mix by pipetting or flicking.
5) Remove all liquid, and wash twice in 200 µl of Bind and Wash buffer, then
once in 200ul of 1X TE.
6) Remove all liquid and re-suspend beads in 200 µl of 1X TE. These beads
should now be around 5x10^9 beads/ml.

2. Emulsion PCR
1) Prepare the aqueous and oil phase as below:

Aqueous phase a:
10X Taq buffer without MgCl2 (Invitrogen)

12 µl

50 mM MgCl2

45 µl

10 mM dNTP mix

17 µl

2 mM reverse primer

1 µl
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Pre-loaded MyOne beads in 1X TE

7.5 µl

Hot-start Taq (5U/µl, Denville)

7 µl

Template DNA at appropriate concentration

1 µl

Nuclease free H2O

22.5 µl

Total volume:

120 µl

Oil phase b:

a.

Tegosoft DEC (Degussa)

500 µl

light mineral oil (Sigma #5904-500ml)

138 µl

ABIL WE09 (Degussa)

48 µl

Total volume:

686 µl

For aqueous phase, add all components except Taq polymerase, mix well

by vortexing. Then add Taq and mix well again.
b.

For oil phase, add all components to a 15 ml polypropylene falcon tube and

vortex well to mix.

2) Add aqueous phase to oil phase, vortex well for 5 min. Distribute mix into
PCR tubes at approximately 50 µl per tube.
3) Run thermal cycle as below:

(1) 94°C

10 minutes

(2) 94°C

15 seconds
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(3) 57°C

30 seconds

(4) 70°C

75 seconds

(5) Go back to (2) for a total of 120 cycles
(6) 70°C

2 minutes

(7) 4°C

hold

3. Breaking emulsion
1) Add 100 µl of isopropanol to each tube or well containing the amplified PCR
mixture. Mix well by pipetting.
2) Pool the isopropanol/PCR mixes into a 15 ml polypropylene falcon tube.
Vortex for 1 minute.
3) Spin down the beads for 30 seconds at 4000 rpm in a table-top
microcentrifuge. Remove supernatant by decanting
4) Add 2 ml of isopropanol and re-suspend the pellet by pipetting. Make sure
no visible clumps in the suspension. Add 1 ml of isopropanol. Vortex for 30
seconds.
5) Spin for 30 seconds at 4000 rpm in a table-top microcentrifuge.
6) Remove supernatant as much as possible. Re-suspend the pellet in 3 ml of
NXS and mix well by vortexing. Make sure that the pellet is VERY well resuspended.
7) Spin down the beads for 30 seconds at 3000 rpm in table-top centrifuge
8) Remove supernatant using a magnetic particle separator
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9) Wash the pellet once in 1 ml of NXS and then twice in 1 ml of 1X TE.
10) Re-suspend in 500 µl of 0.1 M NaOH. Incubate the suspension at room
temperature on a rotary mixer for 5 minutes.
11) Wash once with 500 µl of 0.1 M NaOH, then twice with 500 µl of 1X TE.
12) Re-suspend and combine beads in 30 µl of 1X TE.

4. Bead Capping
1) Prepare the hybridization mixture as below:
6x SSPE with 0.01% Triton X-100

180 µl

1mM Bridging oligo 1

1.8 µl

1mM Bridging oligo 2

1.8 µl

2) Re-suspend beads in the hybridization mixture solution, mix well and
incubate for 10 minutes at 56°C.
3) Mix again, and then incubate the mixture on a rotary mixer for 10 more
minutes at room temperature.
4) Wash the beads twice with 200 µl of TE. Prepare ligation mix as below:
10x T4 Ligase Buffer

10 µl

1mM Capping oligo 1

2 µl

1mM Capping oligo 2

2 µl

T4 DNA ligase (3U/µl)

2 µl

Nuclease free dH2O

84 µl

Total volume:

100 µl
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5) Remove all liquid from beads and re-suspend them in the ligation mix
solution. Incubate the mixture on a rotary mixer for 1 hour at room
temperature.
6) Remove liquid and wash beads once with 200 µl of 1X TE, once with 200 µl of
NX, then twice with 200 µl of 1X TE.
7) Transfer beads to a new tube, wash once with 200 µl of 1X TE, then resuspend the beads in 30 µl of 1X TE.

5. Bead attachment
1) Wash beads three times in 50 µl of 1X PBS.
2) Prepare fresh BS3 solution (2.86 mg of Bis(Sulfosuccinimidyl) suberate in 1 ml
of 1X PBS).
3) Remove all liquid from beads, quickly re-suspend the beads in 35 µl of fresh
BS3 solution
4) Apply the beads onto the glass surface of the center circle on a Teflon coated
glass slide (Erie Scientific) that has been pre-treated with aminosilane. Cover
the circle with a cover slip.
5) Incubate the slide with beads at room temperature for 1 hour without
disturbing.
6) Wash the slide twice with 1X TE for 5 minutes each time to remove any
unattached beads.
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6. Staining the beads with TBA probe (on slide)
1) Add 35 µl of 6x SSPE w/ 0.01% Triton X-100 to each circle, cover with cover
slip.
2) Incubate the slide at 56°C for 10 minutes.
3) Wash immediately with 1x TE twice for 2 minutes on labquake. Add 35 µl of
the following staining solution:

6x SSPE w/ 0.01% Triton X-100

149 µl

1mM 5’-6-FAM-TBA comp oligo

1 µl

Total volume:

150 µl

4) Cover with a cover slip. Incubate the slide on a thermal cycler using a heat
cycle setting as below:
56°C

2 minutes

40°C

10 minutes

25°C

10 minutes

5) Wash twice with 1x TE for 5 minutes each time on a labquake.
6) Spin dry the slide. Add 25 µl of 1x self-seal reagent in TE, cover with a cover
slip.

7. Staining the beads with TBA probe (unattached, in tube)
1) Wash beads wash twice with 200 µl of 6X SSPE.
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2) Prepare the staining solution as below:
6X SSPE

149 µl

1mM 5’-6-FAM-TBA comp oligo

1 µl

Total volume:

150 µl

3) Re-suspend beads in 150 µl of the staining solution. Incubate in a thermal
cycler using the same heating cycles as described above.
4) Wash the stained beads twice with 200 µl of 1XTE.
5) Re-suspend the beads in 25 µl of 1X self-seal reagent in 1X TE, apply the
suspension onto a glass slide, and cover with a cover slip.

8. Staining the beads with thrombin (on slide)
1) Block the slide with SuperStreptavidin blocking buffer for 1 hour at room
temperature.
2) Prepare staining solution as below:
1X PBST

150 µl

Thrombin (Cy3 or Cy5 labeled)

500 nM (final concentration)

Total volume:

150 µl

3) Apply 25 µl of the staining solution onto each circle and cover with a cover
slip. Incubate the slide overnight at room temperature.
4) Wash the stained slide twice with 1X PBST and twice with 1X PBS for 10
minutes each time.
5) Add 25 µl of 1x self-seal reagent in TE, cover with a cover slip.
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9. Staining the beads with thrombin (unattached, in tube)
1) Wash the beads twice with 200 µl of 1X PBST.
2) Prepare the staining solution as below:
1X PBST

150 µl

Thrombin (Cy3 or Cy5 labeled)

500 nM (final concentration)

Total volume:

150 µl

3) Re-suspend beads in 150 µl of the staining solution. Incubate overnight at
room temperature.
4) Wash the stained beads twice with 200 µl of 1X PBST and twice with 200 µl of
1X PBS for 5 minutes each time.
5) Re-suspend the beads in 25 µl of 1x self-seal reagent in 1X PBS, apply the
suspension onto a glass slide, cover with a cover slip.

10. Visualization using Nikon TE2000 microscope
1) Turn on Nikon TE2000 microscope in the following order:
a. X-Cite mercury bulb
b. Nikon Scope
c. Spot Camera
2) Light path of different ports are:
Port 1: eye;
Port 5: camera;
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Port 3: both eye and camera.
3) Emulsion beads are only visible under a 100X objective. Use oil specific for
Nikon microscopes.
4) Lower the platform before load the sample slide. Slowly raise the platform
using the adjusting screw. When the objective hits the oil drop, a sudden
flash of light can be seen. Start micro-tuning at that point.
5) Take one bright field image and one fluorescence image of the same
microscopic field.
6) Use ImageJ to view and measure the photos.
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D-4. Protocol for aminosilane treatment of glass slides

Materials:



Teflon coated glass slide (Erie Scientific)



Glass rack for microslides



0.5% Triton X-100 in dH2O



100% ethanol, dry acetone



aminopropyl triethoxysilane (Thermo Pierce)

Procedure:

1. Load glass slides onto a glass rack with handle.
2. Immerse glass slides in solution of 0.5% Triton X-100 in dH2O. Wash by manually
agitating the rack for 1 minute.
3. Pour all liquid off and wash thoroughly under running water to remove all
detergent. Rinse with dH2O.
4. Pour off all liquid and dry by immersion in 100% ethanol. Remove slides from
ethanol and allow all ethanol to evaporate (aided by use of a Dust-off
compressed air canister if possible).
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5. Prepare 2% aminopropyl triethoxysilane (Pierce) solution in dry acetone in a
glass beaker. Pipette with glass pipettes (the solution will react with
polystyrene).
6. Immerse rack of completely dry (and ethanol-free) glass slides in silane solution
for 30 seconds. Use the handle to manually agitate the rack.
7. Remove and immediately immerse in fresh dry acetone rinse for 1 minute. Use
the handle to manually agitate the rack.
8. Remove rack and blow-dry partially with compressed air (to remove the bulk of
the acetone).
9. Completely air-dry and store under vacuum at RT.
10. When cleaning beakers containing acetone and aminopropyl triethoxysilane, be
sure to rinse with fresh acetone to remove all traces of aminopropyl
triethoxysilane. If present, it will form a white precipitate upon evaporation of
acetone.
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D-5. Protocol for labeling protein with Cy3 or Cy5

Materials:



Protein



0.05M Borate buffer (pH 8.5)



DyLight 549 or 649 microscale antibody labeling kit (Pierce)



Illustra microspin column (GE)

Procedure:

1. Dialyze the protein sample against 0.05M Borate buffer (pH 8.5) overnight.
2. Take 100 µl of dialyzed protein (around 1mg/ml), add to one vial of DyLight 549
or 649 dye (DyLight 549 equals Cy3, DyLight 649 equals Cy5), pipet to mix.
3. Incubate the mixture at room temperature for 1 hour.
4. Take 100 µl of purification resin (from the labeling kit), add to an Illustra
microspin column (GE).
5. Spin the resin at 1000g for 30 seconds.
6. Change collection tube, apply the protein-dye mixture onto the center of the
resin column.
7. Spin the column at 1000g for 30 seconds.
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8. Collect the flow through, measure protein concentration and label efficiency by
UV-Vis absorption.
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